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CDDP  Cis-dichlorodiamminiplatinum      
CDR  Complementary Determining Region     




cm  Centimeter       
CRPC  Castration-Resistant Prostate Cancer 
CTC  Circulating Tumor Cell     
Cy3  Cyanine 3        
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Cy5.5   Cyanine 5.5       
CYP17A1 Cytochrome P450 Family 17 Subfamily A Member 1    
D2O  Deuterium Oxide      
DAPI  4´,6-diamidin-2-phenylindole      
DBD  DNA-Binding Domain      
DDS  Drug Delivery System        
DHEA  Dehydroepiandrosterone 3-Acetate      
DHEA-S  Dehydroepiandrosterone sulfate     
DHT  Dihydrotestosterone      
DIEA  N,N-Diisopropylethylamine      
DLS  Dynamic Light Scattering       
DMF  N,N-Dimethylformamide       
DMSO  Dimethyl Sulfoxide      
DMTMM.BF4  4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium 
tetrafluoroborate   
DTT  Dithiothreitol       
DTX   Docetaxel       
EB  Evans Blue         
ECM  Extracellular Matrix       
EDTA  Ethylenediaminetetraacetic Acid   
EGF  Epidermal Growth Factor      
EGFR  Epidermal Growth Factor Receptor      
ELK-1   ETS like-1        




EPR  Enhanced Permeability and Retention    
Equiv.  Equivalents       
ER  Estrogen Receptor       
ERG  ETS-Related Gene       
ETS  Erythroblast Transformation-Specific     
EZH2  Enhancer of Zeste Homolog 2     
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FBS  Fetal Bovine Serum       
Fc   Antibody Fragment Crystallizable Region 
FDA  Food and Drug Administration      
FGFR  Fibroblast Growth Receptor Factor      
FI  Fluorescence Intensity       
FITC  Fluorescein isothiocyanate 
FKBP5  FK506 Binding Protein 5       
FPLC  Fast Protein Liquid Chromatography      
FR  Folate Receptor      
Fv  Antibody Variable Fragment    
GAU  Glutamic Acid Units       
G-CSF   Granulocyte Colony-Stimulating Factor     
GPCR  G-Protein-Coupled Receptor    
GR  Glucocorticoid Receptor       
h  Hours       
HA  Hyaluronic Acid       
HER2/3  Human Epidermal Growth Factor Receptor 2/3     
HGF   Human Growth Hormone      
HGFR  Hepatocyte Growth Receptor Factor      




HPMA  N-(2-Hydroxypropyl)methacrylamide     
HPN  Serine Peptidase Hepsin       
HSP  Heat Shock Protein      
i.v.  Intravenous       
IC50  Half Maximal Inhibitory Concentration     
IF  Immunofluorescence       
IFP  Interstitial Fluid Pressure     
IGF  Insulin Growth Factor       
IGF-1   Ligand Insulin-like Growth Factor-1      
IGF-1R   Insulin-like Growth Factor 1 Receptor      
IGFBP  Insulin-like Growth factor Binding Protein    
IH  Immunohistochemistry       
IL-6R   Interleukin 6 Receptor       
IL-8   Interleukin 8       
INSR  Insulin Receptor       
IRS1  Insulin Receptor Substrate 1      
K   Kelvin       
Kd  Dissociation Constant       
KDa  Kilodalton       
Kg   Kilogram       
KLK3  kallikrein 3       
L  Liter       
LBD  Ligand-Binding Domain      
LHRH  Hormone-Releasing Hormone      
lncRNA  long non-coding RNA       
Luc   Luciferase       
M   Molar       
mA   Milliampere       




MAPK  Mitogen-Activated Protein Kinase      
mAU  Milli-Absorbance Unit    
mCRPC  Metastatic Castration-Resistant Prostate Cancer 
mg  Milligrams       
mHNPC Metastatic Hormone-Sensitive Prostate Cancer    
MHz  Megahertz       
mins  Minutes       
ml   Milliliter       
mM   Millimolar       
mmol  Millimole       
MMP-9  Metallopeptidase 9       
MPS  Mononuclear Phagocyte System      
MRW  Mean residue weight      
mTOR  Mechanistic Target of Rapamycin      
mTORC1/2  Mechanistic Target of Rapamycin Complex 1/2     
MTS  3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium 
mV   Millivolt       
Mw  Molecular Weight      
NA  Numerical Aperture       
NCE  New Chemical Entity       
NDGA  Nordihydroguaiaretic Acid      
NFKB   Nuclear Factor B       
NHS  N-Hydroxysuccinimide      
nm  Nanometer       
nM  Nanomolar       
NMR  Nuclear Magnetic Resonance      
NP  Nanoparticle     




NT   Non-transfected      
NTD  Amino-Terminal Domain      
OD  Optical Density      
P/S   Penicillin/Streptomycin       
P1NP  Procollagen Type 1 N-Terminal Propeptide    
PAA  Polyamino Acid      
PAP  Prostatic Acid Phosphatase      
PARP  Poly ADP-Ribose Polymerase     
PBS  Phosphate Buffered Saline     
PCa  Prostate Cancer      
PCA3  Prostate Cancer Antigen 3      
PDC  Polymer-Drug Conjugate 
PDI  Polydispersity Index   
PDEPT  Polymer-Directed Enzyme Prodrug Therapy     
PDGFRβ Platelet Derived Growth Factor Receptor Beta    
PECAM-1  Platelet Endothelial Cell Adhesion Molecule-1    
PEG  Polyethylene Glycol       
PELT  Polymer-Enzyme Liposome Therapy      
PFA   Paraformaldehyde       
pfu  Particles Forming Unit     
PGA  Poly-L-Glutamic Acid       
PGR  Progesterone Receptor      
PHLPP  PH domain and Leucine-rich repeat Protein Phosphatase 
PI3K  Phosphoinositide 3-Kinase     
PIN  Prostate Intraepithelial Neoplasia     
PIP3   Phosphatidylinositol-3,4,5-triphosphate     
PK  Pharmacokinetics       
PMS  Phenazine Methosulfate       




ppm  Part Per Million      
PSA  Prostate-Specific Antigen      
PSMA  Prostate-Specific Membrane Antigen      
PT  Polymer Therapeutics       
PTEN  Phosphatase and Tensin Homolog      
PVDF   Polyvinylidene Difluoride       
Ra-223   Radium-223       
RanBP2 Ran Binding Protein 2       
RBCs  Red Blood Cells       
rcf  Relative Centrifugal Force      
RES  Reticuloendothelial System      
RIPA  Radio-Immunoprecipitation Assay (Buffer) 
RLU   Relative Luminescence Units      
rpm   Revolutions Per Minute      
RT  Room Temperature       
s  Second       
s.c.  Subcutaneous      
SATP  N-Succinimidyl-S-acetylthiopropionate      
SCHLAP1 Second Chromosome Locus Associated with Prostate 1    
SCID  Severe Combined Immunodeficiency      
SCR   Scrambled Control siRNA      
SDS   Sodium Dodecyl Sulfate     
SEC  Size Exclusion Chromatography      
SEM  Standard Error of the Mean      
Shc   SHC-transforming protein 1     
siRNA   Small interfering RNA      
SMA   Smooth Muscle Actin      
SPOP  Speckle-type Poz Protein       




STORM  Stochastic Optical Reconstruction Microscopy     
T2E  TMPRSS2: ERG Fusion Gene     
TEMED  N,N,N′,N′-Tetramethylethylenediamine     
tGFP   Turbo Green Fluorescent Protein     
TGN  Trans-Golgi Network       
TIRF  Total Internal Reflection Fluorescence     
TKI  Tyrosine Kinase Inhibitor     
TKR  Tyrosine Kinase Receptor     
Tm  Melting Temperature      
TMB  3,3´,5,5´-Tetramethylbenzine      
TME  Tumor Microenvironment      
TMPRSS2 Transmembrane Serine Protease 2     
UV  Ultraviolet       
V  Voltage       
v/v   Volume/Volume      
VEGF  Vascular Endothelial Growth Factor      
VEGFR2  Vascular Endothelial Growth Factor Receptor 2    
w/v   Weight/Volume      
w/w   Weight/Weight      

































Prostate Cancer (PCa) is currently the most prevalent non-cutaneous 
malignancy and the second most prevalent cancer in men. Advances in early 
diagnosis, identification of biomarkers for specific subtypes, and the application of 
effective treatments represent critical parameters in the clinical management of 
PCa patients. Effective treatment options for cancer in general now include 
combination-based therapies, given the general complexity of cancers and the rise 
of resistance to some single-drug approaches. Furthermore, the modification of 
existing drugs, including polymer conjugation, can allow for greater stability in 
plasma, enhanced tumor targeting, altered cell trafficking, and improved 
pharmacokinetics to foster improvements in patient outcomes. 
Studies have established the TMPRSS2 (androgen-dependent serine 
protease) and ERG (ETS family transcription factor) fusion gene (T2E) as a potential 
biomarker of metastatic castration-resistant PCa, with overexpression observed in 
50-70% of PCa cases. In these cases, the androgen receptor (AR) and insulin-like 
growth factor 1 receptor (IGF-1R) reciprocal signaling pathways potently drive 
tumor progression; therefore, the dual inhibition of these pathways may represent 
a promising means to inhibit PCa progression. 
The inhibition of IGF-1R signaling with an anti-IGF-1R-specific monoclonal 
antibody (mAb - AVE1642) has shown potential in the treatment of T2E-positive 
PCa patients; however, patients treated with anti-IGF-1R inhibitors in several 
clinical trials only experienced a partial response to therapy and suffered from 
significant side toxicities. The application of nanomedicine to PCa has the potential 
to overcome many of the limitations of current therapies in both localized and 
metastatic disease, and we hypothesized that the polymer-modification of 




To this end, we conjugated AVE1642 with a biodegradable and 
biocompatible polypeptide (poly-L-glutamic acid (PGA)) to create PGA-AVE1642, 
which we then evaluated as an optimized treatment approach. While we aimed to 
generate an advanced therapeutic approach, we also sought to fully understand 
the effect of PGA conjugation to a mAb regarding pharmacological activity in vitro 
and in vivo.  
Our initial in vitro analyses showed similar cell viability in the T2E-positive 
VCaP PCa cell line treated with both AVE1642 and PGA-AVE1642, confirming that 
PGA-conjugation does not impede AVE1642 function. PGA-AVE1642 maintained a 
general specificity for T2E-positive cells, but instead of binding to IGF-1R and 
becoming internalized rapidly as occurs for unmodified AVE1642, PGA-AVE1642 
displayed enhanced stability in plasma and stronger binding to IGF-1R, which 
maintained PGA-AVE1642 at the cell membrane and prevented IGF-1R 
internalization.  
We also discovered that PGA-conjugation of AVE1642 altered cellular 
trafficking; while confocal/STORM microscopy in VCaP cells established that 
AVE1642 mainly colocalized with endosomes and clathrin, PGA-AVE1642 mostly 
colocalized with caveolin-1 but not with endosomes, demonstrating  
PGA-conjugation modifies IGF-1R mediated endocytosis probably due to a modified 
interaction with the receptor.  Furthermore, altered trafficking coincided with a 
differential signaling pathway inhibition pattern upon PGA conjugation. While 
unmodified AVE1642 inhibited the PI3K pathway downstream of IGF-1R inhibition, 
PGA-AVE1642 inhibited both the PI3K and MAPK pathways, thereby displaying 
increased anti-tumorigenic potential.  
Subsequent in vivo analyses in a newly developed orthotopic PCa mouse 
model employing luciferase-expressing VCaP cells revealed higher anti-tumoral 




we found that PGA-AVE1642 treatment inhibited both the PI3K and MAPK 
pathways; however, subsequent tumor microenvironmental studies revealed that 
PGA-AVE1642 treatment also potently inhibited tumor blood vessel functionality 
and maturity, cell proliferation, and angiogenesis when compared to treatment 
with unmodified AVE1642. 
Overall, polymer conjugation improves AVE1642 antitumoral activity both 
in vitro and in vivo by stronger IGF-1R inhibition, which avoids the activation of 
MAPK and PI3K downstream signaling pathways preventing cancer cell progression. 
Furthermore, our results suggest that polymer conjugation of AVE1642 promotes 
alterations to the tumor microenvironment in PCa tumor models, thereby 
enhancing therapeutic efficacy. 
As a means to further improve PCa treatment with PGA-AVE1642, we 
looked to evaluate a combination therapy-based approach through the additional 
inhibition of the AR signaling pathway via treatment with the anti-androgen drug 
abiraterone. Polymer-based combination therapies employing synergistic drugs 
aimed at different pharmacological targets represent an exciting means to target 
tumor cells effectively. As a first step towards the generation of a PGA-antibody 
conjugate, we evaluated the combination of AVE1642 or PGA-AVE1642 with free 
abiraterone in vitro and in vivo. 
Our in vitro analyses provided evidence for a synergistic effect for both 
combination therapies in T2E-positive PCa cells; however, we only found synergy 
with regards to primary tumor growth for free AVE1642 in combination with 
abiraterone, and not for PGA-AVE1642. This is most probably due to the differential 
molecular mechanism achieved upon conjugation that it is already providing the 
role that abiraterone plays in T2E-positive PCa tumors. Both combination therapies 
(AVE1642 or PGA-AVE1642 with abiraterone) provided for dual PI3K and MAPK 




still ongoing as even if not synergistic, significant differences have been 
encountered when abiraterone is present not only for free but also for conjugated 
AVE1642. 
Overall, our studies have demonstrated that polymer-conjugation of a 
monoclonal antibody alters the function and improves anti-tumorigenic capacity. 
Furthermore, we have also provided evidence for the anti-tumor efficacy of a new 















































El cáncer de próstata (CaP) es actualmente el tumor maligno no cutáneo 
más común y el segundo cáncer más frecuente en los hombres. Los avances en el 
diagnóstico precoz, la identificación de biomarcadores para subtipos específicos y 
la aplicación de tratamientos efectivos representan parámetros fundamentales en 
el manejo clínico de los pacientes con CaP. Las opciones para tratamientos eficaces 
contra el cáncer ahora incluyen terapias de combinación dada la complejidad 
general de los cánceres y la mayor resistencia a los métodos de un solo fármaco. 
Además, la modificación de los fármacos existentes, como la conjugación de 
polímeros, puede permitir una mayor estabilidad en plasma, una mejor selectividad 
tumoral, la alteración del tráfico celular y una mejora en la farmacocinética para 
favorecer los resultados del paciente. 
Los estudios han establecido el gen de fusión (T2E) compuesto por 
TMPRSS2 (serina proteasa dependiente de andrógenos) y ERG (factor de 
transcripción de la familia ETS) como un biomarcador potencial de CaP metastásico 
resistente a la castración, con una sobreexpresión observada en un 50-70% de los 
casos de CaP. En estos casos, las vías de señalización recíproca entre el receptor de 
andrógenos (AR) y el receptor del factor de crecimiento de insulina 1 (IGF-1R) 
potencialmente impulsan la progresión del tumor; por lo tanto, la doble inhibición 
de estas vías puede representar un método prometedor para inhibir la progresión 
del CaP. 
La inhibición de la señalización de IGF-1R con un anticuerpo monoclonal 
específico anti-IGF-1R (mAb – AVE1642) ha demostrado un gran potencial en el 
tratamiento de los pacientes con CaP T2E positivos, aunque pacientes tratados con 
inhibidores anti-IGF-1R en varios ensayos clínicos solo experimentaron una 
respuesta parcial al tratamiento y sufrieron toxicidades importantes. La aplicación 




novedoso para combatir las limitaciones de las terapias actuales tanto en 
afecciones localizadas como metastásicas, y planteamos la hipótesis de que la 
modificación del AVE1642 con el polímero podría mejorar los resultados 
terapéuticos en el subtipo de pacientes de CaP T2E positivos. 
Para ello, conjugamos AVE1642 con un polipéptido biodegradable y 
biocompatible (ácido poli-L-glutámico (PGA)) para crear PGA-AVE1642, que luego 
evaluamos como un enfoque de tratamiento mejorado. Si bien nuestro objetivo era 
generar una opción terapéutica avanzada, también tratamos de comprender el 
efecto de la conjugación del PGA a un mAb con respecto a la actividad 
farmacológica in vitro e in vivo. 
Nuestros análisis in vitro iniciales mostraron una viabilidad celular similar 
en la línea celular VCaP T2E positiva tratada con AVE1642 y PGA-AVE1642, 
confirmando que la conjugación del PGA no interfiere con la función del AVE1642. 
PGA-AVE1642 mantuvo una especificidad general para las células T2E positivas, 
pero en lugar de unirse al IGF-1R e internalizarse rápidamente como ocurre con el 
AVE1642 no modificado, el PGA-AVE1642 mostró una mayor estabilidad plasmática 
y una unión más fuerte con IGF-1R, que mantuvo al PGA-AVE1642 en la membrana 
celular y evitó la internalización de IGF-1R.  
También descubrimos que la conjugación del PGA al AVE1642 alteró el 
tráfico celular; mientras que la microscopía confocal/STORM en la línea celular 
VCaP determinó que el AVE1642 colocalizaba principalmente con endosomas y 
clatrina, el PGA-AVE1642 colocalizaba en su mayoría con caveolina-1 pero no con 
endosomas, demostrando que la conjugación del PGA modifica la endocitosis 
mediada por IGF-1R, probablemente debido a una interacción diferente con el 
receptor. Además, la alteración del tráfico celular coincidió con un patrón de 
inhibición diferencial en las vías de señalización cuando se conjuga el PGA. Mientras 




PGA-AVE1642 inhibió tanto la vía PI3K como la vía MAPK, mostrando así un mayor 
efecto antitumoral.  
Los análisis posteriores in vivo en un modelo ortotópico de ratón de CaP 
recientemente desarrollado utilizando la línea celular VCaP con expresión de 
luciferasa revelaron una mayor actividad antitumoral para el PGA-AVE1642 en 
comparación con AVE1642 utilizando una dosis equivalente. Una vez más, 
encontramos que el tratamiento con PGA-AVE1642 inhibió las dos vías de 
señalización PI3K y MAPK; sin embargo, estudios posteriores basados en el 
microambiente tumoral mostraron que el tratamiento con PGA-AVE1642 también 
presentaba una alta inhibición de la funcionalidad y madurez de los vasos 
sanguíneos tumorales, de la proliferación celular y de la angiogénesis en 
comparación con el tratamiento con el AVE1642 no modificado. 
En general, la conjugación del polímero mejora la actividad antitumoral de 
AVE1642 tanto in vitro como in vivo al aumentar la inhibición de IGF-1R, que impide 
la activación de las vías de señalización de PI3K y MAPK aguas abajo evitando la 
progresión de las células cancerosas. Además, nuestros resultados sugieren que la 
conjugación del polímero con el AVE1642 induce alteraciones en el microambiente 
tumoral en modelos tumorales de CaP, mejorando así la eficacia terapéutica.  
Para mejorar aún más el tratamiento de CaP usando PGA-AVE1642, 
buscamos evaluar un enfoque basado en la terapia de combinación a través de una 
mayor inhibición de la vía de señalización de AR utilizando abiraterona, un fármaco 
antiandrogénico. Las terapias de combinación basadas en polímeros empleando 
fármacos sinérgicos dirigidos a diferentes dianas farmacológicas proporcionan una 
mayor eficacia para atacar las células tumorales. Como primer paso hacia la 
generación de un anticuerpo conjugado con PGA, se evaluó la combinación de 




Nuestros análisis in vitro proporcionaron evidencia de un efecto sinérgico 
para ambas terapias de combinación en las células de CaP T2E positivas; sin 
embargo, con respecto al crecimiento del tumor primario solo encontramos 
sinergia para el AVE1642 en combinación con abiraterona in vivo, pero no para el 
PGA-AVE1642. Esto se debe muy probablemente al mecanismo molecular 
diferencial logrado en la conjugación que ya está proporcionando el papel que 
desempeña la abiraterona en los tumores de CaP positivos para T2E. Ambas 
terapias de combinación (AVE1642 o PGA-AVE1642 con abiraterona) 
proporcionaron una doble inhibición de las vías de señalización PI3K y MAPK in vivo. 
La exploración sobre el efecto en el microambiente tumoral está aún en curso, ya 
que, aunque no sean sinérgicas, se han encontrado diferencias significativas 
cuando la abiraterona está presente no sólo de forma libre sino también en 
combinación con el conjugado AVE1642. 
En general, nuestros estudios han demostrado que la conjugación del 
polímero a un anticuerpo monoclonal altera su funcionalidad y mejora su capacidad 
antitumoral. Además, también proporcionamos evidencia de la eficacia antitumoral 
de una nueva terapia de combinación potencialmente interesante para el CaP 








































The long-term objective of this Ph.D. thesis is the development of advanced 
therapeutics for the treatment of advanced-stage prostate cancer (PCa) in a 
personalized manner, which currently represents an unmet clinical need.  
In particular, we focused on the design and development of a biocompatible and 
biodegradable polypeptide-based-antibody conjugate (PGA-AVE1642) to block  
IGF-1R to improve therapeutic outcomes in the T2E-positive PCa subtype. 
Furthermore, based on the reciprocal negative feedback between androgen 
receptor (AR) and PI3K/Akt signaling pathways, we also aimed to study a 
combination therapy comprising the combination of AVE1642 or PGA-AVE1642 
with abiraterone to promote a stronger inhibition of both pathways - a strategy 
that could represent a promising means to treat advanced PCa.  
These main objectives will be achieved through the following specific objectives:  
1. The development, synthesis, and chemical characterization of a new 
polymer-based conjugate using a biodegradable and multivalent polymeric 
carrier (poly-L-glutamic acid or PGA) conjugated to a human monoclonal 
antibody anti-IGF-1R (AVE1642) for the treatment of metastatic castration-
resistant prostate cancer (mCRPC). The full characterization of  
PGA-AVE1642 will employ a range of techniques (e.g., SEC, DLS, and  
FUV-CD) to determine parameters such as size, charge, and structure. 
2. The study of the influence of PGA conjugation on AVE1642 stability by 






3. The determination of AVE1642/PGA-AVE1642 cytotoxicity and any 
dependence of cytotoxic activity on the ERG overexpression associated 
with the presence of the T2E fusion gene in various PCa cell lines and 
normal prostate cells. 
4. The study of how PGA conjugation influences cellular trafficking and the 
cellular fate of AVE1642 in vitro by confocal/STORM microscopy in the VCaP 
cell line by labeling of AVE1642 and PGA-AVE1642 with different 
fluorophores. 
5. The investigation of the molecular response of AVE1642 and PGA-AVE1642 
in vitro in the VCaP cell line by protein analysis.  
6. The design and optimization of a suitable in vivo orthotopic mouse model 
of advanced PCa using the VCaP cell line transfected with luciferase, which 
will be used to prove the anti-tumoral activity of AVE1642 and  
PGA-AVE1642, via monitor tumor progression by optical imaging (IVIS 
Spectrum®). Tumors will also be assessed at the protein level to explore the 
potential different molecular responses to AVE1642 and PGA-AVE1642 
treatments. 
7. The evaluation of tumor microenvironment alterations, such as blood 
vessel functionality and maturity, tumor proliferation, and angiogenesis, 
following AVE1642 and PGA-AVE1642 treatment by 
immunohistochemistry.  
8. The study of the synergy between AVE1642/PGA-AVE1642 with 
abiraterone in vitro and in vivo, while evaluating the dependence of both 


















































I.1. Prostate Cancer  
I.1.1. Prostate Cancer Prevalence 
Cancer relates to a set of related diseases in which cells proliferate without 
control and suffer from cell cycle deregulation. Given the involvement of distinct 
tumor-specific oncogenes, each cancer type may require a distinct treatment 
approach. 
Cancer incidence has recently increased drastically due to several factors, 
including increased life expectancy, improvements in diagnosis, and increased 
exposure to several risk factors. According to the estimate of cancer incidence and 
mortality produced by the International Agency for Research on Cancer using the 
GLOBOCAN 2018 platform (male and female sexes combined), lung cancer 
represents the most commonly diagnosed cancer and the leading cause of death. 
This is followed by breast, colorectal, and prostate cancer (PCa) with regards to 
incidence, and colorectal, stomach, and liver cancer regarding the leading cause of 
death [1].  
PCa is the second most frequent cancer in men and the fifth cause of cancer 
deaths around the world [2, 3] (Figures 1.A and B) and the most commonly 
diagnosed cancer in Europe (Figures 1.C and D). 2018 alone saw 1.3 million new 
cases of PCa [3], mostly in men over the age of 65, with a higher prevalence among 
white men and men of African origin [4]. Fortunately, an early diagnosis can provide 
a better prognosis; however, the metastatic form of PCa, mainly affecting the lymph 
nodes and bones, remains challenging to treat and presents with high levels of 





Figure 1: Estimated Prostate Cancer Incidence and Mortality Worldwide (2018).  
A) Estimated number of new cases of different cancers in males. B) Estimated number of 
deaths in different cancers in males. C) Estimated number of new cases of PCa. D) Estimated 
number of deaths from PCa. Adapted from GLOBOCAN 2018. 
I.1.2. Stages and Cellular Classification in Prostate Cancer Progression 
Normal prostate cells are composed of two generic cell types - stromal and 
epithelial cells. Stromal cells include fibroblasts and smooth muscle cells, while 
epithelial cells comprise luminal, basal, and neuroendocrine cells [6]. PCa originates 
from epithelial cells located in the peripheral area of the prostate gland, which 
subsequently spread to the prostate capsule and seminal vesicles before eventually 
metastasizing to the bones and lymph nodes [7]. 
The known stages of PCa progression include prostate intraepithelial 




biological processes and molecular changes characterizing each phase. PIN, a 
precursor to carcinoma, is characterized by telomere shortening, as well as the loss 
of Homeobox protein NKX3-1 expression, the presence of a Transmembrane Serine 
Protease 2: ETS-related gene (TMPRSS2:ERG) fusion gene, mutations to the 
Speckle-type Poz Protein (SPOP) gene, and deregulation of the erythroblast 
transformation-specific (ETS) family of transcription factors. Additionally, PIN 
differs from invasive adenocarcinoma by a lack of stromal invasion and the 
possession of an intact basal membrane [8-11]. Invasive adenocarcinoma occurs 
due to luminal cell hyperproliferation, the loss of the basal epithelium and 
breakdown of the basal membrane, and immune cell infiltration. During this stage, 
the telomerase holoenzyme becomes active, while the cell loses phosphatase and 
tensin homolog (PTEN) and retinoblastoma protein (pRb) function [8-11]. Finally, 
the transition to metastasis involves the loss of epithelial-mesenchymal transition 
(EMT) and the passage of cells into the vascular or lymphatic system that allows for 
tumorigenic seeding in the bones as primary metastases or lung, liver, or pleura as 
secondary metastases [8-11]. At the genetic levels, metastatic PCa cells present 
with the amplification of the proto-oncogene c-Myc, the serine peptidase Hepsin 
(HPN), the proto-oncogene serine/threonine Kinase Pim1, and the epigenetic 
modifying enzyme Enhancer of Zeste Homolog 2 (EZH2) and the loss of  





Figure 2: Prostate Cancer Progression. PCa progression arises from luminal cells located in 
a normal human prostatic duct (1) to PIN (precursor lesions) (2), invasive adenocarcinoma 
(3), and finally metastasis to bone or lymph nodes (4). Adapted from [8-11]. 
Another means to evaluate PCa progression employs the Gleason score - a 
histological assessment of the appearance and distribution of tumor glands. Glands 
are classified into five distinct categories ranging from well-differentiated glands 
with non-invasive cells to aggressive neoplasms with no glandular differentiation. 
Prostate tumors usually present with an appearance and distribution indicative of 
different stages; for this reason, the total score is calculated based on the 
assignation of two categories to each patient being the first number assigned, the 
most common grade in the tumor (Gleason score 1-5), and the second number 
assigned, the following highest grade (Gleason score 1-5). These two numbers are 
then combined to produce a total score for the cancer, which currently is classified 
in five different grades; grade 1 (Gleason score 3+3=6), grade 2 (Gleason score 




(Gleason score 9-10)). Patients with Gleason scores of 2-4 have a good prognosis as 
this represents the initial stages of PCa, while a score of 6 marks less aggressive 
tumors, and a score of 7 marks intermediate tumors. Gleason scores of 8-10 
indicate the presence of aggressive tumors, and patients in this bracket suffer from 
the worst prognosis (Figure 3) [12].  
As mentioned with regards to Gleason scores, heterogeneity characterizes 
PCa at the level of individual tumors, and also between patients. Therefore, genetic 
profiling forms an integral part of treatment.  
 
Figure 3: Gleason Score Grading and Prostate Cancer Progression. Glands that are small, 
close together, uniform, and with minimal signs of cancer are graded with a Gleason score 
of 1. A score of 2 is related to larger glands, still separated by stroma. Notable changes in 
glandular size, which are even further apart, correspond with Gleason score 3, while a score 
of 4 is used when cells have lost their ability to form glands. In Gleason score 5, cells are 





I.2. Prostate Cancer Biomarkers and Sub-molecular 
Classification 
Despite recent advances made in the early detection and treatment of 
localized PCa, the number of deaths caused by this cancer type remains alarmingly 
high. Two main factors are responsible for this fact; the absence of validated and 
predictive biomarkers with a clinical utility in early diagnosis and molecular  
sub-classification of PCa, and the lack of precise and personalized therapies [14].  
The rapid evolution of PCa disease and the absence of effective therapies 
is associated with tumor heterogeneity. Heterogeneity arises from the continual 
variations in the cancer cell genome, leading to the appearance of new tumor 
clones and sub-clones under pressures of external factors [15]. For these reasons, 
the prevalent and heterogeneous nature of PCa requires more precise diagnostics, 
the characterization of malignant potential, and treatment monitoring. The 
identification of PCa at the earliest stage and the optimal choice of a treatment 
modality will provide the best therapeutic outcomes. 
The blood-based biomarker prostate-specific antigen (PSA) detection, a 
glycoprotein enzyme produced exclusively by the prostate gland and encoded by 
the kallikrein 3 gene (KLK3), digital rectal examination, and prostate tissue biopsy 
represent the current clinical tools generally employed to diagnose PCa [16]. 
While PSA-based tests, which first met US FDA approval in 1986, 
revolutionized PCa management and reduced mortality due to early disease 
detection [16], PSA represents a prostate biomarker rather than a PCa biomarker. 
The normal prostate expresses low levels of PSA; however, PSA levels rise due to 
the architectural disruption caused by PCa, but also by benign prostate diseases 
such as prostatitis or benign prostatic hyperplasia [17, 18]. Moreover, two 




for Prostate Cancer [ERSPC] and the Prostate, Lung, Colorectal and Ovarian Cancer 
Screening Trial [PLCO]) recommended against PSA-based screening for PCa due to 
its propensity to provide false-positives and false-negatives [19]. Therefore,  
PSA-based diagnoses do not permit the accurate formulation of treatment 
strategies, a situation that can lead to both under- and over-treatment of patients. 
Overall, the choice of treatment cannot be made using PSA levels alone, 
highlighting the need for the identification of additional biomarkers. 
In recent years, common genetic alterations have been detected in PCa 
samples, such as mutations in AR, alterations in the genes responsible for repairing 
damaged DNA, and fusion genes involving the ETS family transcription factors. In 
addition, constantly evolving technologies have advanced the detection of 
biomarkers from blood and urine samples of PCa patients, which have led to the 
development of new treatment approaches [20].  
An ideal PCa biomarker should integrate information regarding molecular 
subtyping, the biology of disease, and prognosis to guide treatment approaches in 
a quick, easy, and economical manner. Herein, we provide a summary of recently 
identified biomarkers for PCa.  
Integrating genomic, transcriptomic, epigenetic, and metabolomic data has 
led to the description of a rising number of next-generation PCa biomarkers, 
supposing a significant leap forward in PCa clinical management. Furthermore, 
these advances have applications in tumor sub-molecular classification, which 
represents the next crucial step with relevant clinical implications, by increasing the 
accuracy of clinical decision-making and fostering the development of precision 
therapies via patient stratification.  
Next-generation PCa biomarkers include the Prostate Cancer Antigen 3 




mutations and loss of function in PTEN [24]; and chromosomal rearrangement such 
as TMPRSS2:ERG [25].  
PCA3, a highly PCa-specific long non-coding RNA (lncRNA) highly expressed 
in prostate tumors (>95%) [26], was established as a biomarker for PCa by 
Bussemarker et al. [27].  PCA3 controls the transcriptional regulation of AR target 
genes, and, therefore, controls PCa cell growth and survival [28, 29]. In 2012, the 
FDA authorized the use of a commercial kit (PROGENSA™, San Diego, USA) for the 
detection of PCA3 [30] in urine and prostatic fluid.  
The SCHLAP1 lncRNA, highly expressed in aggressive prostate tumors and 
also associates with prostate tumor recurrence and metastasis, suppresses the 
function of tumor suppressor genes [22, 31, 32]. SCHLAP1 can be detected in the 
urine, thereby providing for non-invasive detection.  
The AR-V7 possesses a deletion in exon 7, and its detection in circulating 
tumor cells (CTCs) can be used as a measure of treatment responses in CRPC 
patients [23, 33]. 
Specific and recurrent genomic variations also suppose a potential strategy 
for PCa molecular sub-classification. Mutations and loss of function in the PTEN 
tumor suppressor gene occur in a high percentage of prostate tumors [34]; this 
leads to PI3K signaling pathway activation, Akt phosphorylation, and increased 
tumor cell proliferation and survival. Loss of PTEN function occurs in 50% of 
prostate tumors, with patients suffering from poor prognosis in PCa patients due 
to increased resistance to anti-androgenic treatment [34, 35]. PI3K/Akt activation 
demonstrates the importance of this signaling pathway in PCa and is now 
considered a promising therapeutic target for PCa [36].  
Moreover, insertional chromosomal rearrangements and 




formation of fusion genes. The formation of TMPRSS2-ETS fusion genes derive from 
chromosomal rearrangements common to PCa [37]. While rearrangements have 
been detected between TMPRSS2 (21q22) and ETS family members such as ERG 
(21q21), ETV1 (7p21), ETV3, and ETV4 (17q21) [38], the rearrangement between 
TMPRSS2 (exon 1) and ERG (exon 4) to form the T2E fusion gene is the most 
common. TMPRSS2 encodes a serine protease expressed in PCa cells, whereas ERG 
encodes an oncogenic protein involved in the development of PIN into carcinoma 
and functions in the regulation of the cell cycle and DNA replication [16]. TMPRSS2 
and ERG are located in the same chromosome 21 [39, 40] (Figure 4), and T2E 
formation occurs due to the deletion of those genes lying between them or from a 
chromosomal translocation. The T2E fusion gene comprises the 5´ regulatory 
regions of the TMPRSS2 gene, which contains numerous consensus AR binding 
sites, controlling the expression of the ERG gene [39]. In the presence of the T2E 
fusion gene, androgens drive the expression of ERG, leading to ERG overexpression 
in androgen-dependent tumors [41]. T2E expression is observed in approximately 
50-70% of PCa patients, defining a particular T2E PCa subtype that is indicative of 
poor prognosis [42]. Those PCa patients positive for T2E expression can be treated 
specifically with therapies focused on ERG gene overexpression [43]; however, 
recent scientific studies have also demonstrated a relationship between T2E 





Figure 4: TMPRSS2-ERG Rearrangement and ERG Overexpression. The T2E fusion gene 
occurs via the deletion of those genes lying between the ERG and TMPRSS2 or by a 
chromosomal translocation. The androgen-regulated promotor of TMPRSS2 then drives 
ERG overexpression and the subsequent expression of ETS target genes.  
This doctoral thesis focuses on of the generation of personalized 
nanomedicines for the TMPRSS2-ERG fusion gene expressing PCa subtype. 
I.3. Role of Insulin-Like Growth Factor System in Prostate 
Cancer 
Various growth factors, such as insulin growth factor (IGF) and epidermal 
growth factor (EGF), are important mitogens for PCa. Growth factors bind to the 
tyrosine kinase receptors (TKRs) located in the cellular membrane to activate 
downstream signaling pathways, including mitogen-activated protein kinases 
(Ras/Raf/MAPK) and Phosphoinositide 3-kinase, protein Kinase B, and mechanistic 
target of rapamycin (PI3K/Akt/mTOR) to promote PCa cell growth and proliferation. 
IGF-1R plays a vital role in both normal prostate gland growth and cancer 
development and progression. Studies of IGF signaling in human PCa suggests that 




The IGF signaling pathway comprises various TKR, such as IGF-1R and INSR 
(INSR-A and INSR-B), and non-TKR such as IGF-2R. The primary ligands for these 
receptors include IGF-1, IGF-2, and insulin [46, 47]. Moreover, Insulin-like Growth 
factor Binding Proteins (IGFBPs) bind to IGFs to aid their transport and protection 
[48, 49].  
  IGF-1R, a transmembrane TKR, comprises two extracellular α-chains  
(130 kDa) and two transmembrane-intracellular β-subunits (95 kDa) formed into a 
disulfide-linked α2-β2 heterodimeric glycoprotein complex. The α-chains form the 
growth factor binding site while the β-subunits possess intrinsic tyrosine kinase 
activity. IGF-1R displays a 60% sequence homology to the insulin receptor (INSR) 
and possesses a higher affinity for IGF-1 and significantly lower affinity for IGF-2 
and insulin [46, 48]. IGF-2R is a monomeric transmembrane protein consisting of a 
large extracellular domain and short cytoplasmic tail. IGF-2R displays multiple 
similarities to the mannose-6-phosphate-receptor acts in the transport of 
lysosomal enzymes and possesses high affinity for IGF-2. Additionally, IGF-2R lacks 
tyrosine kinase activity and does not transduce mitogenic IGF-2 signals [46].  
Both IGF-1 and insulin can bind to hybrid receptors (IGF-1R/INSR-A or  
IGF-1R/INSR-B), but with significantly lower affinity when compared to IGF-1R and 
INSR homodimers. While, for example, IGF-1 binding to IGF-1R promotes receptor 
homodimerization, binding of IGF-1 to hybrid receptors promotes 





Figure 5: Insulin Growth Factor Family. The IGF system is composed of TKRs such as  
IGF-1R, INSR-A, INSR-B, and hybrid receptors IGF-1R/INSR-A/B and non-TKRs such as  
IGF-2R. IGF-1 ligands bind to IGF-1R and hybrid receptors, IGF-2 ligands bind to IGF-2R,  
IGF-1R, and INSR-A, and insulin ligands bind to hybrid receptors, INSR-A, and INSR-B.  
I.3.1. IGF-1R Signaling Pathways and Internalization 
IGF-1/IGF-2 binding to IGF-1R prompts autophosphorylation of the tyrosine 
kinase domain due to conformational changes to the receptor that activates the  
β subunits kinase domain. Subsequent PI3K/Akt/mTOR and Ras/Raf/MAPK 
signaling pathway activation occurs through binding to intracellular adaptor 
proteins, including insulin receptor substrate 1 (IRS1) and Shc [48].  
IRS-1 is activated by IGF-1R, and then binds to the p85 subunit of PI3K to 
promote the synthesis of phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 then 
activates protein kinase B (Akt), which activates mTOR to regulate cell growth, 
survival, and cell cycle regulation and avoid pro-apoptotic signaling [50]. The 
phosphatase PTEN regulates this pathway through the dephosphorylation of PIP3; 
therefore, the loss of PTEN activity increases PIP3 levels and activates mTOR 
signaling. However, Shc activation promotes the movement of small G protein Ras 
and protein serine kinase Raf to the inner cell surface through the son-of-sevenless 




signaling pathway, resulting in the transcription of genes related to cell 
proliferation (such as cyclins type D) in addition to promoting cell differentiation via 
transduction of mitogenic signals by ETS like-1 (ELK-1) transcription activator  
[46, 50]. The existence of crosstalk between the PI3K/Akt/mTOR and Ras/Raf/MAPK 
signaling pathways leads to compensatory activatory/inhibitory mechanisms [51] 
(Figure 6).  
Following internalization after ligand binding, IGF-1R becomes directed to 
the endosomal system where are processed for return to the plasma membrane 
(recycling), or undergo to the lysosomes, or can translocate to the nucleus after 
IGF-1R SUMOylation to promote IGF-1R target gene activation [52-54] (Figure 6). 
Of note, activation of the IRS-1 signaling pathway does not require IGF-1R 







Figure 6: Insulin Growth Factor-1 Receptor Signaling Pathway. IGF-1R activation due to 
IGF-1 binding promotes the phosphorylation and activation of the PI3K/Akt/mTOR and 
Ras/Raf/MAPK signaling pathways, which elicit differing biological effects. These signaling 
pathways regulate each other via compensatory mechanisms (red line). IGF-1R 
internalization promotes Shc phosphorylation and MAPK pathway activation followed by 
IGF-1R degradation, recycling to the cellular membrane, or translocation to the nucleus 
after transport through the endosomal pathway. 
IGF-1R internalization is mediated by both clathrin-dependent and 
caveolin-1-dependent endocytic pathways. Inhibition of both internalization routes 
in Ewing’s sarcoma and HaCaT cells blocks IGF-1R internalization [56, 57]. 
Interestingly, clathrin-mediated endocytosis regulates both Ras/Raf/MAPK and the 
PI3K/Akt/mTOR signaling pathways, whereas caveolin-1-mediated endocytosis 
regulates only the PI3K/Akt/mTOR signaling pathway. In the case of caveolin-1-




phosphorylation, which then promotes IRS-1 phosphorylation and PI3K/Akt/mTOR 
pathway activation [58]. In contrast, clathrin-mediated endocytosis promotes Shc 
and IRS-1 phosphorylation, thereby activating the Ras/Raf/MAPK and 
PI3K/Akt/mTOR signaling pathways, respectively [56] (Figure 7).  
 
Figure 7: Model of IGF-1R pathway Regulating Endocytosis. A) Schematic representation 
of clathrin-internalization-dependent IGF-1R signaling. B) Schematic representation of 
caveolin-internalization-dependent IGF-1R signaling. 
I.3.2. Feedback Regulation between Phosphoinositide 3-kinase and 
Androgen Receptor Signaling Pathways 
PCa is characterized by its dependence on AR and the activation of the PI3K 
signaling pathway, and these two oncogenic pathways regulate each other by 
reciprocal negative feedback to control tumor growth; when one pathway is 




promotes the activation of human epidermal growth factor receptor 2/3 (HER2/3) 
by reducing the inhibitory effect of mechanistic target of rapamycin complex 1/2 
(mTORC1/2) on HER2/3. This effect allows AR pathway activation in the absence of 
androgens through the AR phosphorylation by Akt downstream HER2/3 signaling 
pathway and subsequent AR binding to ARE target sequences [59, 60]. 
In contrast, AR inhibition leads to a decrease in FK506 binding protein 5 
(FKBP5) protein levels, which then inactivates the PH domain and Leucine-rich 
repeat Protein Phosphatases (PHLPP), thereby causing phosphorylation of the Akt 
Ser-473 and the activation of Akt signaling (Figure 8).  
 
Figure 8: Crosstalk Between the Androgen Receptor and Phosphoinositide 3-kinase 
Signaling Pathways. Inhibition of the PI3K signaling pathway stimulates HER2/3 receptor 
promoting AR phosphorylation and activation, while AR inhibition decrease FKBP5 levels 
leading to Akt phosphorylation and activation. Adapted from [61]. 
I.3.3. The Role of Insulin Growth Factor-1 Receptor in Prostate Cancer 
Development  
While IGF-1R participates in the growth and development of normal 
prostate glands, it also plays a role in tumorigenic initiation. High IGF-1 levels and 
low IGFBP-3 levels associate either a greater predisposition for PCa development 
[62]. Furthermore, the relation between the T2E fusion gene and IGF-1R was 




presence of androgens via an androgen-responsive promoter located in TMPRSS2, 
leading to increased ERG levels. In addition, the overexpressed ERG binds directly 
to the IGF-1R promoter region, and thus increases the IGF-1R expression.  
Additionally, T2E expression correlates with higher IGF-1R expression at the 
mRNA and protein level (Figure 9) [63].  
 
Figure 9: ERG Overexpression is Related to Insulin Growth Factor-1 Receptor 
Transcription. AR binds to the TMPRSS2 promoter region, which induces ERG 
overexpression via the T2E fusion gene. In turn, ERG transcriptionally activated IGF-1R 







These findings provide the rationale followed in this doctoral thesis and 
our studies on the mechanism of action and cellular trafficking in order to 
determine the signaling pathway with an anti-IGF-1R-targeted monoclonal 
antibody. Furthermore, due to AR and PI3K oncogenic pathways cross-regulation 
by reciprocal feedback, we aimed to evaluate a combinatorial therapy based on 
the administration of an anti-androgen drug and an anti-IGF-1R therapy in an 
orthotopic PCa mouse model, in the hope of a synergistic anti-cancer effect. 
I.4. Castration-resistant Prostate Cancer  
Almost  all PCa cases are adenocarcinomas; malignant tumors formed from 
glandular structures in epithelial tissue. Primary or localized PCa present a wide 
range of treatment options that vary according to patient age, clinical tumor stage, 
PCa biomarker levels, or Gleason score. Radical prostatectomy and radiotherapy 
(external beam therapy or brachytherapy) represent standard local treatments for 
localized PCa. Regardless of the initial positive results of these therapies, the 
recurrence of the disease occurs in one-third of patients. At this stage of recurrent 
and advanced PCa, androgen deprivation therapy (ADT) represents the current 
gold-standard treatment [64]. ADT is based on surgical or chemical castration 
through the administration of different drugs such as luteinizing hormone-releasing 
hormone (LHRH) agonist/antagonist, AR antagonists, or androgen synthesis 
inhibitors, which will be described in more detail below.  
PCa is considered a hormone-dependent tumor in which the AR is needed 
to promote tumor progression; however, patients can develop treatment 
resistance and display tumor relapse after 18-24 months. The resulting CRPC, 
previously known as hormone-refractory PCa [65-67], still displays a response to 




I.4.1. Molecular Mechanisms Involved in Castration-Resistant Prostate 
Cancer 
The understanding of the molecular mechanisms involved in CRPC 
development includes AR-dependent mechanisms, AR-independent mechanisms 
and AR-bypassing signaling, as described below, will aid in the development of 
novel therapeutics [69].  
I.4.1.1. Androgen Receptor-dependent Mechanisms 
Androgens, such as the hormones testosterone and dihydrotestosterone 
(DHT), bind to the AR and help to mediate PCa progression. AR, which becomes 
overexpressed in CRPC patients, exhibits four different functional domains; the 
ligand-binding domain (LBD), DNA-binding domain (DBD), hinge area, and the 
variable region (amino-terminal domain, NTD), with the latter domain presenting 
phosphorylation sites that promote AR activation [70]. In the absence of androgens, 
the inactive AR localizes mainly to the cytoplasm and interacts with heat shock 
proteins (HSPs) to avoid nuclear transport. DHT, which is converted from 
testosterone by the 5α-reductase enzyme, binds to the AR through the LBD, 
promoting changes to the AR conformation. These changes allow the release of 
HSPs and the subsequent phosphorylation of AR, causing AR dimerization and 
successive translocation into the nucleus. The AR then binds to androgen response 
elements (AREs) located in the promoter/enhancer regions of genes that promote 
cell proliferation, activate anti-apoptotic pathways, and regulate several 
androgenic genes such as prostate-specific antigen (PSA) or TMPRSS2:ERG fusion 
gene (Figure 10.A) [71]. 
Several aspects of the AR-dependent response can explain CRPC evolution, 
including the amplification of the AR gene, overexpression of the AR protein, AR 




of AR co-regulators, and synthesis of adrenal androgens and intratumoral 
androgens [72]. 
High AR protein expression via AR gene amplification represents a common 
occurrence in CRPC patients [73, 74]. AR overexpression leads to receptor 
hypersensitivity, thereby allowing low levels of androgens to prompt heightened 
tumor cell proliferation [75].  
AR mutations are more common in advanced PCa stages than in early-stage 
disease, and while more than 100 mutations have been documented, the most 
prevalent mutations occur in the NTD and LBD regions. Most of NTD mutations 
occur following ADT and increase AR response to DHT; furthermore, mutations in 
the LBD region increase AR activity and decrease ligand specificity [76, 77]. Other 
mutations in the LBD region can alter AR antagonist properties changing the 
effectiveness of treatments; in this way, AR antagonists can act as agonists and thus 
promote tumor growth [77]. The most frequent AR mutation (T878A) increases the 
binding sensitivity of AR for steroid hormones, such as progesterone and estrogen 
[78].  
AR-Vs present in the cytoplasm and the nucleus include truncated AR forms 
lacking the LBD regions prompting the activation of the NTD and DBD regions in a 
stimuli-insensitive manner [79]. Therefore, said AR-Vs (AR-V 1-7) promote AR target 
gene activation and transcription independently of the presence of androgens [80]. 
Of note, the nuclear-localized AR-V7 is the most abundant truncated form of AR in 
CRPC patients and associates with a worse prognosis [81].  
 The altered expression of AR co-regulators can modify the transcriptional 
activity of AR, indicating that these co-regulators may regulate CRPC progression. 
Most co-regulators are enzymes that regulate other proteins by phosphorylation, 
methylation, acetylation, or ubiquitination [82]. Co-regulators can be divided into 




of the AR [83], while the loss of co-repressor expression or function can lead to an 
increase in AR-mediated gene transcription [84]. 
As 90% of testosterone is produced in the testicles (with the remaining 10% 
generated in the adrenal glands), medical and surgical castration can reduce 
testosterone levels in the blood; however, CRPC still develops in this situation, 
suggesting the existence of an alternative androgen production pathway [85, 86]. 
Indeed, studies have found that prostate tumor cells convert adrenal androgenic 
precursors such as dehydroepiandrosterone (DHEA) and sulfated-
dehydroepiandrosterone (DHEA-S) into DHT to support their own growth; this 
represents one of the so-called “back-door” pathways of androgen synthesis. ADT 
does not affect DHEA/DHEA-S levels, and 3β-hydroxysteroid dehydrogenase 
(3βHSD1) and 3-beta-hydroxysteroid dehydrogenase type-2 (3βHSD2) enzymes 
converts them into androstenedione (AD) in the suprarenal glands and prostate, 
respectively [87]. Next, the primary and the secondary “back-door” pathways 
prevalent in CRPC uses androstanediol and 5α-androstenedione (5α-dione) 
respectively to convert AD into DHT, bypassing testosterone synthesis. Additionally, 
tumor cells can also produce androgens by de novo synthesis from cholesterol [85, 
88, 89].  
I.4.1.2. Androgen Receptor-independent Mechanisms 
CRPC evolution results from the failure of ADT, which inhibits AR-driven 
proliferation and survival pathways by targeting the AR signaling axis. Reactivation 
of AR through the androgen-dependent mechanisms describe above has been 
identified as the primary driver of CRPC. Androgen-independent signaling pathways 
can provide additional mechanisms supporting CRPC development [90]. Androgen 
receptor-independent mechanisms involved in CRPC development (Figure 10.B) 
can be divided into three different pathways; the PI3K/Akt/mTOR, Src, and Growth 




Activation of PI3K/Akt/mTOR pathway through G-protein-coupled 
receptors (GPCRs) or TKRs promotes proliferation, cell, survival, and angiogenesis 
in CRPC [91, 92]. The loss of expression of PTEN tumor suppressor, via mutations, 
promoter methylation, microRNA interference, phosphorylation, or delocalization 
from the plasma membrane [93-95] activate the PI3K/Akt/mTOR pathway [96, 97]. 
The activation of the Src proto-oncogene tyrosine-protein kinase signaling 
pathway during CRPC development promotes cell growth, inhibition of  
anti-apoptotic pathways, and tumor progression regardless of androgen levels [98]. 
Furthermore, this pathway promotes angiogenesis via the regulation of vascular 
endothelial growth factor (VEGF) and interleukin 8 (IL-8) expression by the 
induction of metallopeptidase 9 (MMP-9) [99-101]. Additionally, Src signaling can 
activate nuclear factor KB (NFkB) to promote bone metastasis of PCa [102].  
In the absence of androgens or in the presence of extremely low levels of 
androgens, AR can still be activated and translocated into the nucleus to promote 
cell survival, tumor growth, and CRPC evolution. AR activation occurs through the 
actions of various growth factor receptors, such as IGF-1R, epidermal growth factor 
receptor (EGFR), and interleukin 6 receptor (IL-6R), which can all activates PI3K, 
MAPK, and signal transducer and activator of transcription 3 (STAT3) pathways 
[103, 104]. Activation of AR via phosphorylation occurs thanks to various 
mechanisms depending on the pathway involved. Activated IGF-1R, via IGF-1 
binding, interacts with AR through integrin beta (β1A) [105]. In the case of IL-6R, a 
physical interaction between STAT3 and AR promotes AR phosphorylation [106]. 
EGFR activation induced by EGF ligand binding promotes MAPK signaling pathway 





Figure 10: Schematic of Androgen-dependent and -independent Signaling. A) Androgen-
dependent Signaling. Testosterone is transformed into DHT by the 5α-reductase enzyme; 
DHT then binds and activates AR so prompting the release of HSPs. AR then dimerizes and 
translocates to the nucleus to bind ARE sequences to promote the expression of  
PCa-associated genes. B) Androgen-independent Signaling. Protein kinase signaling 
pathways promote androgen-responsive gene transcription by activating the PI3K, MAPK, 
and STAT3 signaling pathways. 
I.4.1.3. Androgen Receptor-bypassing Signaling 
AR-bypassing signaling is based on the activation of AR transcription genes 
which promote tumor proliferation through others steroids hormone nuclear 
receptors different from AR. Steroid hormone nuclear receptors such as the AR, 
estrogen receptor (ER), progesterone receptor (PGR), glucocorticoid receptor (GR), 
and mineralocorticoid receptor act as transcription factors. All present a common 
structure of four domains: the NTD, DBD, hinge region, and LBD [108]. AR and GR 




genes involved in the development of CRPC [109]. Moreover, mutations to the LBD 
region of the AR (L701H and T877A) allow the AR to respond to glucocorticoids and 
promote tumor cell proliferation [77]. Furthermore, progesterone, apart from 
acting as a precursor for androgen synthesis de novo in PCa, the PGR is structurally 
related to the AR and also activates AR target genes crucial to PCa progression  
[110, 111]. The therapeutic blockade of AR promotes the increased expression of 
GR, so suggesting GR and PGR as therapeutic targets for PCa treatment as both 
steroid receptors play an essential role in the development of CRPC (Figure 11) 
[112].  
 
Figure 11: Schematic of Glucocorticoid Receptor Activation through Androgen Receptor 
Suppression. AR inhibition by enzalutamide or abiraterone leads to increased levels of the 
GR due to the relief of AR-mediated feedback repression of GR expression, which binds to 
the same DNA region as the AR and results in the tumor progression and the transcription 




I.4.2. Castration-Resistant Prostate Cancer Therapies: Current Therapeutic 
Approaches 
Despite recent advances in PCa molecular biology that have allowed the 
improvement of current treatment strategies and the development of novel clinical 
approaches, mortality rates in CRPC patients remain high. Traditional therapies 
employed to treat CRPC include hormonal therapy, chemotherapy, 
immunotherapy, and radiotherapy.  
New hormonal therapies have been developed based on the critical role 
that AR plays in PCa. The evolution of PCa to CRPC relies on the capacity of cancer 
cells to grow with extremely low levels of androgens and is due to aberrations in 
AR that maintain transcriptional activity in the absence of the binding-ligand 
domain. Abiraterone acetate was approved by the FDA in 2011 as a treatment for 
patients with CRPC previously treated with docetaxel, based on the critical role that 
AR plays in PCa [113, 114]. Abiraterone acetate is an irreversible, highly selective 
inhibitor of Cytochrome P450 Family 17 Subfamily A Member 1 (CYP17) enzyme 
that offers clinical benefit to patients with hormone-refractory prostate cancer by 
inhibiting androgen, estrogen, and glucocorticoid synthesis in testis, adrenal glands, 
and prostate tumors. In addition, the second generation of DHT antagonist ligands 
has been designed that aim to prevent AR activation and nuclear translocation, thus 
blocking AR target genes synthesis in CRPC patients. Antagonists have a greater 
affinity for the AR, competitively binds to the ligand-domain, thereby prompting 
higher levels of inhibition. These include Enzalutamide, approved by FDA in 2012 
for mCRPC following docetaxel [115], and Apalutamide, which possesses a chemical 
structure similar to enzalutamide and was approved by FDA in 2018 for  
non-metastatic castration-sensitive PCa [116]. Interestingly, hormonal therapies 




The current recommendation for mCRPC treatment is based on the use of 
chemotherapeutic treatments include docetaxel and cabazitaxel, which were 
approved by the FDA in 2004 and 2010, respectively [117, 118]. Both drugs are 
taxanes and inhibit cell division and cause cell death by binding to microtubules to 
prevent cellular mitosis. Furthermore, taxanes also inhibit the nuclear translocation 
of AR [119, 120]. However, these strategies only provide for a median overall 
survival of 18 months due to the development of different mechanisms of 
resistance [121].  
Novel therapeutic approaches include Sipuleucel-T and Radium-223  
(Ra-223). Sipuleucel-T, the first immunotherapy for CRPC approved in 2010 by the 
FDA [122], is an autologous cellular immunotherapy (cancer vaccine) in which 
patient-derived peripheral blood mononuclear cells are cultured in the presence of 
recombinant prostatic acid phosphatase (PAP) coupled to granulocyte-
macrophage-colony-stimulating factor to prompt the maturation of antigen-
presenting cells [123]. Ra-223, an alpha therapy that specifically targets bone 
metastases, was approved by the FDA in Japan in 2013 for the treatment of CRPC 
patients [124, 125]. Ra-223 mimics calcium and binds to the bone mineral 
hydroxyapatite present in bone metastases and damages DNA, leading to an anti-
tumor effect.  
Advanced PCa is divided into three different stages - (i) metastatic 
hormone-sensitive PCa (mHNPC), (ii) non-metastatic CRPC, and (iii) metastatic 
CRPC (mCRPC) – which require different treatment approaches (Figure 12). 
mHNPC patients are treated with ADT and chemotherapies such as 
abiraterone acetate and docetaxel, non-metastatic CRPC patients are treated with 
ADT with enzalutamide or apalutamide, and mCRPC patients are treated with 
different drugs combinations depending on the first, second, or third line therapy. 




(Abiraterone/Enzalutamide) or chemotherapy (Docetaxel/Cabazitaxel), and for 
asymptomatic patient therapy is based on the use and immunotherapy  
(Sipuleucel-T). The second line for symptomatic patients is based on the use of 
chemotherapy (Docetaxel/Cabazitaxel) or radiopharmaceuticals (Ra-223), and for 
asymptomatic patient therapy is based on ADT (Abiraterone/Enzalutamide). The 
third line for symptomatic patients is based on the use of chemotherapy 
(Cabazitaxel) or radioisotope (Ra-223), and for asymptomatic patient therapy is 
based on the use of chemotherapy (Docetaxel/Cabazitaxel). 
 
Figure 12: Treatment Sequencing Strategy for Advanced Prostate Cancer. mHNPC 
therapies employ hormonal therapy and chemotherapy and non-metastatic CRPC therapies 
use hormonal therapy alone. Meanwhile mCRPC first line therapy uses a combination of 
hormonal therapy, chemotherapy and immunotherapy, while second line uses hormonal 
therapy, chemotherapy and radiotherapy, and while the third line focuses on chemotherapy 
and radiotherapy. S treatment for symptomatic patients, a treatment for asymptomatic 




I.4.3. Castration-Resistant Prostate Cancer Therapies: Potential 
Therapeutic Approaches 
Unfortunately, in spite of the increased arsenal of drugs employed to treat 
advanced PCa, a lack of targeting and efficiency has failed to improve survival rates 
and reduce side effects. However, recent advances in PCa treatment and drug 
discovery offer different treatment options and novel therapies which are being 
evaluated in clinical trials in the hope of improving therapeutic outcomes. 
Clinical trial studies have explored different targeted therapies, including 
poly ADP-ribose polymerase (PARP) inhibitors, angiogenesis inhibitors, and growth 
factor receptor inhibitors.   
I.4.3.1. PARP Inhibitors 
Damage to DNA due to exposure to ultraviolet (UV) light, ionizing radiation, 
chemicals, and cellular metabolism or derived from replication errors must be 
recognized and repaired for proper cell function. The BRCA (Breast cancer 
susceptibility protein) and PARP proteins repair DNA through homologous 
recombination repair (HRR) and nucleotide excision repair (NER), respectively; 
however, the altered expression or function of proteins involved in DNA damage 
repair can mute the DNA damage response, heighten mutation load, and promote 
the development of tumorigenesis [126]. Mutations to the BRCA1 and 2 genes lead 
to the reduced repair of DNA double-strand breaks (DSBs); however, cancer cells 
lacking functional BRCA1 or 2 can continue to grow due to the presence of PARP 
proteins that repair single-strand breaks (SSBs) [71, 72]. 
 CRPC is characterized by BRCA2 mutations [127] and suffers problems 
related to a dysfunctional DNA damage repair [128], thereby highlighting PARP 




prevent the repair of SSBs, leading to the accumulation of mutations, and eventual 
cell death [129, 130].  
The PARP inhibitor Olaparib has provided promising results in selected 
mCRPC patients in phase III clinical trials [131], while Veliparib [132], Niraparib 
[133], and Rucaparib [134] have also been studied in clinical trials alone and in 
combination with other drugs [123].  
I.4.3.2. Angiogenesis Inhibitors 
Angiogenesis, the formation of new blood vessels from other existing 
vessels, occurs in various steps [135, 136] and is regulated by a balance between 
pro-angiogenic and anti-angiogenic factors. However, an increase in pro-angiogenic 
factors, including endothelial growth factor (VEGF)-A and basic fibroblast growth 
factor (bFGF) [137-139], leads to dysregulated angiogenesis in cancer patients. 
 VEGF signaling promotes the generation of new vessels by binding to 
VEGFR, and advanced stage PCa patients present with elevated levels of VEGF-A, 
indicative of a worse prognosis for PCa patients [140]. For this reason, VEGFR 
targeting can inhibit angiogenesis in cancer patients [139, 141]. Such inhibitors can 
either prevent VEGF ligand binding to VEGFR or block the VEGFR itself to prevent 
pro-angiogenic signaling, inhibit the formation of new blood vessels, and decrease 
tumor growth and the development of metastasis.   
Examples used in clinical trials include Bevacizumab, a humanized 
monoclonal antibody that inhibits VEGF-A binding to VEGFR2 on endothelial cells 
[142], Aflibercept, a protein that binds to VEGF-A to prevent receptor binding [143], 
Sunitinib, a multi-targeted TKR inhibitor targeting VEGFR2 and Platelet-derived 





Unfortunately, anti-angiogenic therapies have not proved successful due to 
an increased rate of toxicity and adverse effects such as lymphopenia, neutropenia, 
and anemia [146]. Furthermore, treatment can also fail due to PCa heterogeneity; 
currently, we lack biomarkers that can select those patients who may benefit from 
antiangiogenic therapies. For this reason, the study of the angiogenic signaling 
pathway may provide information that allows the design of effective PCa 
therapeutics. 
I.4.3.3. Growth Factor Receptor Inhibitors 
Aberrantly increased levels of growth factors, such as EGFR, fibroblast 
growth receptor factor (FGFR), hepatocyte growth receptor factor (HGFR) and  
IGF-1R [147], bind to cell membrane receptors to promote proliferation, survival, 
and migration of PCa cells [148]. Therefore, they represent therapeutic targets for 
the inhibition of PCa tumor growth and metastasis. 
With a focus on IGF-1R, current strategies in clinical trials have been 
developed to avoid its activation, including tyrosine kinase inhibitors (TKIs), IGF 
neutralizing antibodies, and anti-IGF-1R monoclonal antibodies (mAbs). 
a) Insulin Growth Factor-1 Receptor Tyrosine Kinase Activity Inhibitors 
 IGF-1R TKIs are small molecules that nullify the effect of IGF binding to its 
receptor (IGF-1R). As the INSR-A and INSR-B receptors share some similarities with 
the IGF-1R, inhibitors may interact with all three receptor types [149]. However, 
INSR-B inhibition can modify glucose metabolism by producing hyperglycemia 
[150], and because of this, clinical studies have not yielded promising results. 
Furthermore, IGF-1R TKIs suffer from short half-lives, so they do not completely 
block tyrosine kinase activity [151]. IGF-1R TKIs in clinical trials for PCa include 




nordihydroguaiaretic Acid (NDGA) in patients with non-metastatic recurrent PCa 
and non-metastatic relapsed PCa [311].  
b) Insulin Growth Factor-neutralizing Antibodies 
Humanized IGF-neutralizing monoclonal antibodies bind to and block the 
interaction of IGF1 and IGF2 with IGF-1R, INSR-A, and the hybrids receptors  
IGF-1R/INSR-A or IGF-1R/INSR-B. This approach suffers from fewer side effects 
(such as hyperglycemia) as the homodimer INSR-B receptor is unaffected [153]. 
One mAb (Xentuzumab) that neutralizes the IGF1 and IGF2 ligands is currently 
under evaluation in clinical trials for PCa in combination with enzalutamide  
[154, 311].  
c) Anti-Insulin Growth Factor-1 Receptor Monoclonal Antibodies 
Anti-IGF-1R mAbs bind to the alpha subunit of IGF-1R to prevent IGF from 
binding to the receptor and avoid signaling pathway activation and inhibit cancer 
cell growth and proliferation [155]. mAbs also promote receptor internalization and 
degradation [155]. Of note, anti-IGF-1R mAbs possess a high specificity for IGF-1R 
with respect to the insulin receptor (INSR), although some can bind hybrid 
receptors composed of IGF-1R and INSR isoforms which forms a heterodimer 
receptor (IGF-1R/INSR-A or IGF-1R/INSR-B), thereby promoting a decrease in insulin 
receptor activity that can produce side effects such as hyperglycemia [156]. 
Unfortunately, some reports have noted that anti-IGF-1R mAbs can actually act as 
agonists, thereby promoting pathway signaling activation [157]. 
Anti-IGF-1R mAbs for PCa evaluated in clinical trials include Ganitumab in 
mCRPC [158-160], Figitumumab combined with pegvisomant for prostatic 




IGF-1R inhibitors as single agents or in combination with other therapeutic 
strategies have been evaluated in clinical trial in CRPC patients; however, patients 
only experienced a partial response to therapy due to resistance mechanisms, 
incomplete blockage of the signaling pathways, or inadequate treatment, while also 
suffering from significant side toxicities (neutropenia, diarrhea, hyperglycemia, 
etc.). For these reasons, some clinical trials of mAbs were discontinued [162, 163]. 
Of these mAbs, we sought to evaluate a modified AVE1642 in this doctoral thesis, 
as a single or combinatorial therapeutic approach, to inhibit the IGF-1R signaling 
pathway. 
I.5. Nanomedicine for PCa treatment: Principal Aspects and 
Classification  
Conventional treatments for PCa consist of surgical tumor resection, 
radiotherapy, or chemotherapy. Radiotherapy and chemotherapy treatments can 
cause damage to healthy tissues close to the tumor due to their non-specificity, low 
efficacy, and low bioavailability. Furthermore, it remains challenging to control 
pharmacokinetics due to several factors, such as the different transient states of 
the drug in adhesion, metabolism, excretion, and distribution. Chemotherapy can 
lead to the development of drug resistance; therefore, encountering new, efficient, 
personalized, and targeted treatment approaches represents a pressing concern. 
Furthermore, faster cancer progression promotes hypoxic and necrotic regions, 
which represent challenging targets for systemic treatments [164]. For this reason, 
the development of advanced therapeutics such as nanomedicines may represent 
a promising means to improve the specificity and efficacy of anti-cancer therapeutic 
agents while decreasing side effects [165, 166].  
The development of nanomedicine for anti-cancer therapies can provide 




the chemical stability of treatments, (ii) modify pharmacokinetics and 
pharmacodynamics, thereby enhancing accumulation in the pathological site (by 
the EPR passive effect [167-169] or active targeting, See Section I.6 for further 
detail) and protecting compounds from non-specific organ accumulation, 
biodegradation or excretion, (iii) improve the distribution and penetration of 
treatments by specifically targeting tumor cells allowing a controlled release of the 
drug and reduced toxicity and adverse effects on healthy cells, (iv) improve 
therapeutic efficacy and effectiveness, and (v) inhibit drug-resistance due to 
different cell  internalization mechanisms [170, 171].   
There are already more than 50 nanomedicines in routine clinical use and 
75 nanosystems in clinical trials [172]. Nanomedicine can be classified in different 
product families, which include lipid-based nanocarriers, polymer therapeutics, 
polymeric nanoparticles, crosslinked (nano) gels, bioactive synthetic 





Figure 13: Established Nanotherapeutic Platforms. Modified from [170]. 
Perhaps the most promising nanomedicinal approaches involve multivalent 
carriers that can allow the simultaneous delivery of two or more anticancer drugs 
in a synergistic ratio, thus allowing an efficient combination therapy. Relevant 
clinical milestones for combination nanomedicines include Combiplex®, a liposome 
including a combination of two chemotherapeutic agents recently approved by the 
FDA [173]. 
After adequate rational design, nanomedicines can cross biological barriers 
and transport drugs specifically to target sites thus reducing any adverse effects on 
healthy tissues. As biological barriers represent the bodies primary defense 
mechanism and block the penetration of foreign substances, the development of 




I.5.1. Biological Barriers to Nanomedicine 
First Level: Absorption 
One of the first limitations to treatments with nanomedicine is the 
distribution throughout the body via the bloodstream. Initial design strategies must 
allow nanomedicines to reach their destination and maintain their characteristics 
and integrity in response to different physiological conditions, including the 
presence of proteases, redox potential, different pH, etc. While intravenous 
injection is commonly employed and allows for adequate drug distribution, other 
administration routes, including topical administration, oral, different mucosal 
barriers, are also employed [175].  
Second Level: Circulatory Barriers 
The reticuloendothelial system (RES), the immune system, and the hepatic 
system also represent barriers to the desired output of an administered 
nanomedicine as they function to recognize and eliminate foreign objects. Loading, 
form, and size of nanomedicines are related to glomerular filtration [189]. The 
addition of polyethylene glycol moieties to nanomedicines (PEGylation) can avoid 
recognition by the RES; Doxil®, a PEGylated liposomal formulation of doxorubicin 
employed for anti-cancer treatments [177, 178], represents the first example of this 
strategy. Nevertheless, some nanoparticles present long retention times, which can 
lead to systemic toxicity causing an inflammatory reaction and decreasing 
therapeutic efficacy [176, 190]. For this reason, nanomedicines must be designed 
with suitable properties to obtain better renal filtration and thus avoid toxicity [191, 
192]. As recognition by phagocytes, another immune system component, can lead 
to nanomedicine clearance, the surface modification of nanomedicines with 





Third Level: Tissue-specific Barriers and Tumor Stroma 
Some organs exhibit specific barriers, including blood-brain, ocular, retinal, 
testis barriers, and blood-thymus barriers [175]. A detailed description of these 
barriers lies out with the scope in this doctoral thesis; however, more information 
can be found in the following references [180-184]. 
The tumor microenvironment (TME) represents the cellular environment in 
which the tumor exists and is formed by non-cancerous cells and stromal 
components, such as the extracellular matrix (ECM), blood vessels, infiltrating 
inflammatory cells, and a variety of associated tissue-specific cells [185, 186].  
The advanced design of nanomedicine to allow highly effective delivery of 
nanomedicine to tumors, has further enhanced its therapeutic benefits. However, 
these advances have not yet been able to overcome the delivery barriers of a TME 
due to a heterogeneous blood flow, dense ECM, abundant stroma cells, and high 
interstitial fluid pressure (IFP), which severely impede the vascular transport of 
nanomedicines, hinder its effective extravasation, and prevent its interstitial 
transport to achieve an equal distribution within tumors [185, 186]. Therefore, 
modulation of tumor microenvironment, including different strategies such as 
improving tumor perfusion, facilitating tumor extravasation, or enhancing 
interstitial transport, has now emerged as an important strategy to improve 
nanomedicine delivery to tumors [309]. 
Fourth Level: Cellular Barriers 
Nanomedicines can internalize into the cell using routes that depend on 
molecular weight (Mw). Passive diffusion occurs when the Mw of the nanomedicine 
is less than 1KDa, while nanomedicines with a Mw higher than this internalize 





Fifth Level: Subcellular Barriers 
While the nucleus and the mitochondria represent challenging organelles 
to target, nanomedicines display certain advantages that can make therapeutic 
targeting possible [175]. Endocytic processes define the cellular trafficking of 
nanomedicines to different nanomedicines follow an endocytic pathway by 
clathrin-mediated endocytosis for transport to the lysosome, which can allow for 
nanomedicine degradation and drug release in the case of polymer/peptide-based 
nanomedicines (described below) [175]. In clathrin-mediated endocytosis, only 
endosomal escape ensures access of the nanomedicine to the proper target 
organelle. Moreover, nanomedicines can also be targeted to the peroxisomes or 
reticulum endoplasmic; in these cases, the incorporation of specific targeting 
sequences are required [187, 188]. 
 
Figure 14: Biological barriers represented at five various levels. The blood-brain barrier 
(BBB). Adapted from [175].  
I.5.2. Current Studies in Nanomedicine for Prostate Cancer 
Apart from the general biological barriers described above, the design of 




(i) anatomical barriers; the prostate is divided into different regions, which are 
regulated by androgens, (ii) physiological barriers; disease progression variations 
occur in the lymphatic system affecting the transport of the drug, and (iii) cellular 
and molecular barriers; PCa physiopathology affects the distribution of drugs [193]. 
Ongoing research regarding these physiological barriers and a greater 
understanding of the disease have prompted the design of nanomedicinal and 
strategies for PCa treatment (See Table 1). Nanoparticle formulations displayed 
decreased toxicity in patients, while the nanoencapsulation of chemotherapeutic 
agents improved their bioactivity leading to an increase in the specificity and 
efficacy of the drug [194].  
Table 1: Examples of nanomedicines for the treatment of PCa. Adapted from [194]. 
Nanomedicinal approaches to PCa treatment often take advantage of 
specific proteins overexpressed on the cancer cell surface, a strategy that aims to 
boost therapeutic outcomes and eliminate the often-adverse effects caused by the 
administration of the free drug on non-target cells and tissues. Relevant proteins 





PSMA is a transmembrane protein located in prostate tissues whose 
overexpression relates to the progression and evolution of PCa [196]. 
Nanomedicinal approaches employing PSMA-specific aptamers, single-stranded 
oligonucleotides (ssDNA and RNA) that recognize different target molecules and 
are more resistant to heat and pH variations compared to antibodies [197], have 
been employed to target docetaxel-loaded nanoparticles to prostate cancer cells to 
improve drug effectiveness [198]. Furthermore, nanomedicinal approaches also 
include BIND-014, a docetaxel within a matrix of polylactic acid nanoparticle 
covered with a coating of polyethylene glycol in which are ligands targeted to 
PSMA. This nanoparticle was the first PMSA-targeted nanomedicine evaluated in 
clinical trials for mCRPC. Preclinical studies in xenograft mice PCa models showed 
an increase in antitumoral activity [199] and a subsequent Phase I clinical trial 
provided evidence for BIND-014 safety and determined the appropriate dose 
(60mg/m2 every 3 weeks) to proceed with the experiments in further phase II 
clinical trial [200]. Phase II clinical trials confirmed the safety and tolerability of 
BIND-014 in patients with mCRPC, although the trial failed to provide evidence of 
significantly enhanced tumor accumulation and was discontinued [172, 201].  
FR receptors are overexpressed in several types of cancer and has been 
used in combination with gene therapy to treat PCa [202]. As an example, on study 
employed surface modified gold nanoparticles with polyethyleneimine that had 
been covalently functionalized with folic acid (FR ligand) for the complexation of a 
small interfering RNA (siRNA) via electrostatic interactions. These nanoparticles 
were designed as non-viral vectors for gene therapy and resulted in significant 
endogenous gene silencing following by endolysosomal escape in comparison with 
non-targeted formulations [203]. 
CD44, a hyaluronic acid (HA) receptor, is overexpressed on prostate cancer 




PCa cells [204]. As an example, the attachment of HA to the anticarcinogenic drug 
cis-dichlorodiamminiplatinum (II) (CDDP), was used to treat those CD44-positive 
PCa, with an observed increase in antitumorigenic activity compared with those 
cells with lower CD44 cellular expression [205].  
CD24 expression associates with the early development and subsequent 
progression of PCa and one study demonstrated that a docetaxel-loaded 
nanoparticle conjugated with an anti-CD24 antibody promoted higher drug 
accumulation in cancer cells [206]. 
OsteoDex, a poly-bisphosphonate containing the polysaccharide dextran, 
alendronate, and guanidine, currently represents the only nanomedicine for 
mCRPC (skeletal metastasis) being evaluated in clinical trials. Alendronate binds to 
hydroxyapatite to inhibit osteoclast-mediated bone resorption [207], dextran is a 
polysaccharide formed by different glucose molecules and guanidine is used to 
modify the poly-bisphosphonate molecule in order to promote higher Alendronate 
effectivity. OsteoDex binds to hydroxyapatite, where it promotes a cytotoxic effect 
on the osteoclasts, and promotes a cytotoxic effect in tumoral cells, with preclinical 
in vivo and in vitro studies demonstrating a potent anti-tumoral efficacy in PCa cells 
[208-210]. Phase I clinical studies found OsteoDex to be well-tolerated with mild 
side effects, and phase II are currently under way. The main objective of the phase 
II clinical trial is to evaluate the relative change of response in different bone 
metabolism markers to bone metabolism such as human serum bone alkaline 
phosphatase (B-ALP) and N-terminal propeptide of type 1 collagen (P1NP) using 
different OsteoDex doses (3.0, 6.0 and 9.0 mg/kg) [311]. 
Finally, different routes of nanomedicine administration for the treatment 
of PCa are being explored both in preclinical studies and in clinical trials, including 




routes. Each administration route presents advantages and disadvantages for the 
release of nanomedicines, which are described in Figure 15 [211].  
 
Figure 15: Drug Delivery Strategies for Prostate Cancer Therapy. Modified from [211]. 
I.6. Polymers Therapeutics 
Polymer Therapeutics are considered the first generation of polymeric 
nanomedicines (5-100 nm in diameter) and have already demonstrated clinical 
benefits [212-214]. They are considered as "new chemical entities" (NCEs) and not 
as simple conventional systems for the transport of drugs, that simply captures, 
solubilizes, or releases the drug in a controlled manner without using the chemical 
conjugation. In contrast, polymer therapeutics are divided into five hybrids  
nano-constructions, which use water-soluble polymers that can be bio-active 
and/or as an inert carrier that for the chemical conjugation of bioactive molecules 




decade of research findings, and they hope to offer benefits to patients and open 
new markets in the pharmaceutical industry [216, 217]. 
The potential of polymer therapeutic can be illustrated by the appearance 
of two polymer therapeutics among the 10 top-selling drugs in the USA in 2013. 
Copaxone® (Teva Pharmaceutical Industries, Petah Tikva, Israel) a polymeric drug 
(glatiramer acetate) has been used in the treatment of relapsing-remitting multiple 
sclerosis, while Neulasta® (Amgen, California, USA), a polyethylene glycol  
(PEG)-filgrastim conjugate has been used for the treatment of neutropenia in 
patients with malign tumors [218]. 
I.6.1. Classification of Polymer Therapeutics 
Polymer therapeutics are composed of different macromolecular families, 
including polymer-drug conjugates (PDCs) [214, 219, 220], polymer-peptide or 
polymer-protein conjugates [221, 222], polymeric drugs [223], polymeric micelles 
[224, 225], characterized by a covalent bond between the drug and the polymer, 
and multicomponent polyplexes which are develop as non-viral vectors [225, 226] 
(Figure 16).  
In this doctoral thesis, we focused on the development of a polymer-





Figure 16: Overview of the Polymer Therapeutics Family. Adapted from [213]. 
All of the polymer therapeutics described employ specific water-soluble 
polymers, thus achieving a better administration of drugs in patients to improve 
drug, protein, or gene delivery. In addition, they allow greater diversity in their 
chemical synthesis, weight, and control of molecular loading. Furthermore, 
polymer therapeutics allow the combination of several drugs, and biological 
characteristics can be used to promote drug release under specific conditions  
(pH-sensitive or peptidase-sensitive linkers are widely used) [212]. Since the first 
polymer-protein conjugate (PEG-adenosine deaminase [ADAGEN TM]) appeared on 
the market in 1990, the polymer therapeutics field has come to be considered a 





Besides linear polymers, polymeric structures include graft, star, 
multivalent, dendrimer, and dendronized polymers. Potential advantages of these 
architectures include enhanced chemical composition, multivalency, and the 
establishment of a defined three-dimensional cross-linked system with potentially 
longer blood circulation time (Figure 17) [213, 228]. 
 
Figure 17: Overview of Novel Polymeric Structures. Adapted from [213]. 
Due to their intrinsic characteristics at the nanoscale (conjugate size < 25 
nm), polymer therapeutics offer advantages compared to other nanomedicines 
such as (i) greater ability to cross different biological barriers using different types 
of cellular trafficking, thus reaching places that other nanocarriers cannot reach and 
(ii) improve drug pharmacokinetics due to the presence of bio-sensitive chemicals, 
(iii) greater water solubility, (iv) increase plasma half-life by means of a higher 
hydrodynamic volume decreasing kidney clearance, (v) protection against 
proteolytic enzymes, or non-specific cellular uptake, and (vi) prevention or 




I.6.2. Enhanced Permeability and Retention Effect 
The advantages of polymer therapeutics relate to their controllable size and 
the related macromolecular properties. After intravenous administration, polymer 
therapeutics can extravasate more selectively at tumor tissues by passive targeting 
due to increased permeability of blood vessels and lack of lymphatic drainage (due 
to high IFP caused by increased density in the components of the ECM). Most 
nanomedicines in the clinics rely on passive targeting effect provided by this  
so-called enhanced permeability and retention (EPR) effect [229], first described by 
Matsumura and Maeda in 1986 [232]. This effect allows more considerable passive 
accumulation in the tumor and retains macromolecules in the tumor tissues 
compared to free drugs, thus improving therapeutic efficacy [231, 233]. 
Nanomedicines with a Mw between 40-800 KDa and 20-200nm show a 
predisposition to accumulate in the tumor via the EPR effect [230], while the 
associated longer blood half-lives also promote tumor uptake (Figure 18) [231]. 
Furthermore, for the development nanomedicines, various physicochemical 
properties such as surface loading, size, and size distribution need to be considered 
because these properties can affect the EPR effect [234]. 
However, there exist limitations to the EPR effect [235], including the 
significant heterogeneity in patients with the same disease or between different 
cancer types, which them promotes different nanomedicine distribution profiles 
[236, 237].  
However, strategies also exist to potentiate the EPR effect to boost the 
therapeutic outcomes of nanomedicine; these include pharmacological strategies 
to modulate vessel permeabilization, vessel normalization, vessel disruption or 
vessel promotion, and physical strategies, including hyperthermia, radiotherapy, 





Figure 18: Passive Targeting via the Enhanced Permeability and Retention Effect. Due to 
deficient lymphatic drainage and the space between endothelial cells present in the tumor 
vasculature, nanomedicines can preferentially accumulate in the tumor. Nanoparticles 
must be >5 nm in size to avoid rapid renal filtration by increasing blood circulation time and 
<200nm to be able to extravasate the vasculature. Modified from [230]. 
I.6.3. Intracellular Trafficking of Polymer Therapeutics  
After tumor accumulation, endocytotic mechanisms control the 
intracellular journey of polymer therapeutics into the tumor cell. The endocytosis 
of polymer therapeutics can occur via clathrin/caveolin-dependent and/or -
independent vesicular pathways or by macropinocytosis. Of note, the endocytic 
pathways employed by a given polymer therapeutic will be differ based in individual 
characteristics, with the lysosomotropic route and the endosomotropic route 
having particularly relevance (Figure 19) [238]. 
The design of polymer-protein conjugates for clinical use aims for increased 
protein blood circulation time by improving serum stability and protection against 
immune clearance or proteolytic degradation, without the need for intracellular 




endosomotropic transport given a requirement for intracellular trafficking of 
proteins or peptides [215], including the use of biodegradable linkers. In this case, 
the endocytosed vesicle containing the polymer therapeutic will be transferred to 
the early endosomes, from where the nanoparticles can be directed to different 
organelles such as the reticulum endoplasmic, the trans-Golgi network, late 
endosomes (resulting from early endosome maturation), or the can be recycled by 
exocytosis. In this endosomotropic transport, the nanoparticles are directed to the 
late endosomes and will subsequently be released via membrane destabilization 
produced by the interaction between the nanoparticles with the endosomal 
membrane, osmotic rupture due to the presence of amines in the nanoparticles, or 
particle expansion causing a rupture of the endosomal membrane [239], thereby 
preventing protein degradation in the lysosome. 
In contrast, polymer-drug conjugates mostly require lysosomotropic 
intracellular transport, in which the bioactive agent must be protected from 
proteolytic degradation. In this case, polymer therapeutics are internalized via 
endocytosis and become directed to the early and late endosomes, and finally to 
the lysosome, where the presence of proteolytic enzymes (such as cathepsin B) or 
acidic pH permit drug release from the polymer, by the degradation of the polymer 
itself or a cleavable linking moiety [240][213]. The lysosomes present ion channels 
and transmembrane proteins to transport the drug to the cytosol to access the 





Figure 19: Overview of Lysosomotropic and Endosomotropic Routes Employed for the 
Delivery of Nanomedicines. Lysosomotropic transport (release through the lysosome) is 
suitable for bioactive agents protected from proteolytic degradation, while endosomotropic 
transport (release through the endosome) is preferred for the trafficking of proteins or 
peptides. Modified from [213]. 
I.6.4. Polymer-based Combination Therapies 
The multivalency of polymeric carriers allows the binding of one or more 
active agents (e.g. a drug) to provide synergistic effects following their site-specific 
release at a desired ratio. However, there exist four main types of polymer-based 
combination therapies (Figure 20) [241]. 
I. Type I: polymer-drug conjugate + free drug(s) or a different type of therapy 
(i.e., radiotherapy), with examples already in the clinic [241] 
II. Type II: polymer-drug conjugate + polymer-drug conjugate 
III. Type III: Single polymeric carrier carrying a combination of drugs, ensuring 
the delivery of both drugs to the same cell at the same time, thereby 
potentiating synergism and therapeutic efficacy 
IV. 4. Type IV: Polymer-directed enzyme prodrug therapy (PDEPT) + polymer-





Figure 20: Polymer-based Combination Therapies. Modified from [241]. 
In this thesis, we evaluated a novel treatment strategy based on a 
polymer-monoclonal antibody polymer conjugate in combination with the free 
form of a small anti-androgen drug to generate a novel combination therapy. 
Specifically, we assessed the anti-tumor activity of a PGA-conjugated antibody in 
combination with abiraterone for the treatment of CRPC (Type I). 
However, the overall complexity of the development of combination 
therapies leads to certain challenges [241], which include: 
(i) The identification of optimal drug combinations and ratios for synergistic 
effects 
(ii) The requirement for strict control of drug release kinetics 
(iii) The possibility of reduced loading capacity due to steric impediments 
(iv) The overall enhanced complexity of the nanosystem due to the 




I.7. Polymer Conjugates as Therapeutics 
The translation of polymer conjugation into clinical practice has 
demonstrated their huge potential in the improvement of patient outcomes. 
Recent advances in this area, which include biodegradable polymeric backbones 
and new conjugation chemistries, have driven their application in the treatment of 
a wide range of conditions.  
In this section, we discuss two main polymer conjugate families: polymer-
protein and polymer-drug conjugates.  
I.7.1. Polymer-protein Conjugates 
Abuchowski et al. reported the first polymer-protein conjugate (PPC) in 
1977, observing altered immunological properties and circulation half-life of bovine 
serum albumin (BSA) following the covalent attachment of PEG [242, 243]. PEG is a 
biocompatible polymer that presents singular characteristics, such as higher water 
solubility, flexible, and neutral charges, suitable for use in the pharmaceutical 
industry. Through steric repulsions, PEG decreases protein immunogenicity by 
covering antigenic epitopes [244]. Moreover, steric repulsion avoids protein 
degradation, improves proteolytic resistance, and inhibits opsonization by the 
mononuclear phagocyte system. Furthermore, PEG-conjugation increases blood 
circulation time by reducing renal filtration produced by an increase in 
hydrodynamic volume and molecular weight. Additionally, PEG-conjugation 
improves protein solubility, bioavailability, stability, and reduces toxicity [245, 246]. 
PEGylation of proteins as a strategy has also reached the clinic, with various 
therapies have approved for the treatment of a range of diseases (Table 2) [247]. 
Adagen®, a PEG-adenosine deaminase conjugate, was approved by the FDA in 1990 




(SCID), related to a deficiency of the enzyme adenosine deaminase [227]. Other 
examples include Oncaspar® (PEG-L-asparaginase) for the treatment of 
lymphoblastic leukemia [248], Mircera® (PEG-epoetin beta) for the treatment of 
renal anemia in patients with chronic kidney disease, and two new polymer 
therapeutic proteins marketed in 2018 including Palynziq® (PEG-phenylalanine 
ammonia lyase) for lower blood levels of phenylalanine and Jivi® (PEG-factor VIII) 
for the treatment of hemophilia A (Table 2) [249].  
These promising results prompted the clinical evaluation of various other 
PEGylated proteins, including nucleic acids, cytokines, enzymes, growth factors, 
and antibodies (Table 2,3 and 4). In particular, antibodies and antibody fragments 
are widely used therapeutic agents, and in this thesis, we focused on the study of 
a polymer-antibody conjugate.  
Antibodies, immune proteins known as immunoglobulins, consists of four 
polypeptides chains comprising two identical heavy chains and two identical light 
chains, which form a flexible “Y” structure. Each chain possesses a variable region 
(V) and a constant region (C). The V regions, located at the amino-terminal group 
of the light and heavy chains, are involved in antigen-binding and vary greatly 
between different antibodies. In addition, these regions are subdivided into 
complementary determining regions (CDRs) that directly contact the antigen 
surface. The C region determines the isotype; in particular, the isotype of the heavy 
chain determines the functional properties of the antibody. Antibodies are divided 
into five different classes based on the C region structure - IgM, IgG, IgA, IgD, and 
IgE. The light chains are bound to heavy chains by covalent interactions through 
disulfide bonds. 
Antibody fragmentation by proteolytic digestion produces antigen-binding 
fragment (Fab) generated from variable and constant regions, variable fragments 




from the constant region in the heavy chain. While the Fab and Fv fractions 
recognize the antigen, the Fc fragments are responsible for complement fixation 
(Figure 21) [250].  
 
 
Figure 21: Antibody Structure. Antibodies are composed of two light chains and two heavy 
chains. Variable regions containing complementary determining regions recognize the 
antigen, and the constant regions determine the antibody functional properties. Antibody 
fragmentation generates different fragment regions such as variable fraction, antigen-
binding fragment, and crystallizable fragment. 
Antibodies are currently used for different applications in which cancer 
treatment being one of the most explored fields. Regarding polymer-antibody 
conjugates, the production of antibodies that have been genetically engineered to 
lack immunogenicity has led to a low number of studies evaluating the PEGylation 
of antibodies [251, 252]. In addition, the prohibitive cost of antibody production in 
mammalian cell culture has been replaced by a more economical system based on 




Both the PEGylation of antibodies/antibody fragments have been studied 
as potential treatments for cancer, with higher tumor accumulation observed; 
however, the advantages observed, including increased blood circulation time, are 
greater for antibody fragments [253-256]. Furthermore, their small size, rapid 
penetration into the tumors, and the lack of Fc region have made PEGylated 
antibody fragments a focus for basic research and therapeutic applications [246]. 
Of significant note, the non-biodegradable nature of PEG represents a 
significant limitation to clinical application. The increase in the molecular weight of 
PEGylated proteins has a negative effect due to avoid glomerular filtration, 
moreover, can activate the immune system responses and promote lysosomal 
storage disease related with the polymer accumulation [257]. 
New biodegradable alternatives to PEG include polyoxazolidines or 
polypept(o)ides such as polysarcosines, which can improve pharmacokinetics, and 
offer new opportunities to develop novel polymer-protein conjugates [258-260]. 
I.7.2. Polymer-drug Conjugates  
Polymer-drug conjugates (PDCs) are macromolecular structures in which 
one or more therapeutic agents are attached to a polymeric carrier by covalent 
bonds. Advantages of PDCs include higher solubility, a longer half-life, and a drug 
release depending on tumor vascularization. The first PDC aiming to improve 
therapeutic drug efficacy by conjugation to macromolecules was described in 1955 
by Von Horst Jatzkewitz [261]; the conjugation of poly(vinylpyrrolidone) to 
mescaline led to a longer retention time and control of intracellular release [262].  
The main components of PDCs are the bioactive agent, a polymer-drug 
linker, and a water-soluble polymeric carrier [270]. However, multivalent polymers 




backbone allowing, for example, the introduction of targeting residues [271] or 
more than one drug for combination therapies (See Section I.6.4) [227].  
Their general success has led to clinical trials of several PDCs, including: 
I. Poly(N-hydroxypropyl methacrylamide)-Doxorrubicin (polyHPMA)-Dox, 
with (PK2) and without (PK1) galactosamine as active residue [271-274] 
II. PGA conjugates of paclitaxel (XyotaxTM or OpaxioTM) or camptothecin  
(CT-2106) [275-277] 
III. PEG-cyclodextrin-camptothecin nanoparticulated conjugate (CRLX101 or 
IT-101) [278, 279] 
IV. PEG-polypeptide block copolymer conjugated with SN-38 (NK-012), 
Doxorubicin (NK-911), or Cisplatin (NC-6004) [280-282]  
PK1, the first clinically investigated water-soluble PDC, comprises 
Doxorubicin bound to an HPMA copolymer by a lysosomal cleavable peptidyl linker 
[213]. In preclinical mice models studies, PK1 showed elevated antitumoral efficacy, 
with higher tumor accumulation, a better safety profile, and prolonged plasma 
circulation time compared to unconjugated doxorubicin [283]. After a successful 
Phase I clinical trial [284] and promising data arising from Phase II, PK1 was 
discontinued due to economic decisions on behalf of the parent company [285]. 
Higher molecular weight and the lack of biodegradability in the first 
generation of PEG and HMPA conjugates produced several limitations related to 
side product accumulation. To solve this problem, water-soluble, biocompatible, 
and biodegradable alternatives such as polycarbonates or polypeptides are being 
explored for further drug conjugation [286, 287]. Additionally, alterations to 
polymer architecture, molecular weight, and linking chemistry can optimize drug 





PDC marketed include Movantik®, approved by the FDA in 2014 for the 
treatment of opioid-induced constipation in adult patients with chronic  
non-oncologic pain (Table 2); furthermore, Copaxone® and Neulasta®, which 





































Another separate field of research is based on using targeted polymers           
-antibodies- with small molecules conjugates as a therapeutic agent in order to 
direct the drug to a specific target. In 1958, Mathé et al conjugated for the first time 
drugs to immunoglobulins, known as antibody-drug conjugates (ADCs), establishing 
the first platform for PDCs. Specifically, there are four ADCs approved by the FDA 
highlighting Gemtuzumab ozogamicin (Mylotarg™) to treat acute myeloid leukemia 
[263], trastuzumab emtansine (Kadcyla™) to treat breast cancer [264], brentuximab 
vedotin (Adcetris®) for adult patients with Hodgkin´s lymphoma (HL) [265] and 
Inotuzumab ozogamicin (Besponsa™) for acute lymphoblastic leukemia [266], 
additionally approximately 50 are in clinical trials [267]. Ringsdorf, in 1975, 
conceptualized the development of biocompatible polymers as efficient drug 
carriers, causing a switch in the field of PDCs [268, 269]. 
Combining advantages of both PDCs and ADCs strategies the therapeutic 
potential can be increased [290-293]. Antibody-targeted polymer-drug conjugates 
provide better pharmacokinetics and bioavailability, improving therapeutic 
effectiveness compared to ADCs [294, 295]. In this way, the dosage of the drug 
administered is reduced, decreasing side effects and improving therapeutic 
specificity in the target cell [294, 295].  
Doxorubicin is one of the most commonly used chemotherapeutic agents 
in antibody-targeted PDCs [291]. Several studies have demonstrated benefits both 
in vivo and in vitro, providing higher specificity, reduced drug toxicity, increased 






I.8. Polypeptide-Based Conjugates as Therapeutics 
Polyamino acids (PAA or polypeptide) present notable biocompatibility and 
biodegradability mimicking natural proteins, which has promoted their exploration 
as a therapeutic strategy [296-298]. The increase in the number of polypeptide-
based conjugates evaluated in preclinical and clinical trials demonstrate the 
applicability of polypeptide-based materials for drug delivery [297].  
Polypeptide-based conjugates have been applied in numerous areas of 
medicine, including the elaboration of anti-microbial [299, 300], anti-cancer  
[301, 302], anti-virus [303], anti-apoptotic [301], anti-diabetic [304], and  
anti-tuberculosis drugs [304], as well as magnetic resonance imaging agents [305], 
and theragnostic agents [306]. Furthermore, polypeptides also present advantages 
due to their structural versatility, which allows the formation of multiple 
architectures with different physicochemical features (loading, polarity, and 
hydrophilicity).  
Several features should be considered for the design of a polypeptide-
based drug conjugate including (i) the structural elements (matrix, linker, drug 
nature, ligand pattern, and surface modification), (ii) the physico-chemical 
properties (size, charge, conformation, geometry, and topology), and (iii) the 
biological barriers previously explained (See Section I.5.1). 
Moreover, the selection of the adequate administration route, the cellular 
target, the tumor environment, and the dosing schedule are required to obtain a 
successful translation of a drug delivery system and achieve an optimal therapeutic 
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II.1.1. Chemical and Biological Reagents  
Poly-L-glutamic acid (PGA, acid form, 200 glutamic acid units) was 
purchased from Polypeptide Therapeutics Solutions (PTS, Spain). AVE1642 was 
provided by Sanofi-Aventis (Bridgewater, New Jersey, USA). N-succinimidyl-S-
acetylthiopropionate (SATP), sterile 96-well plates, DharmaFECT® reagent, 
penicillin/streptomycin (P/S), NuncTM Lab-TekTM chamber slides, trypsin-EDTA, and 
Prostate Specific Antigen (PSA) (Free)/KLK3 Human ELISA Kit were purchased from 
Thermo Scientific (Waltham, Massachusetts, USA). Vivaspin centrifugal 
concentrator tubes, protein markers, ECL Prime Western Blotting Detection 
Reagent, and Hyperfilm™ MP were purchased from GE Healthcare (Chicago, Illinois, 
USA). Dithiothreitol (DTT), N-hydroxysuccinimide (NHS), fetal bovine serum (FBS), 
dextran, phenazine methosulfate (PMS), cathepsin B inhibitor CA-074, Insulin-like 
Growth Factor-I (IGF-1), 4´,6-diamidin-2-phenylindole (DAPI), Bradford reagent, 
bovine serum albumin (BSA), Evans Blue dye (EB), formamide, sunflower oil, benzyl 
alcohol, deuterium oxide (D2O), GLOX solution, glucose, cysteamine, glucose 
oxidase, catalase, bromophenol blue, Ammonium persulfate (APS), 
Tetramethylethylenediamine (TEMED), Dimethyl sulfoxide (DMSO) and all other 
chemicals were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Anhydrous 
N,N-dimethylformamide (DMF, ≥99.8% anhydrous) was purchased from Scharlab 
SL (Sentmenat, Spain). T75 flasks, sterile 24-well plates, 12-well plates, and 6-well 
plates were provided by Sarstedt (Nümbrecht, Germany). EIA/RIA (ELISA) 96-well 
plate and white 96-well plates were from Corning Costar® (Corning, New York, 
USA). Stop solution and 3,3´,5,5´-Tetramethylbenzine (TMB) substrate were 
purchased from Abcam (Cambridge, UK). Luciferase (Luc2) Lentiviral Vector and 
Turbo Green Fluorescent Protein (tGFP) were provided by Innoprot (Vizcaya, Spain). 




Promega (Madison, Wisconsin, USA). Cyanine 3, cyanine 5, and cyanine 5.5 dyes 
were purchased from Lumiprobe GmbH (Hannover, Germany). Geneticin (G418) 
and Sodium Dodecyl Sulfate (SDS) were purchased from Fisher (Loughborough, UK). 
Abiraterone, Abiraterone Acetate, and Dehydroepiandrosterone 3-acetate (DHEA) 
were provided by Medchem Express (Monmouth Junction, NJ, USA). 
siGENOME_siRNA (siERG) and scrambled siGENOME_non-targeting_siRNA (SCR) 
were purchased from Thermo Scientific (Lafayette, Colorado, USA). Mounting 
medium and fluorescein-labeled Ricinus communis agglutinin I (FITC-Lectin) were 
purchased from Vector Laboratories (Burlingame, California, USA). 
Paraformaldehyde (PFA) was provided by Electron Microscopy Sciences (Hatfield, 
Pennsylvania, USA). Protease inhibitor cocktail (IC 1X) and phosphatase inhibitor 
cocktail (PhosSTOP 1X) were purchased from Roche (Basel, Switzerland). Black 96-
well plates and XenoLight D-luciferin potassium salt were purchased from Perkin 
Elmer (Waltham, Massachusetts, USA). Acrylamide/Bisacrylamide was provided by 
VWR Live Science (Radnor, Pennsylvania, USA). Adhesion microscope slides were 
purchased from Marienfeld-Superior (Lauda-Königshofen, Germany). Mowiol®  
4-88 was provided by Carl Roth (Karlsruhe, Germany). 0.22µm filters were 
purchased from Jet Biofil (Guangzhou, China). Insulin syringes (29G), absorbable 
sutures 6/0, and isoflurane were purchased form B. Braun VetCare (Barcelona, 
Spain). Morphine was provided by B. Braun Medical (Barcelona, Spain). 
Buprenorphine was purchased from RB Pharmaceuticals Ltd (Benckiser, UK). 
Reusable straight 20 gauge feeding needles were provided by InterFocus (Linton, 
UK). Ultrapure water with a resistivity of 18 MΩ.cm was used in all aqueous 







II.1.2. Cell Lines and Culture Conditions 
Table 1 describes the prostate cancer (PCa) cell lines, the growth media 
used, and the main characteristics of each cell line. Cells were maintained at 37ºC 
in an atmosphere of 5% carbon dioxide and 95% air and underwent passaging 
weekly in T75 flasks. The complete medium was changed twice a week. All 
experiments were performed with cells between passage number 10 to 19. 
II.1.2.1. Cell Line Growth Medium 
 
Table 1. Summary of the origin, growth medium, and characteristics of the different PCa 






Table 2 and 3 describes the antibodies employed in this thesis. 






Table 2. Summary of primary antibodies employed in this thesis. 






Table 3. Summary of secondary antibodies employed in this thesis. 
II.1.4. Animals 
Male C.B-17/IcrHan®Hsd-Prkdcscid mice provided by Envigo Laboratories 
Inc. (Gannat, France) at 6-8 weeks of age were used for all animal experiments  
[1-4].  
All mice were kept in a specific-pathogen-free facility under constant 
temperature and humidity using a 12 h light-dark cycle. Food pellets and water 
were supplied ad-libitum during the whole experiment in all cases. Additionally, to 
ensure animal well-being, general aspects such as grooming conduct, tumor size, 
body weight, and behavior were evaluated daily. 
II.2. Methods 
II.2.1. AVE1642 and PGA-AVE1642 Synthesis  
II.2.1.1. Synthesis of Pyridyl Disulfide-modified PGA 
200 mg of PGA (1.55 mmol glutamic acid repeat unit, 1 equivalent (equiv.)) 





(DMTMM.BF4) (0.77 mmol, 0.5 equiv.) synthesized mainly as described in [5] was 
dissolved in 4 ml of anhydrous DMF and added. The reaction mixture was stirred 
for 20 minutes (mins) to activate the carboxyl acid groups of PGA. Then, 72 mg of 
pyridyl dithiol cysteamine (0.39 mmol, 0.25 equiv.) synthesized according to 
previously reported methods [6] (dissolved in 1 ml of anhydrous DMF) was added 
and the pH adjusted to 8 by the addition of N,N-diisopropylethylamine (DIEA). The 
reaction mixture was then stirred at room temperature (RT) for 48 h, and DMF was 
evaporated under vacuum. The product was precipitated in cold ether and dried 
under vacuum. Then, PGA-PD was dissolved in 10 ml of 1 M sodium bicarbonate to 
obtain the water-soluble sodium salt form of the polymer. After complete 
dissolution, the buffer was exchanged for Milli-Q water with resistivity of 18 MΩ.cm 
(Milli-Q® ultrapure) by ultrafiltration using vivaspin tubes with a molecular weight 
cut-off (MWCO) of 3 kDa (Figure 1). The purified product was recovered by freeze-
drying — yield: 80%. 
 
Scheme 1: Modification of PGA with pyridyl dithiol via DMTMM BF4 activation. 
 The degree of functionalization was determined by nuclear magnetic 
resonance (NMR). NMR spectra were recorded at 27ºC (300 K) on a 300 
UltrashieldTM (Bruker; Billerica, Massachusetts, USA). Data were processed with the 
Mestrenova software (Bruker; Billerica, Massachusetts, USA). PGA solutions were 




II.2.1.2. Modification of AVE1642 with N-succinimidyl-S-
acetylthiopropionate 
AVE1642 was modified with N-succinimidyl-S-acetylthiopropionate (SATP) 
using a previously described well-established protocol [7]. Briefly, SATP (25 equiv., 
2 mg/ml solution in DMSO) was added to 0.55 mg/ml solution of AVE1642 in PBS 
pH 7.4. The mixture was incubated at RT for 30 mins stirring at 250 revolutions per 
minute (rpm). Then, the reaction was purified by ultrafiltration with vivaspin 
centrifugal concentrator tubes with an MWCO of 50 kDa.  
II.2.1.3. Conjugation of SATP-modified AVE1642 to PGA-PD 
AVE1642-SATP solution in PBS was mixed with a PGA-PD (5 equiv.) solution 
in PBS and 9.1% v/v deacetylation buffer (0.5 M hydroxylamine-HCl in PBS, 25mM 
EDTA) to yield thiolated AVE1642. The reaction mixture was incubated overnight at 
RT stirring at 250 rpm. The purification of the final conjugate was performed by 
ultrafiltration (vivaspin MWCO 50kDa). The antibody concentration in the  
PGA-AVE1642 solution was determined using fast protein liquid chromatography 
(FPLC) and a calibration curve of known concentrations of AVE1642. Briefly, 
PGA-AVE1642 was treated with 50 mM DTT for 30 mins at RT to detach the polymer 
from the antibody, and the sample was injected in an AKTA Ettan LC FPLC System 
(GE Healthcare; Chicago, Illinois, USA) equipped with a Superdex 200 5/150 GL 
column (GE Healthcare; Chicago, Illinois, USA) working at a flow rate of 0.18 ml/min. 
Elution was carried out with a buffer of Tris 50 mM, NaCl 150 mM pH 7.5, and 
absorbance was measured at 280 nm. The calibration curve was generated by 
injecting AVE1642 standards incubated with DTT in the same conditions and 





Figure 2: Calibration curve of AVE1642 treated with 50 mM DTT determined using gel 
filtration with standard concentrations. Absorbance was measured at 280 nm. Each 
standard was injected four times. The black line in the upper right corner shows the linear 
fitting of the calibration curve. 
II.2.2. Labeling of AVE1642 and PGA-AVE1642 with Cyanine Dyes 
100 mg of PGA-PD (18.5% mol PD derivatization, 2.8 x 10-3 mmol polymer 
chain, 1 equiv.) in the sodium salt form was dissolved in 4 ml of PBS pH 7.4. Then, 
5.4 mg of EDC and 3.2 mg of NHS (0.028 mmol of each, 10 equiv. with respect to 
the polymer chain) were dissolved in PBS and added to the solution. The reaction 
mixture was stirred for 20 mins to activate the carboxyl acid groups of PGA. Then, 
9.2 mg of Cy5-amine or 10.6 mg of Cy5.5-amine (0.014 mmol of each, 5 equiv. with 
respect to the polymer chain) were added, and the reaction was stirred overnight. 
The excess of unreacted dye was removed by dialysis against Milli-Q water, and the 
product was lyophilized. Dye content was determined measuring the absorbance 
at 646 nm for Cy5 and at 684 nm for Cy5.5. The final polymer was used for the 




A 2 mg/ml solution of AVE in PBS pH 7.4 was added of 5 equiv. of Cy3-NHS 
or Cy5.5-NHS, previously dissolved in DMSO, and left to react for 4 h at RT. The 
excess of unreacted dye was removed by ultracentrifugation. Dye content and 
antibody concentration were measured by UV-Vis spectroscopy.  
II.2.3. Characterization of AVE1642 and PGA-AVE1642  
II.2.3.1. Amino-acid Analysis 
The molar ratio between the polymer and the antibody in the  
PGA-AVE1642 conjugate was determined by amino acid analysis (University of 
Barcelona, Spain) using the following standardized protocol. 
Briefly, 100 µl of the solution samples were hydrolyzed in 6 M hydrochloric 
acid at 110ºC for 24 h. Aliquots of α-aminobutyric acid (AABA) solutions (2.5 mM) 
were added as an internal standard. The samples were then evaporated, 
resuspended in high-performance liquid chromatography (HPLC) water (500 µl), 
and filtered (0.45 µm). The filtered solution of samples was further diluted in HPLC 
water (200 µl). Subsequently, the samples were derivatized with 6-aminoquinolyl-
N-hydroxysuccinimidyl carbamate (AQC) according to the Waters AccQ-TagTM 
method [8]. AccQ-Tag derivatized amino acids were analyzed by HPLC with UV 
detection (λ=254nm) (Waters 600 HPLC gradient system equipped with a Waters 
2487 UV detector) and Empower 2 software.  
II.2.3.2. Ultraviolet-Visible Spectroscopy 
Ultraviolet-visible spectroscopy (UV-VIS) measurements were performed 
using a JASCO V-630 spectrophotometer at 25ºC with 1.0 cm matched quartz cells 
and with a spectral bandwidth of 0.5 nm. AVE1642 concentration was determined 




II.2.3.3. Size-exclusion Chromatography 
Analytical size exclusion chromatography (SEC) was performed on an Ettan 
LC FPLC (GE Healthcare; Chicago, Illinois, USA) system equipped with a Superdex 
200 5/150 GL column (GE Healthcare; Chicago, Illinois, USA) working at a flow rate 
of 0.18 ml/min. Elution was conducted with Tris 50 mM, NaCl 150 mM pH 7.5, and 
absorbance was measured at 220nm. 
II.2.3.4. SDS-PAGE Electrophoresis 
Electrophoresis (SDS-PAGE) was performed via the Laemmli-SDS-Page 
protocol [9]. Samples were mixed (1:2) with loading buffer (50 mM Tris HCl, 2% SDS, 
0.1% bromophenol blue, 10% glycerol) and incubated for 5 min at 95ºC to denature 
the protein. Samples were then loaded into an SDS gel (5% acrylamide, 0.1 cm 
thickness) and run at 150 V for approximately 1 h 45 mins. Proteins were then 
visualized by Coomassie blue staining.  
II.2.3.5. Dynamic Light Scattering and Zeta Potential Measurements 
Dynamic light scattering (DLS) and zeta potential measurements were 
performed at 25ºC using a Malvern Zetasizer Nano ZS instrument (Worcestershire, 
UK) equipped with a 532 nm laser at a fixed scattering angle of 173º. AVE1642 and 
its derivatives were prepared in PBS at 0.2 mg/ml, and the solutions were filtered 
through a 0.22 μm cellulose membrane filter before analysis. Size distribution was 
measured (diameter, nm) in triplicate for each sample. Automatic optimization of 
beam focusing, and attenuation was applied for each sample. Zeta potential 
measurements were performed using disposable folded capillary cells (Malvern, 
Worcestershire, UK). 
Thermal denaturation was evaluated by DLS by monitoring the 




85ºC. Samples were prepared in PBS at a protein concentration of 0.2 mg/ml. 
Measurements were performed with an incremental step of 5ºC and an 
equilibration time of 3 mins. 
II.2.3.6. Circular Dichroism Spectroscopy 
The secondary structure of AVE1642 and its derivatives were investigated 
by circular dichroism (CD) using a J-815 CD Spectrometer (Jasco Corporation; Tokyo, 
Japan). The instrument was connected to a Peltier thermostated cell holder (PTC-
423, Jasco Corporation; Tokyo, Japan) with a recirculating cooler (JULABO F250, 
Jasco Corporation; Tokyo, Japan). Samples were dissolved in PBS pH 7.4 at a protein 
concentration of 0.1 mg/ml. The spectra were collected between 200 and 250 nm 
by the average of three continuous scanning at a speed of 20 nm/min. Experiments 
were conducted in a quartz cuvette with a path length of 0.1 cm. CD data were 
converted to mean residue ellipticity, expressed in deg cm2 dmol−1, by applying the 
formula ΘMWR = Θobs (MRW)/10L[C], where Θobs is the observed ellipticity in degrees, 
the MRW is the mean residue weight of the protein, [C] is the protein concentration 
in mg/ml, and L is the optical path length in centimeters. The conjugate was 
incubated with 50 mM DTT for 30 mins at RT to investigate the secondary structure 
of the antibody of the PGA-AVE1642 derivative after the removal of the polymer. 
Then, the sample was purified by ultracentrifugation with a vivaspin MWCO 50 kDa 
filter to remove PGA. AVE1642 after PGA removal was analyzed by CD to evaluate 
the secondary structure of the antibody. 
CD was also used to evaluate the thermal stability of AVE1642 and its 
derivatives. During the experiment, the temperature was increased from 25ºC to 
90ºC at a rate of 2ºC/min while the molar ellipticity was monitored at 216 nm to 
investigate any modifications to the β-sheet structure of the antibody. The 
measurements were conducted using a Jasco J-1500 CD Spectrometer (Jasco 




(PTC-517, Jasco Corporation; Tokyo, Japan) and a Jasco CTU-100 circulating bath. 
Samples were prepared in PBS at 0.1 mg/ml, and the experiments were conducted 
in a quartz cuvette with a path length of 0.5 cm. The temperature was recorded 
directly using a temperature probe placed inside the cuvette. 
II.2.3.7. ELISA assays 
ELISA assays were performed to evaluate the stability and affinity of 
AVE1642 and PGA-AVE1642. For stability studies, both compounds were incubated 
separately at 37ºC at 500 rpm for 0, 24, 46, and 72 h. A 5 µg/ml solution of each 
sample was diluted in 300 µl of FBS. Furthermore, two calibration curves were 
performed (for AVE1642 and PGA-AVE1642) using the same AVE1642 equiv. 
concentrations (0, 0.025, 0.1, 0.5, 1, 3 and 5 µg/ml). The different calibration curve 
points were diluted with 300 µl of FBS serum without previous incubation. In 
contrast, for affinity studies, different concentrations of AVE1642 and  
PGA-AVE1642 (from 0.025 to 10 µg/ml) were prepared in PBS without previous 
incubation (Figure 3). 
Figure 3: AVE1642 and PGA-AVE1642 calibration curves. A and B) Graphs represent 
Absorbance vs. concentration (µg/ml). The absorbance intensity was evaluated at different 
AVE1642 and PGA-AVE1642 concentrations (0, 0.025, 0.1, 0.5, 1, 3, and 5 µg/ml AVE1642 




In an EIA/RIA (ELISA) 96-well plate, 40 µg/ml of VCaP cellular lysate diluted 
with PBS was added to each well to give 50µl total volume; as a control, wells with 
PBS without VCaP cellular lysate were also included. The plate was covered with an 
adhesive sealing sheet and incubated overnight, shaking at 4ºC. Next, the lysates 
were washed three times with washing buffer (200 µl of PBS and 0.2% (v/v) Tween 
20), blocked with 100 µl of 0.2% (v/v) Tween 20 and 5 % (w/v) skimmed milk 
(blocking buffer), and then incubated for 2 h shaking at RT. After removing the 
blocking buffer, the lysates were washed twice with washing buffer. Subsequently, 
100 µl of each calibration curve and 100 µl of different samples were added to the 
wells (in duplicate). The plate was covered with an adhesive sealing sheet and 
incubated overnight, shaking at 4ºC. 
The lysates were then washed three times with 200 µl of washing buffer. 
Next, 100 µl of anti-human (1/5000) primary antibody diluted in blocking buffer and 
was incubated for 2 h at RT, shaking. The lysates were then washed three times, 
and 100µl TMB was added to each well and then incubated for 30 mins at RT, 
shaking in the dark. After this time, 100 µl of stop solution was added, and the 
absorbance was measured in a spectrophotometer at OD450nm.  
II.2.3.8. Hemolysis Assays 
Mouse red blood cells (RBCs) were isolated to determine if AVE1642/ 
PGA-AV1642 promoted hemolysis. Healthy C.B-17/IcrHan®Hsd-Prkdcscid male mice 
were euthanized with CO2 atmosphere and blood immediately extracted from the 
heart using a heparinized syringe 0.1% (w/v) and collected in a 15 ml falcon tube. 
Tubes were then centrifuged for 10 mins at 3000 rpm at 4ºC to isolate erythrocytes 
from the plasma. The supernatant plasma was carefully removed, and the tubes 
containing erythrocytes were filled to a total volume of 10 ml with fresh PBS pH 7.4, 




removed again, and this procedure was reproduced 4-5 times until clear PBS was 
obtained.  
The supernatant was discarded, and a 2% suspension of fresh erythrocytes 
(w/v) in PBS was prepared. 2 mg/ml dextran was used as a negative control, 1% 
Triton X-100 (w/v) as a positive control, and 250 µg/ml AVE1642 and PGA-AVE1642 
solutions in PBS were assessed. 100 µl of each sample was added to wells of a  
U-shaped non-sterile 96-well plate with 100 µl of erythrocytes; the plate was then 
covered with an adhesive sealing sheet and incubated for 1 h at 37ºC. The plate 
was then centrifuged for 10 mins at 3000 rpm at RT, and 100 µl of the supernatant 
of each well (avoiding the pellet) was transferred to a corresponding well in a new 
non-sterile 96-well plate. Finally, the absorbance was measured in a 
spectrophotometer at OD570nm. 
II.2.4. Lentiviral Infection Protocol 
 For the in vivo PCa model, the VCaP cell line was virally infected separately 
with the Luciferase (Luc2) Lentiviral Vector (Photinus Pyralis Cumate) to express 
luciferase and for Turbo Green Fluorescent Protein (tGFP) as a positive transfection 
control. 1.2 x 106 VCaP cells (around 133,000 cells/cm2) were seeded in a 6-well 
plate in 2 ml of complete medium per well. The cells were incubated at 37ºC in a 
5% CO2 atmosphere. Once the cells were at 80% confluence, the medium was 
removed, and the cells were washed with sterile PBS. Luc2 and tGPF stocks contains 
1-2 x 107 and 0.5-1 x 107 particles forming units (pfu)/ml, respectively. Both 
lentiviral solutions were prepared separately by adding 240 µl of each lentivirus to 
960 µl of complete medium. After PBS washing, each lentiviral virus was incubated 
for 24 h at 37ºC in a 5% CO2 atmosphere, after which point both solutions were 




500 µg/ml of the antibiotic geneticin (G418) was added in the complete 
medium to select positive cells for lentiviral infection. To detect stable luciferase-
expressing cells (VCaP-Luc2), 10,000 cells in 100 µl of complete medium was added 
to a well in a white 96-well plate. 20µl of Bright-GloTM Luciferase Assay System was 
next added, and the fluorescence was immediately evaluated in relative 
luminescence units (RLU) in the spectrophotometer. In the case of tGFP 
(VCaP-GFP), 250,000 cells were resuspended in complete medium, and the 
percentage of selected cells was measured by fluorescence through flow 
cytometry. Prior to cellular injection in vivo, we measured the fluorescence in the 
VCaP-Luc2 cell line by spectrophotometer to check luciferase stability. 
II.2.5. In vitro Toxicity Studies  
Cells were seeded in a sterile 96-well plate in 50 l of complete medium. 
23,000 VCaP and VCaP-Luc2 cells (around 67,000 cells/cm2) were incubated for 72h 
and 10,000 LnCaP, DU-145, 22Rv1, PC-3, and RWPE-1 cells (around 28,000 
cells/cm2) were incubated for 24 h at 37ºC and a 5% CO2 atmosphere before testing 
the various treatments. Different incubation times were used to test cells while in 
exponential growth. 100l of sterile PBS was added to unused wells in the 
periphery to avoid medium evaporation. 
Four different PGA-AVE1642 conjugates, each one with different PGA 
chains conjugated to the AVE642 (in a ratio of 2:1; 4:1; 5:1 and 10:1 PGA chain: 
AVE1642), and free AVE1642 were prepared in a range of concentrations in 
AVE1642 equiv. (0.006 to 100 µg/ml). Abiraterone was prepared from 0.03 to  
10 µg/ml, and both combinations therapies PGA-AVE1642 (2:1) + Abiraterone and 
AVE1642 + Abiraterone were prepared at 1:10 ratio  
(PGA-AVE1642/AVE1642:Abiraterone). The VCaP cell line was also treated only 
with PGA at different concentrations (from 0.0064 to 64.37 µg/ml) of PGA equiv. as 




 All treatments were incubated for 72 h, and after this time, without 
removing medium, 20µl of MTS/PMS was added at a 20/1 ratio to each well and 
incubated for 6 h (in the case of VCaP and VCaP-Luc2 cells) and 3 h (in the case of 
the other PCa cell types and normal prostate cell type). Different incubation times 
were selected due to VCaP cell line presenting lower doubling time and 
mitochondrial breathing compared to the other cell lines. Finally, the samples were 
measured in the spectrophotometer at OD490-500nm.  
GraphPad Prism 8 software was used to fit a dose-response curve to 
determine IC50 values. Once the toxicity results were obtained, any synergistic 
effect between AVE1642 and PGA-AVE1642 with Abiraterone was evaluated by a 
Combination Index (CI) measurement employing CompuSyn software [10]. The CI 
concept was described by Chou et al. in 1984 [11]; the CI value quantitatively 
defines synergism (CI<1), additive effects (CI=1), or antagonism (CI>1). 
II.2.6. ERG Gene Silencing by siRNA 
Short interfering RNA knockdown of human ERG was performed with 
siGENOME_siRNA (siERG), as reported in [12] and [13]. Scrambled siGENOME_non 
targeting_siRNA (SCR) was used as a siRNA control, and non-transfected cells were 
used as a negative control. 120,000 VCaP cells (around 67,000 cells/cm2) were 
seeded in a 24-well plate in a final volume of 500 µl complete growth medium, and 
cells were incubated for 24 h before the transfection. 
siERG and SCR were prepared before the transfection following the next 
protocol. ERG siRNA (0.025 µM) and 0.625 µl of DharmaFECT® were mixed in  
100 µl final volume using medium without FBS or P/S. This solution was incubated 
at RT for 20 mins in an Eppendorf. Non-targeting siRNA was prepared separately 
with the same procedure. Then, 400 µl of complete growth medium was added to 




non-transfected cells, the medium was replaced with only complete growth 
medium.  
The media for each condition were then replaced by complete growth 
medium and 24 h later, VCaP cells from each condition were exposed for 72 h to 
AVE1642 (0.1 µg/ml), PGA-AVE1642 (0.1 µg/ml AVE1642 equiv.), Abiraterone  
(1 µg/ml), AVE1642 + Abiraterone (0.1+1 µg/ml), PGA-AVE1642 + Abiraterone 
(0.1+1 µg/ml), and PGA (0.085 µg/ml).  
 
II.2.7. AVE1642 and PGA-AVE1642 Internalization Studies 
II.2.7.1. Flow Cytometry 
A calibration curve was constructed to evaluate the fluorescence intensity 
(FI) to compare the date between AVE1642-Cy5.5 and PGA-AVE1642-Cy5.5  
(See Section II.2.2) and avoid quenching. Calibration curves used 0.05, 0.1, 0.2, and  
0.3 mg/ml of polymer equiv. (PGA) of PGA-AVE1642-Cy5.5 (AVE1642: 1.95 mg/ml, 
PGA: 1.21 mg/ml and Cy5.5: 0.30% (w/w)) and 0.08, 0.16, 0.32, and 0.49 mg/ml of 
AVE1642 equiv. for AVE1642-Cy5.5 (AVE1642: 2.33 mg/ml and Cy5.5: 0.36% (w/w)) 
(Figure 4). All concentrations were prepared in PBS, and 100 µl of each was added 
to a black 96-well plate and the fluorescence measured in a Victor2 
spectrophotometer (PerkinElmer; Waltham, Massachusetts, USA) at an FI for 




Figure 4: AVE1642-Cy5.5 and PGA-AVE1642-Cy5.5 Fluorescence Calibration Curves. 
Graphs represent fluorescence vs. concentration (mg/ml). A) Fluorescence intensity was 
assessed for PGA-AVE1642-Cy5.5 concentrations of 0.05, 0.1, 0.2, and 0.3 mg/ml polymer. 
B) AVE1642-Cy5.5 concentrations of 0.08, 0.16, 0.32, and 0.49 mg/ml AVE1642 equiv. Data 
expressed as mean±SEM, n=3. 
240,000 VCaP cells (around 67,000 cells/cm2) were seeded in a 12-well 
plate in 1 ml of complete medium. After 72 h, 2 µM of cathepsin B inhibitor CA-074 
was incubated for 30 mins to avoid PGA degradation. Next, the plates were divided 
according to different temperatures tested; plates were kept at 37ºC and 4ºC to 
study energy-dependent meditated endocytosis. 
Then, AVE1642-Cy5.5 and PGA-AVE1642-Cy5.5 were incubated at  
0.16 mg/ml AVE1642 equiv. concentration for AVE1642-Cy5.5 and 0.1 mg/ml 
polymer concentration for PGA-AVE1642-Cy5.5 for up to 3 h at 37ºC and 4ºC. Next, 
all plates were placed on ice, medium removed, and wells washed three times with 
1 ml 0.1% (w/v) PBS-BSA.  
Cells were detached by careful pipetting and collected in a final volume of 
400 l of PBS in a 1.5 ml Eppendorf. Data were obtained with the CytoFLEX S flow 




II.2.7.2. Confocal Microscopy 
133,000 VCaP cells (around 67,000 cells/cm2) were seeded in a 24-well 
plate in 500 l of complete medium on a sterile round glass slide (Ø 15mm). After 
72 h of incubation, the medium was replaced, and the cells were treated with  
0.1 mg/ml polymer concentration for the PGA-AVE1642-Cy5.5 and 0.16 mg/ml 
AVE1642 equiv. for AVE1642-Cy5.5 (according to the calibration curve performed 
in the Section II.2.7.1) in 150 l final total volume diluted with complete medium 
for 30 mins.  
The cells were then washed once with 500 l PBS for 5 mins, PBS removed, 
and cells fixed with 500 l 2% (w/v) PFA in PBS for 20 mins at 37ºC. The cells were 
then washed three times with 500 l PBS and afterward, cells were blocked in 500l 
with 10% (v/v) FBS diluted with PBS for 1 h at 37ºC. 
Next, round glass slides were placed in a glass microscope slide, and the 
cells were incubated overnight at 4ºC in a humidified chamber with 50 l of the 
following primary antibodies combinations diluted in 10% (v/v) FBS: (i) anti-rabbit 
IGF-1R-β (1/100) with anti-mouse EEA1 (1/1000); (ii) anti-rabbit LAMP1 (1/1000); 
(iii) anti-rabbit IGF-1R-β (1/100) with anti-mouse Clathrin (1/50); (iv) anti-rabbit 
IGF-1R-β (1/100) with anti-goat Caveolin-1 (1/50). 
The following day, round glass slides were washed three times with 100 l 
PBS and incubated for 1 h in the dark at RT in 50 l of the following secondary 
antibodies combination diluted in 5% (v/v) FBS: (i) Alexa Fluor anti-rabbit-488 
(1/1000) with anti-mouse-Pacific blue (1/600); (ii) Alexa Fluor anti-rabbit-488 
(1/1000); (iii) Alexa Fluor anti-rabbit-488 (1/1000) with Alexa Fluor anti-mouse-568 





Finally, the secondary antibodies were removed, and the round glass slides 
were washed three times with 100 l PBS and covered with a coverslip using 
VectaShield Mounting Medium for fluorescence with or without DAPI to preserve 
the fluorescence of the sample. 
All confocal images were taken with the confocal laser scanning microscope 
(Leica TCS SP8; Wetzlar, Germany), and the images were analyzed using the LAS X 
Life Science software. 
II.2.7.3. Stochastic Optical Reconstruction Microscopy 
AVE1642 and PGA-AVE1642 were labeled with two different fluorophores, 
Cyanine 3 (Cy3) and Cyanine 5 (Cy5), respectively (See Section II.2.2). To avoid 
quenching and employ the correct concentration range, we generated a calibration 
curve for each compound using 0.0005 to 0.005 mg/ml polymer equiv. (PGA) in PBS 
in the case of PGA-AVE1642-Cy5 (AVE1642: 2.595 mg/ml, PGA-Cy5: 0.018 mg/ml 
and Cy5: 6.9% (w/w)) and 0.072 to 0.72 mg/ml of AVE1642 equiv. in PBS for 
AVE1642-Cy3 (AVE1642: 2.22 mg/ml and Cy3: 1.68% (w/w)) (Figure 5). 100µl of 
each concentration was added to the wells of a black 96-well plate in duplicate, and 
the fluorescence measured in the spectrophotometer at a specific FI (Cy3; 561nm, 





Figure 5: AVE1642-Cy3 and PGA-AVE1642-Cy5 Fluorescence Calibration Curves. The 
graphs show fluorescence counts vs. concentration (mg/ml). A) AVE1642-Cy3 
concentrations of 0.072, 0.144, 0.288, and 0.433 mg/ml AVE1642 equiv. B) Fluorescence 
intensity was assessed for PGA-AVE1642-Cy5 concentrations of 0.0005, 0.001, 0.002, and 
0.003 mg/ml polymer. Data expressed as mean±SEM, n=3. 
VCaP cells were seeded at around 67,000 cells/cm2 in a final volume of 
400µl complete medium on a NuncTM Lab-TekTM chamber slide. After 72 h of 
incubation, the medium was removed, and the cells were incubated at 37ºC with 
the combination of 0.001 µg/ml polymer concentration for the PGA-AVE1642-Cy5 
and 0.03 µg/ml AVE1642 concentration for AVE1642-Cy3 at different times (5, 15, 
30, 60 and 180 mins) in 200µl complete medium. 
Following treatment, the media was removed, cells were washed with PBS, 
the cells were fixed with 400µl of 4% PFA for 20 mins at RT, and then cells were 
washed three times with PBS. Finally, 200µl of Storm Buffer (20 µl glucose (50%), 
20 µl cysteamine (MEA 1M), 2 µl GLOX (14 mg glucose oxidase + 50 μl catalase  
(17 mg/ml)) with PBS were added, and images were taken in Nikon N-STORM 4.0 




II.2.8. IGF-1R Internalization Analysis 
23,000 VCaP cells (around 67,000 cells/cm2) were seeded in a 96-well plate 
in a total volume of 100 l complete medium. Cells were incubated for 72 h and 
then treated for 15, 30, and 60 mins with 0.1 g/ml of natural ligand Insulin-like 
Growth Factor-I (IGF-1) as a positive control, AVE1642, and PGA-AVE1642. A  
non-treated negative control cell sample was also employed.  
After the allotted times, the media was removed, and the cells were 
washed once using 100 l of PBS for 5 mins. Cells were then fixed with 100 l of 2% 
(w/v) PFA in PBS for 20 mins at 37ºC. Subsequently, the wells were washed three 
times for 5 mins with 100 l of PBS and then 100 l of blocking buffer was added 
to each well for 1 h at 37ºC to avoid non-specific antibody binding. 
Cells were incubated overnight at 4ºC, shaking with 50 l of anti-rabbit IGF-
1R-β primary antibody (1/100) diluted in 10% (v/v) FBS. The primary antibody was 
then removed, and the cells washed three times for 5 mins with 100 l PBS. Then, 
50 l of the secondary antibody Alexa Fluor anti-rabbit-488 (1/500) was added in 
each well diluted in 5% (v/v) FBS. The plate was incubated for 1 h, shaking in the 
dark at RT. After 1 h, the medium was removed, and the cells were washed three 
times for 5 mins with 100 l PBS. 5 g/ml of DAPI (1/500) diluted in PBS was added 
to each well in a 100 l final volume.  
Data acquisition was performed in an IN-Cell Analyzer 2200 instrument  
(GE Healthcare; UK), an inverted epifluorescence microscope equipped with a solid-
state illumination source, different objectives, and excitation/emission filters. The 
images were collected through a 16-bit sCMOS camera. Three pairs of 
excitation/emission dichroic filters were used to acquire the images: 390/18 
excitation and 432.5/48 emission for DAPI, 475/28 excitation and 511.5/23 




used to collect twenty images for each well. After the acquisition, the images were 
analyzed in the IN-Cell Workstation software (GE Healthcare; UK). Cell 
segmentation was used to analyze cellular intensity. The cells were segmented, 
defining a perimeter expressed in µm around the nuclei membrane. The cell 
intensity of Alexa Fluor 488 was analyzed, and the mean of each well was obtained. 
II.2.9. Protein Analysis in Cell and Tumor Samples 
II.2.9.1. Cellular Pellet Processing  
Detection of endogenous protein levels was analyzed in different 
exponentially growing PCa and normal prostate cell lines (VCaP, LnCaP, DU-145, 
22Rv1, PC-3, RWPE-1, and VCaP-Luc2). All the PCa cell lines were attached in a T75 
flask at a cell passage number between 15 and 19. To detach cells, the medium was 
removed, and all the flasks were washed once with 3 ml of sterile PBS. After 
removing sterile PBS, 2 ml of trypsin was added, and all the flasks were incubated 
for 1 min at 37ºC. Once the cells were detached, 8 ml of corresponding complete 
growth medium was added to inactivate the trypsin, and the cells were collected in 
a 15 ml falcon.  
For mechanisms of action studies, 600,000 VCaP cells (around 67,000 
cells/cm2) were seeded in a 6-well plate in 2 ml of complete medium, and the cells 
were incubated for 72 h. The medium was then removed, and the cells treated with 
the positive ligand (IGF-1), AVE1642, and PGA-AVE1642 at 0.1 g/ml in 2 ml final 
volume for 15 and 30 mins. Then the cells were detached and collected in a 15 ml 
falcon as described above. 
Then, the cells were centrifuged for 5 mins at 1,600 rpm to obtain the 
cellular pellet. After discarding the supernatant, the falcons which contained the 





II.2.9.2. Tumoral Sample Processing 
Tumors treated with AVE1642 and PGA-AVE1642 alone and in combination 
with Abiraterone Acetate (AA) were frozen in liquid nitrogen and stored at -80ºC 
after their removal from mice. Tumors were then processed in a mortar in the 
presence of liquid nitrogen to avoid protein degradation. Once a powder was 
obtained, the samples were added to a 2 ml Eppendorf and were stored at -80ºC. 
A small amount of each sample was collected with a spatula and placed in a 1.5 ml 
Eppendorf to extract tumor proteins.  
II.2.9.3. Cellular and Tumoral Extraction and Quantification 
To extract the cellular and tumoral proteins and avoid proteolysis and 
dephosphorylation, 50 l (for cellular samples) and 100 l (for tumoral samples) of 
extraction buffer (IC 1X and a PhosSTOP 1X diluted in Radio-immunoprecipitation 
[RIPA] buffer [0.15M sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 1% 
SDS, 50 mM Tris, pH 8.0 with Milli-Q water]) was added, and the samples were 
incubated for 10 mins on ice and then vortexed for 10 secs for three cycles. Next, 
the samples were centrifuged 20 mins at 13,200 rpm at 4ºC. The supernatants were 
collected in a new Eppendorf, and the pellets were discarded.  
Protein quantification was determined through by Bradford assay. First, a 
standard calibration curve was constructed using dilutions of BSA in PBS. Next, all 
samples were prepared at a 1:10 dilution with PBS. Then, 5 l of samples for the 
calibration curve and experimental samples were added in a non-sterile 96-well 
plate. 200 l of Bradford reagent was then added to each well, and after 7 mins, 
the absorbance was measured in a spectrophotometer at OD595nm. The protein 




II.2.9.4. Protein Detection 
Protein samples were prepared for Western blotting, employing 50 g of 
protein for phosphorylated proteins and 20 g for non-phosphorylated proteins. 
Both were prepared with 7.5 l of 4X Loading Buffer (250mM Tris-HCl pH 6.8, 
140mM SDS, 30 mM bromophenol blue, 27 mM glycerol, and 0.1 mM DTT) and PBS 
to obtain a final volume of 30 l. Then, the samples were denatured at 95ºC for 7 
mins to ensure protein denaturation.  
Proteins were run on a 1.5 mm-thick gel of 8% polyacrylamide (w/v) 
concentration following previous specifications [14] for optimal separation of high 
molecular weight proteins. Polyacrylamide gels were composed of resolving and 
stacking gels; resolving gels were prepared with 40% (w/v) 
acrylamide/bisacrylamide stock (29:1) and Milli-Q water with 2.5 μl 1.5 M Tris-HCl 
pH 8.8, in which 100 μl of 10% (w/v) APS and 10 μl of TEMED were added for gel 
polymerization; stacking gels were prepared with 500 μl 40% (w/v) 
acrylamide/bisacrylamide, 1 ml 0.5 M Tris-HCl pH 6.8, 2.42 μl Milli-Q water, 40 μl 
10% (w/v) APS, and 4 μl TEMED. 
To eliminate bubbles from separating gel before polymerization, 200-300μl 
of 2-isopropanol were laid over the separating gel and then subsequently removed 
after acrylamide polymerization with water. The stacking gel mix was placed over 
the separating gel, and a comb with 10 wells was placed in the gel before gel 
polymerization. Vertical gel electrophoresis was performed in Mini-Protean Tetra 
Cell cuvettes (Bio-Rad); gels were placed into the apparatus and 30 l of samples 
and 7 l of protein marker was loaded into the wells. Protein gels were run in 
Running buffer 1X (25 mM Tris-Base, 192 mM glycine, and 0.1% (w/v) SDS 20% in 
type II water) at a constant voltage of 95 V during 10 mins and then 120 V until 




After protein separation, the proteins were blotted to a polyvinylidene 
difluoride (PVDF) transfer membrane. Prior to the transfer, the membrane was 
activated in methanol for 30 secs and then, in a transfer cassette “sandwich” was 
constructed (from bottom to top – cathode(-) to anode (+)) of one sponge, two 
Whatman blotting papers, the polyacrylamide gel, the activated PVDF membrane, 
another two Whatman blotting papers, and one sponge. This sandwich was placed 
at 4ºC in a Mini-Protean Tetra Cell cuvettes (Bio-Rad) with an icebox, an agitator, 
and transfer buffer (4.13 mM Glycine, 5 mM Tris with type II water) and run at 
400mA constant amperage for 2 h. 
Once transfer assays were finished, PVDF membranes were incubated with 
Ponceau solution (1% (w/v) Ponceau with 1% (v/v) acetic acid in type II water for 
2 mins to verify adequate protein transfer. PVDF membranes were then blocked 
with PBS pH 7.4 with 0.0005% Tween 20 and 5% (w/v) skimmed milk at RT shaking 
for 1h.  
After removal of the blocking solution, the membrane was incubated with 
different primary antibodies (anti-rabbit p-IGF-1R-β (Mw:95 kDa), anti-mouse p-Shc 
(Mw: 63 KDa), anti-rabbit p-MAPK (Mw: 42 KDa), anti-rabbit p-IRS-1 (Mw: 180 KDa), 
anti-rabbit p-PI3K (Mw: 85 KDa), anti-rabbit IGF-1R-β (Mw: 95 kDa), anti-rabbit 
Androgen Receptor (AR) (Mw: 110 KDa), anti-mouse ERG (Mw: 55 KDa) and  
anti-mouse α-tubulin (Mw: 50 KDa) diluted in PBS-Tween 20 with 5% (w/v) 
skimmed milk) and incubated overnight shaking at 4ºC . The next day, the primary 
antibodies were removed, and the membrane was washed three times with  
PBS-Tween 20 buffer for 10 mins. The membrane was then incubated for 1 h 
shaking at RT with secondary anti-rabbit and anti-mouse antibodies diluted in  
PBS-Tween 20 with 5% (w/v) skimmed milk. Afterward, the membrane was washed 




The ECLTM Prime Western Blotting Detection Reagent substrate was used 
for chemiluminescent detection. The substrates A and B (ratio 1:1), were mixed and 
poured over the membrane and incubated at RT in the dark for 30 secs. Any excess 
of the solution was removed, and the membrane was placed in a HypercassetteTM, 
and a Curix 60 film processor was used to visualize the signal in an Amersham 
HyperfilmTM MP. Finally, Western blotting images were analyzed by densitometry 
using ImageJ software, and the proteins levels were normalized to the 
housekeeping protein α-tubulin.  
II.2.10. In Vivo Analyses 
II.2.10.1. Ethical Considerations 
Animal experiments performed were planned following the European 
Communities Council Directive (86/609/ECC) guidelines and by the Spanish Royal 
Decree 1201/2005. All experimental procedures were approved by the Institutional 
171 Animal Care and Use Committee and carried out by accredited and trained 
staff, meeting the animal care rules.  
II.2.10.2. Development of Orthotopic Prostate Cancer Mouse Model 
The orthotopic PCa mice model used C.B-17/IcrHan®Hsd-Prkdcscid male 
strain at 6-8 weeks of age. Thirty mins before surgery, a subcutaneous injection of 
morphine 2% (5 mg/kg) was administered, and then the mice were anesthetized by 
isoflurane inhalation with (2-5%) throughout the surgical process. Once the ventral 
prostate gland was localized, 1 x 106 VCaP-Luc2 cells prepared within 1:3 (v/v) of 
Matrigel and DMEM complete medium in a final volume of 40 µl were 
orthotopically implanted using an insulin syringe (29G). Next, the muscular area and 
the skin were sutured separately, employing absorbable 6/0 sutures. Post-surgery, 
subcutaneous buprenorphine (0.1 mg/kg) was administered every 12 h for 72 h as 




Tumor growth was measured twice a week via in vivo bioluminescence by 
Xenogen IVIS® Spectrum (Caliper Life Sciences; Hopkinton, Massachusetts, USA) for 
seven weeks, at which point the tumors reached a maximum size permitted of  
1.2 cm3 [15, 16]. To be able to visualize the tumor luminescence, 150 mg/kg of 
XenoLight D-luciferin Potassium Salt in sterile PBS was administered 
subcutaneously as a bioluminescent substrate. Immediately, mice were 
anesthetized, and 10 mins after injection mice were introduced in the IVIS® 
Spectrum. Tumor images were acquired using the following parameters: Exposure 
time: 10 mins, Binning: 8, F/Stop: 1, Emission Filter: Open and Field of View: C. With 
these parameters, the luminescent tumor signal will be acquired within 20 mins 
post luciferin injection. In the following animal experiments, we used this schedule. 
Finally, the luminescence in the tumors was analyzed with the Living Image® 
(64-bit) program. 
II.2.10.3. Enhanced Permeability and Retention Effect Analysis 
The orthotopic PCa mice model previously developed was studied to 
analyze the enhanced permeability and retention (EPR) effect. Evans Blue (EB) dye 
BSA (8:1 ratio) dissolved in a 0.9% sodium chloride solution was injected 
intravenously at 10 mg/kg. Each week, a group of six tumor-bearing untreated mice 
was euthanized 1 h after EB/BSA injection; the tumor growth was weighed and 
measured by caliper after tumor extraction. Tumors were washed with PBS and 
incubated at 60ºC for 48 h in 3 ml of formamide to extract the dye from the tumor. 
The percentage of dye accumulated in the tumor was measured by the 
spectrophotometer at OD620nm [17-19] and compared against an EB/BSA calibration 





Figure 6: Calibration Curve for Evans blue:BSA Solution. The graphs show the absorbance 
vs. concentration (µg/ml) at 2, 4, 8, 16, and 32 µg/ml Evans blue:BSA solution. Data 
expressed as mean±SEM, n=3. 
II.2.10.4. Biodistribution Experiment and Fluorescent Quantification 
C.B-17/IcrHan®Hsd-Prkdcscid mice at maximum EPR effect (0.05 cm3) were 
also used for biodistribution studies. Twelve mice were used (n=4). A concentration 
of 10 mg/kg of AVE1642 equiv. was intravenously (i.v.) injected through the tail vein 
for labeled PGA-AVE1642-Cy5.5 (AVE1642: 4 mg/ml, PGA-Cy5.5: 0.24% (w/w)) and 
AVE1642-Cy5.5 (AVE1642: 4 mg/ml, Cy5.5: 0.26% (w/w)). Mice were euthanized at 
4 h post-administration, as this represents the maximum tumor accumulation time 
observed for other PGAs [20-22]. Tumors were carefully removed, weighed, and 
stored at -80ºC for subsequent homogenization and fluorescent quantification. 
For fluorescence quantification, the tumor was resuspended in 1 ml of cold 
PBS and vigorously mixed. The suspensions were centrifuged at 4000 rpm for 1h at 
4ºC, and the supernatants were collected for fluorescent measurement. Tumor 
supernatants were measured in triplicate (100 µl) in a black 96-well plate using a 
spectrophotometer (595 nm excitation and 680 nm emission). Furthermore, two 
calibration curves were performed, one for AVE1642-Cy5.5 and another for  




1, 5, and 10 µg/ml), in order to analyze tumor fluorescence levels (Figure 7). Final 
fluorescent measurements were standardized according to tissue weight. 
 
Figure 7: AVE1642-Cy5.5 and PGA-AVE1642-Cy5.5 Fluorescence Calibration Curves. A and 
B) Graphs represent fluorescence vs. concentration (mg/ml) at 0.5, 1, 5, 10 µg/ml AVE1642 
equiv. Data expressed as mean±SEM, n=3. 
II.2.10.5. Antitumoral Activity Analysis 
Compounds were administered once tumors reached a size that allows for 
the maximum EPR effect (0.05 cm3, corresponding to week 2) with at least 6 animals 
used in each group. 
AVE1642 and PGA-AVE1642 as a single and combination therapy with AA 
were i.v. administered starting from the second week at 10 mg/kg once a week for 
four weeks. AA was administered by oral gavage (20 Gauge, 30 mm length) at  
200 mg/kg once a day for 35 days, also starting on week 2, and DHEA as a 
testosterone/estrogen precursor was subcutaneously administered daily at 0.1 mg 
as a supplement. AA and DHEA were previously dissolved in 95% sunflower oil/5% 
benzyl alcohol and 10% DMSO, respectively. 
When control animal tumors (animals without treatment) reached a size of 
1.2 cm3 (corresponding the seventh week), all animals were euthanized via carbon 




extraction. Blood was also extracted from the heart employing 21G x 1” needles  
(Ø 0.80 x 25 mm), and insulin syringes 10 µl 0.1% (w/v) EDTA was added in the 
insulin syringes to avoid clotting. 100 µl of each sample was centrifuged for 10 mins 
at 4000 rpm at 4ºC to obtain the plasma used to quantify PSA levels using a Human 
PSA free (KLK3) ELISA following the manufacturer’s instruction.  
II.2.10.6. Tumor Immunohistochemistry  
At the experimental endpoint, those mice used for immunohistochemical 
analyses were injected with 80 µl of FITC-Lectin to aid in the identification of 
perfused vessels within tumors. The resected tumors were embedded in Tissue-
Tek® and frozen in a metal container containing isopropanol located in a box with 
dry ice. The samples were stored in -80ºC fridge until histological analyses.  
Cryosections were made from Tissue-Tek® embedded and frozen tumors 
with the use of a Cryostat (CM3050 S, Leica; Wetzlar, Germany). Slices with a 
thickness of 8 µm were taken from distinct levels of the tumor tissue to consider 
distinct parts of the tumor. Two 8 µm-thick slices were fixed on each adhesion 
microscope slide that was stored at -80ºC until use in various immunofluorescence 
experiments. 
Analysis of CD31, α-SMA, VGFR2, and Ki67 levels employed a similar 
experimental procedure. To remove the embedding Tissue-Tek® material, slides 
were washed in PBS for 2 mins, fixed with 80% methanol for 5 mins at RT, and then 
with acetone at -20ºC for 2 mins. Slides were then washed three times with PBS for 
5 mins. The tumor slices were then surrounded by the hydrophobic marker Pap-
Pen® which is used to prevent the aqueous staining solution from spreading out of 
the sections. To facilitate the diffusion of the Ki67 antibody towards its specific 
nuclear target, an additional permeabilization step with 0.1% Triton-X 100 in PBS  




and incubated at RT in a humid chamber for 1 h with the respective primary 
antibody diluted in 12% BSA. Tumor slides were then washed three times for 5 mins 
with PBS and incubated for 45 mins at RT in a humid chamber with the secondary 
antibody solution in 12% BSA (DAPI was included in this solution to detect nuclei). 
After washing three times with PBS for 5 mins, the slides were mounted with 
Mowiol® 4-88 and coverslip (24 x 50mm) to be stored at 4ºC. Mowiol® 4-88 is an 
embedding medium, and “anti-fade” agent used to reduce light-scattering and 
light-induced fading (photobleaching) of the fluorophore.  
Images at 20X were taken to quantify the area fraction percentage (AF%) 
(percentage of the fluorescent signal of each protein marker). Moreover, images at 
10X were taken to evaluate the vessel functionality and maturity.  
The stained tumor sections were analyzed using the fluorescence 
microscope Axio Imager M2 (Carl Zeiss Oberkochen) with Axio Vision SE64 Rel. 4.9 
software. In each tumor section, 3 and 6 representative images at 10X and 20X 
magnification respectively were acquired from the “core” area (the most central 
part of the tumor). The images were analyzed using the Microscope Dongle 
program. 
 
II.3. Statistical Analysis 
All values obtained were plotted, displayed as ± SEM from n ≥ 3 assays. 
Animals experiments were performed using 6-9 animals per group. Statistical 
significance was evaluated using a paired t-test, two-way ANOVA, test t, or ANOVA 
test depending on the type of test performed; comparisons with p<0.0001 (****), 
p<0.001 (***), p<0.01 (**), and p<0.05 (*) were considered statistically significant 
with a 95% confidence interval. GraphPad Prism 8 software was used to performed 
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PGA Conjugation Alters AVE1642 






























III.1. Antecedents and Background 
As described in the general introduction, several studies have detailed the 
biological consequences of TMPRSS2:ERG (T2E) fusion gene presence in PCa. 
Insulin-like growth factors (IGF) also play an important role in PCa development; 
specifically, IGF-1R promotes normal prostate gland growth and development and 
can, therefore, contribute to PCa progression.  
The presence of the T2E fusion gene has been correlated with increased 
levels of IGF-1R, while T2E also aids in the classification of PCa patients subtype and 
the development of specific therapies strategies [1].  
Therapeutic approaches for cancer treatment that block IGF-1R activity, 
including monoclonal antibody (mAb) inhibitors of IGF-1R, IGF-1R tyrosine kinase 
inhibitors, or IGF-1/IGF-2 neutralizing mAbs, inhibit the activation of intracellular 
PI3K and MAPK signaling pathways implicated in cell growth and proliferation  
[2, 3]. Several clinical trials have evaluated IGF-1R inhibiting mAbs in CRPC patients; 
these include Cixutumumab, Figitumumab, and AMG479 as single agents or in 
combination with other drugs. However, these therapies failed to display their 
expected therapeutic potential due to incomplete pathway inhibition or the 
presence of side toxicities that prompted the clinical trial termination [4].  
With a focus on mAb inhibitors of IGF-1R, we sought to evaluate a polymer 
therapeutics strategy in the hope of improving pathway inhibition, reduce side 
toxicities, and, therefore, improve therapeutic outcomes in PCa patients [5]. In this 
chapter, we synthesized and fully characterized a polymer-mAb conjugate as an 
advanced PCa treatment option. Specifically, we conjugated AVE1642, an  
anti-IGF-1R mAb, with poly-L-glutamic acid (PGA)-based polymer (generating  




our lab [6, 7] and then compared anti-tumorigenic activity to the parental mAb 
through both in vitro and in vivo analyses. 
AVE1642 is a humanized mAb version of the murine mAb EM164 directed 
against the IGF-1R. Anti-IGF-1R mAb AVE1642 specifically binds and blocks IGF-1R 
located in the cellular membrane preventing the binding of the natural ligand  
IGF-1 and the subsequent activation of an intracellular signaling pathway, which 
result in a decrease in cellular proliferation and the induction of apoptosis. 
Furthermore, it is reported that AVE1642 induces the regression of human 
xenografts tumors, inhibits metastasis, and enhances chemosensitivity [8, 9].  
Mancarella et al. demonstrated that the monoclonal antibody anti-IGF-1R 
(AVE1642) presented specific cytotoxic effects in T2E-positive PCa cell lines [10].  
Previous studies demonstrated the murine mAb EM164 effectiveness in 
different cellular models such as pancreatic, colon, neuroblastoma, or human 
myeloma cells. In both neuroblastoma and human myeloma cells, it is reported that 
EM164 inhibits Akt and MAPK signaling pathways; furthermore, it produces an 
arrest in the cell cycle in the G1 phase. In addition, xenograft neuroblastoma mice 
animal studies treated with EM164 intravenously at 40mg/kg twice a week for 4 
weeks showed significant antitumor activity, and a synergistic effect in combination 
with temozolomide (100mg/kg) administered orally for 5 days [11, 12]. 
Phase I clinical trials of AVE1642 in PCa, pancreatic cancer, and non-small-
cell lung cancer (NSCLC), documented tolerability and safety when administered at 
6 mg/kg three times per week in combination with other anti-cancer therapies, 
including docetaxel, gemcitabine, and erlotinib [13]. For instance, phase II clinical 
trials using anti-IGF-1R mAb inhibitors only experienced a partial response to 
therapy and a lot of side effects (neutropenia, diarrhea, hyperglycemia, etc.) in 




Currently, AVE1642 is being evaluated in clinical trials in different studies 
such as multiple myeloma, liver carcinoma, and in postmenopausal patients with 
advanced hormone-dependent breast cancer [53]. 
III.2. Synthesis of PGA-conjugated AVE1642 
As stated in the introduction section, polypeptides offer significant 
advantages as a polymeric carrier system; therefore, we have selected 
polyglutamates (PGA) as biodegradable multivalent polymeric carrier following well 
stablished synthetic methodologies in our lab [7, 16] to design our 
immunoconjugate. Overall, our conjugation strategy involved the modification of 
the lysine residues of AVE1642 with a linker that would form cleavable disulfide 
bonds with a modified PGA polymer [7], thereby generating PGA-AVE1642. 
III.2.1. Synthesis of Pyridyl Dithiol-modified PGA 
We derivatized PGA (200 glutamic acid units (GAU), polydispersity index 
(PDI) 1.15) with pyridyl dithiol ethylamine using DMTMM BF4 (4-(4,6-dimethoxy-
1,3,5-triazin-2-yl)-4-methylmorpholinium tetrafluoroborate) as a carboxylic acid 
activator. We then purified (precipitation in ether) and analyzed the derivatized 
polymer (PGA-PD) by NMR to quantify the degree of modification (See Chapter II, 
Section II.2.1.1) (Figure 1).  
The ratio of the integrals of the pyridine ring (7.26, 7.79 and 8.36 ppm) to 
the integral of the main chain proton of PGA (4.35 ppm) was used to calculate the 
percentage derivatization of PGA with pyridyl dithiol groups, and from this, the 
molecular weight (Mw) of the modified polymer was also calculated (Mn of the 
pyridyl dithiol GA unit is 297 and of the GA unit, 151). The degree of 
functionalization was determined by nuclear magnetic resonance (NMR) at 18-24 




This analysis established that the subsequent polymer conjugation of 
AVE1642 employed PGA with a degree of pyridyl dithiol modification between 18.5-
23.8%, which corresponds to a modification of ~36 to 48 glutamic acid units (GAU) 
out of the total 200. From the percentage of modification, we calculated an 
approximate molecular weight (Mw) of PGA-PD between 35.4 and 37.2 kDa. 
 
 
Figure 1: Representative 1H-NMR spectrum of PGA-PD in D2O. 1H-NMR (300 MHz, D2O, 
ppm): 1.95-2.29 (m, C-CH2CH2-COONa of PGA side-chain protons), 2.94 and 3.46 (m, CH2CH2 
of ethylamine), 4.35 (m, NH-CH-CO of PGA main chain), 7.26 (m, ArH), 7.79 (m, ArH), 8.36 
(m, ArH).  
III.2.2. Synthesis of N-Succinimidyl-S-acetylthiopropionate-modified 
AVE1642 
We next introduced protected thiol groups into the AVE1642 backbone by 
partially modifying the accessible lysine residues with an N-Succinimidyl-S-
acetylthiopropionate (SATP) linker that can form stable amide bonds with primary 




storage; furthermore, these protective groups can be easily removed via 
hydroxylamine hydrochloride treatment to expose free sulfhydryl groups. AVE1642 
contains approximately 90 lysine residues, with around 30 accessible for 
modification [17]. We performed the SATP modification of AVE1642 (to create 
AVE1642-SATP) with the degree of functionalization 25 equiv. of SATP per antibody, 
randomly modifying the amine groups of the exposed lysine residues. The yield of 
the reaction was 85%. 
III.2.3. Design and Synthesis of PGA-AVE1642 Conjugates 
The conjugation of PGA-PD to AVE1642-SATP exploited the formation of 
reduction-sensitive disulfide bonds between the PD groups of the modified PGA 
and the sulfhydryl groups introduced into the structure of AVE1642. While naturally 
occurring cysteine residues should not be involved in the coupling reaction, as they 
are present in the disulfide-bonded state, we do note that studies have detected 
free sulfhydryl groups in IgG samples from serum and recombinant antibodies [18]. 
We performed the conjugation reaction in the presence of hydroxylamine 
hydrochloride to deprotect the acetyl group of AVE1642-SATP using different equiv. 
of PGA (from 5 to 25 equiv.), producing PGA-AVE1642 with different degree of 
functionalization (from 2 to 10). We removed any excess of the unreacted polymer 
by ultracentrifugation. The quantification of PGA chains attached to a molecule of 
AVE1642 was determined by amino acid analysis. 
Focusing on the most straightforward approach, with the least PGA chains 
per mAb, we prepared two batches of PGA-AVE1642 conjugates in which the 
quantification of PGA chains was 2.2 and 2.8, respectively. The yield of both 
reactions was 70%. This data confirms the reproducibility of established 




Figure 2 shows a schematic representation of the general synthetic strategy 
followed to achieve PGA-AVE1642 conjugates.  
Figure 2: Reaction Scheme of AVE1642 Conjugation to PGA. A) PGA is modified by the PD 
group to obtain PGA-PD. B) AVE1642 is modified by SATP and subsequently conjugated with 
PGA-PD to obtain the final product PGA-AVE1642.  
III.3. Cytotoxicity Analysis Suggests that High Levels of PGA 
Conjugation do not Negatively Influence AVE1642 Activity in 
the Adequate Prostate Cancer (PCa) Cell Line.  
III.3.1. Selection of Adequate PCa Cell model 
AR positively regulates TMPRSS2 gene expression, thereby leading to high 
levels of the expression of this transmembrane serine protease in prostate tissue. 
However, upon the formation of the T2E fusion gene, which is overexpressed in 
certain PCa cell lines [19, 20], the androgen-responsive promoter of the TMPRSS2 
genes becomes rearranged within the coding region of the ETS-related gene (ERG), 
leading to ERG overexpression [21, 22]. High levels of ERG protein then 




analyzed the protein expression levels of IGF-1R-β, AR, and ERG in a panel of PCa 
cell lines (VCaP, LnCaP, DU-145, 22Rv1, PC-3) and a normal prostate cell line  
(RWPE-1) by Western blot (Figures 3.A and B) to confirm the optimal cell line in 
which to assess PGA-AVE1642 activity. 
Overall, we discovered that VCaP cells expressed the highest levels of  
IGF-1R-β and AR when compared to the other cell lines, while VCaP cells were the 
only cell line to show detectable levels of ERG protein expression (Figures 3.A  
and B). 
Figure 3: Protein Expression Profiles of Select PCa Cell Lines. A) Western blot analysis of 
IGF-1R-β, AR, ERG, and α-tubulin in VCaP, LnCaP, DU-145, 22Rv1, and PC-3 PCa cell lines and 
RWPE-1 as a normal prostate tissue. B) Quantified protein expression relative to α-tubulin 
expression in each PCa cell line. Data expressed as mean±SEM, n=3.  
 These findings support previous studies reporting that VCaP cells possess 
the T2E fusion gene and, therefore, overexpress ERG and IGF-1R [23-26]. 
Furthermore, these findings confirm VCaP cells as the best cell line candidate from 





III.3.2. Cytotoxicity of AVE1642 derivatives 
Before continuing with an exhaustive characterization with all synthesized 
conjugates, we analyzed cytotoxicity via MTT assay using a concentration range of 
0.003-50 µg/ml AVE1642 equiv. and a 72h incubation in VCaP cells (Figure 4). The 
full characterization of the VCaP cell line can be found in Section III.4. Overall, we 
discovered a trend towards lower cell viability in response to increasing 
concentrations of PGA-AVE1642 conjugates; however, we failed to observe any 
significant correlation between PGA chain number and cytotoxicity. 
Overall, this suggests that increasing levels of PGA modification do not 
significantly influence the cytotoxicity/function of AVE1642, high levels of PGA 
conjugation do not negatively influence AVE1642 activity. However, for chemical 
economy and simplicity, we moved ahead with the 2:1 PGA-AVE1642 (average 2.8 
PGA chains per AVE1642, Table 1) conjugate (minimal modification) for all 
subsequent experiments in this thesis.  
 
Figure 4: AVE1642 Activity Unaltered after PGA Modification. Graphs represent VCaP cell 
viability following exposure to PGA-AVE1642 conjugates with increasing numbers of PGA 
chains per AVE1642 compared to AVE1642 as control versus concentration (µg/ml AVE1642 
equiv.). VCaP cells were treated with all the compounds at for 72 h at 37ºC at concentrations 




III.4. Characterization of 2:1 PGA-AVE1642 conjugate 
We performed full characterization of selected 2:1 PGA-AVE1642 conjugate 
in order to fully understand how PGA could alter mAb conformation and to assess 
size, charge, and structure aiming to have the premises for a batch to batch 
reproducibility process that would facilitate translation if needed. 
III.4.1.  SDS-PAGE Gel Electrophoresis Analysis 
We first characterized the PGA-AVE1642 conjugate by SDS-PAGE (sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis) to assess hydrodynamic 
volume. Figure 5 shows the appearance of unmodified AVE1642 (Mw = 178.5 kDa) 
as a band at 150-160 kDa, while SATP-modified AVE1642 presented a similar band 
pattern and, therefore, size. Of note, we did not observe additional species at 
higher Mw, suggesting the absence of protein dimers or aggregates upon 
derivatization. The SDS-PAGE analysis of PGA-AVE1642 established a shift to a 
higher Mw when compared to AVE1642 with a smeared band present between 160 
and 220 kDa. PGA alone cannot be detected by SDS PAGE using Coomassie blue 
staining, although the observed increase in the Mw after polymer conjugation 
provides evidence of the successful formation of PGA-AVE1642 conjugate. 
 
Figure 5: SDS-PAGE (5%) of AVE1642 (≈ 150-160 kDa; L1); PGA-AVE1642 (≈ 160-220 kDa; L2) 
and AVE1642-SATP (≈150-160 kDa; L3). M1 and M2 are protein markers for different 




III.4.2. Size Analysis by Size Exclusion Chromatography  
We next analyzed compound size (hydrodynamic radius) by size exclusion 
chromatography (SEC), which is based on the separation of compounds by their 
hydrodynamic volumes: higher molecular weights provide smaller elution volumes 
and vice-versa. We found an elution volume of unconjugated AVE1642 of 1.7 ml, 
while the peak of the polymer-antibody conjugate shifted to 1.5 ml, indicating an 
increase in the hydrodynamic radius.  
SATP conjugation to AVE1642 failed to alter the retention volume 
significantly and, therefore, size, as expected. Peak PGA-PD displayed a retention 
volume of 2 ml (Figure 6.A). In the presence of 50 mM dithiothreitol (DTT), a 
reducing agent that reduces disulfide bridges, AVE1642 maintained its stability as 
the elution peak did not change from the retention volume (1.7 ml). However, the 
incubation of PGA-AVE1642 with DTT led to linker cleavage as the elution peak 
shifted to a value similar to the retention volume of unconjugated AVE1642 





Figure 6: SEC profiles of A) AVE1642 (discontinuous black line), AVE1642-SATP (continuous 
grey line), PGA-AVE1642 (continuous black line), PGA-PD (black dotted line), and  
B) PGA-AVE1642 (continuous black line), PGA-AVE1642 incubated with DTT (continuous 
grey line), AVE1642 incubated with DTT (discontinuous black line). The y-axis of the 
chromatogram is a measure of the intensity of absorbance at 280 nm (in units of mAU, or 
milli-absorbance units). 
III.4.3. Size and Charge Analysis by Dynamic Light Scattering and  
Z-Potential Analyses 
Dynamic light scattering (DLS) analysis provides another estimate of size, 
and we established a hydrodynamic diameter of 13.5 ± 1.7 nm (by intensity) and 
7.4 ± 0.6 nm (by number) for unconjugated AVE1642 [27]. Upon conjugation with 




intensity) and 9.4 ± 0.5 nm (by number) due to the contribution of the PGA chains 
(Figure 7.A and B). 
Figure 7: DLS-based evaluation of the average diameter for A) AVE1642 and PGA-AVE1642 
by intensity. B) AVE1642 and PGA-AVE1642 by number. 
Zeta potential analysis (provides a measure of charge) of AVE1642 in PBS 
(pH 7.4) revealed a near-neutral value (-0.5 mV). Once conjugated to PGA, the 
presence of additional carboxylic groups from the polymer in the conjugate 
increased the negative charge, and we determined a zeta potential value of -11.7 
mV for PGA-AVE1642. 
III.4.4. Structural Analysis by Circular Dichroism 
We evaluated the secondary structure of AVE1642 and its derivatives by 
far-UV circular dichroism (FUV-CD) spectroscopy, measuring ellipticity between 200 
and 250 nm. We found an AVE1642 spectrum characterized by a single negative 
peak with a minimum at a wavelength of 216 nm (Figure 8), as expected for the β-
sheet structure of the immunoglobulin fold [28]. SATP modification of AVE1642 
failed to change the secondary structure, as the dichroic signal of AVE1642-SATP 
remained similar to unmodified AVE1642. At neutral pH, PGA exhibits an extended 
or disordered random coil due to Coulombic repulsion between ionized glutamate 




conjugation perturbed the β-sheet structure of the antibody given the observed 
change in the dichroic signal; however, these changes can be attributed to the 
additional contribution of the PGA spectra rather than a significant alteration to 
antibody conformation.  
We next treated PGA-AVE1642 with DTT to promote the disruption of the 
antibody-PGA linkers to evaluate whether PGA conjugation irreversibly modifies 
the AVE1642 structure. FUV-CD analysis following DTT treatment and removal of 
free PGA by ultracentrifugation established that native AVE1642 and AVE1642 after 
PGA removal displayed similar CD spectra, suggesting that the conjugation process 
did not alter the secondary structure of the antibody (Figure 8). 
 
Figure 8: FUV-CD spectra of AVE1642, AVE1642-SATP, PGA-AVE1642, AVE1642 after PGA 
removal, and PGA-PD.   
Finally, we employed CD analysis at 216 nm with a temperature range 
between 25 to 90ºC to assess thermal stability (Figures 9.A and B). We failed to 
observe any change to the dichroic signal for AVE1642 and AVE1642-SATP below 
65ºC; however, above this temperature, the antibody began to denature until the 
signal reached a minimum at approximately 77-79ºC.  Denaturation then rapidly 




PGA-AVE1642 exhibited a stable dichroic signal until 55ºC, although heat-
induced denaturation failed to promote precipitation of the conjugate, suggesting 
that PGA-conjugation increased AVE1642 stability at higher temperatures (Figure 
9.A). We assumed 100% folding of protein structure at 25ºC and 100% unfolded 
when the ellipticity reached a minimum; from these values, we calculated melting 
temperatures (Tm) for AVE1642, AVE1642-SATP, and PGA-AVE1642 of 72.5±0.2, 
71.7±0.1, and 68±0.1 °C, respectively (Figure 9.B).  
 
Figure 9. Evaluation of Thermal Denaturation of AVE1642, AVE1642-SATP, and  
PGA-AVE1642 by CD. A) Effect of temperature on molar ellipticity at a wavelength of 216 
nm. B) fraction of unfolded protein in the range 25-90ºC. The fraction of unfolded protein 
was calculated by assuming samples were completely folded and completely unfolded at 
25ºC and when the ellipticity reached the minimum, respectively. 
Overall, the characterization of PGA-AVE1642 demonstrated the successful 
nature of the conjugation process as the hydrodynamic volume of PGA-AVE1642 
conjugate increased due to the presence of the polymer, as shown by SEC,  
SDS-PAGE, and DLS analysis. Moreover, we provided further evidence for PGA 
conjugation by the increment in the negative charge of the conjugate, as measured 
by zeta potential analysis. Finally, CD analysis demonstrated the lack of any 




The following table shows a summary of the different characterization 
techniques used above (Table 1).  
 
a. As determined by amino acid analysis b. As determined by DLS c. As determined by CD. 
Table 1: Summary of the different characterization techniques.  
III.5. PGA-conjugation Enhances Stability, Improves Affinity 
for IGF-1R and Maintains Hemocompatibility of AVE1642 
We next evaluated the stability, function (by assessing affinity for IGF-1R), 
and hemocompatibility in mouse serum of AVE1642 and PGA-AVE1642 in order to 
investigate AVE1642 benefits after PGA conjugation and test safety before testing 
both compounds in further animal studies.  
III.5.1. PGA-conjugation Protects AVE1642 from Degradation 
We performed stability studies based on an ELISA assay to evaluate the 
capacity of AVE1642 and PGA-AVE1642 to bind IGF-1R. We incubated 5 µg/ml of 
AVE1642 and PGA-AVE1642 at 37ºC in standard FBS from 24 to 72 hours to study 
AVE1642 degradation, and then assessed levels of IGF-1R binding in a VCaP protein 
lysate that contains high levels of IGF-1R. Any antibody will lead to reduced target 
binding, as quantified through AVE1642 and PGA-AVE1642 calibration curves  
(See Chapter II, Section II.2.3.7). Figure 10 shows the relative degradation  
(in percentage) of AVE1642 and PGA-AVE1642 over time (hours). When compared 




significantly increased degradation at all time points analyzed, reaching 80% 
degradation by 72 hours. These results suggest that PGA conjugation improves 
AVE1642 stability and, therefore, supports enhanced functionality over extended 
times following administration.  
 
Figure 10: AVE1642 and PGA-AVE1642 Stability Studies. Graphs depict the percentage of 
degradation vs. time (24, 48, and 72 hours). Data expressed as mean±SEM, n=3. Statistical 
analysis performed using a paired t-test, *p< 0.05.  
III.5.2. PGA Conjugation Enhances the Affinity of AVE1642 for IGF-1R 
We employed IGF-1R receptor-binding assays with AVE1642 and  
PGA-AVE1642 to evaluate their affinity for IGF-1R in VCaP cell lysate using an ELISA 
assay. We employed varying concentrations of AVE1642 and PGA-AVE1642 (0-10 
µg/ml AVE1642 equiv.) diluted in 1X PBS and incubated in the VCaP cell lysate to 
detect the concentration at which the IGF-1R begins to saturate. 
Figure 11 demonstrates the absorbance of both compounds at various 
concentrations (µg/ml AVE1642 equiv.), showing that PGA-AVE1642 produces an 
IGF-1R saturation at 2 µg/ml AVE1642 equiv. (observed as a plateau in absorbance). 
However, we failed to observe IGF-1R saturation with AVE1642 at any of the 




AVE1642 for IGF-1R. Moreover, PGA-AVE1642 showed significantly higher 
absorbance over all the concentrations compared with the AVE1642 suggesting 
higher PGA-AVE1642 binding to IGF-1R compared to AVE1642 treatment.  
We also used this data to determine various parameters, including the 
dissociation constant (Kd) and the maximum binding (Bmax). For the AVE1642 
Kd=3.058 nM and Bmax=2.675 fmol/mg protein, moreover for the PGA-AVE1642 
Kd=0.4524 nM and Bmax=2.971 fmol/mg protein. The Kd is the concentration of the 
ligand that occupies half of the receptors at equilibrium, and the Bmax represents 
the density of available receptors. While PGA-AVE1642 and AVE1642 displayed 
similar Bmax values, we discovered a clear difference between Kd values. PGA-
AVE1642 possessed a higher Kd than AVE1642, again suggesting an increase in 
affinity for IGF-1R. Of note, the similar Bmax values for both compounds indicate a 
similar level of IGF-1R expression in the VCaP cell lysate. 
 
Figure 11: IGF-1R Receptor-binding Assays Comparing PGA-AVE1642 with AVE1642. 
Graphs depict absorbance vs. concentration (µg/ml). The assay was performed at different 
AVE1642 and PGA-AVE1642 concentrations in 40 µg of VCaP cell lysate. Data expressed as 
mean±SEM, n=3. Statistical analysis was performed using a paired t-test, **p< 0.01. 
Overall, we demonstrate that PGA-AVE1642 possesses a higher affinity for 




when compared to the unconjugated mAb.  Therefore, we provide evidence that 
PGA conjugation improves the interaction of AVE1642 with IGF-1R. 
III.5.3. PGA Conjugation of AVE1642 does not Promote Hemolysis 
We next performed hemolytic studies using isolated male  
C.B-17/IcrHan®Hsd-Prkdcscid red blood cells (RBCs) to study hemocompatibility 
(and, therefore, safety) of AVE1642 and PGA-AVE1642. We incubated both 
compounds at 125 µg/ml final concentration (AVE1642 equiv.) in RBCs and 
compared the log percentage of hemolysis to Triton X-100 (positive control) and 
dextran (negative control) treatments (Figure 12). We failed to encounter any 
significant levels of hemolysis upon treatment with AVE1642 and PGA-AVE1642 as 
both gave values similar to the negative control demonstrating hemocompatibility.  
  
Figure 12: Hemolysis Studies. Hemolytic studies were performed in C.B-17/IcrHan®Hsd-
Prkdcscid male mice erythrocytes employing 125 µg/ml of AVE1642 and PGA-AVE1642 
(AVE1642 equiv.), Triton X-100 as a positive control (stated 100%) and dextran as a negative 





III.6. AVE1642 and PGA-AVE1642 Displays Cell Line Specific 
Cytotoxic Activity 
We next investigated the cytotoxic effects of AVE1642, PGA-AVE1642, and 
PGA alone by assessing cell survival in VCaP cells to determine IC50 values of each 
compound and in additional PCa and normal prostate cell lines to confirm specificity 
regarding the presence of T2E.  
III.6.1. Cytotoxicity of AVE1642 and PGA-AVE1642 in VCaP Cells 
We treated VCaP cells with AVE1642 and PGA-AVE1642 at concentrations 
between 0.003 and 50 µg/ml of AVE1642 equiv. for 72 h. We then calculated the 
amount of PGA equiv. at each PGA-AVE1642 concentration used to be used as 
control at concentrations (between 0.0064 and 64.37 µg/ml) to confirm whether 
any differences in PGA-AVE1642 efficacy relate to PGA conjugation or presence of 
PGA. 
Figures 13.A and B demonstrate the alterations to VCaP cell viability 
following treatment with increasing concentrations of AVE1642, PGA-AVE1642, and 
PGA by MTS assay. Figure 13.A establishes that AVE1642 or PGA-AVE1642 act in a 
similar manner (increased cytotoxicity/decreased cell viability with an increase in 
concentration) with an IC50 for both compounds established as 0.1 µg/ml AVE1642 
equiv. Of note, the plateau in the cell viability curve may indicate the presence of 
IGF-1R saturation. Meanwhile, Figure 13.B establishes a lack of cellular toxicity 




Figure 13: Cytotoxic effects of AVE1642, PGA-AVE1642, and PGA in VCaP Cells Measured 
by MTS Assay. A) Cell viability following treatment with AVE1642 and PGA-AVE1642. VCaP 
cells were treated with both compounds for 72 h at 37ºC using concentrations between 
0.003 and 50 µg/ml AVE1642 equiv. B) VCaP Cell viability following PGA treatment. VCaP 
cells were treated with PGA at concentrations between 0.0064 and 64.37 µg/ml for 72 h. 
Data expressed as mean±SEM, n>3. 
 Overall, these data suggest that AVE1642 induces cytotoxicity, PGA 
conjugation of AVE1642 does not negatively influence this cytotoxicity, and PGA 
alone does not promote cytotoxicity in VCaP cells. 
III.6.2. Lack of Cytotoxicity of AVE1642 and PGA-AVE1642 in Alternative 
PCa Cell Lines 
We next exposed LnCaP, DU-145, 22Rv1, PC-3 and RWPE-1 cells (and VCaP 
as control) to AVE1642 (Figure 14.A) and PGA-AVE1642 conjugate (Figure 14.B) at 
concentrations between 0.003 and 50 µg/ml AVE1642 equiv. for 72 h and assessed 
cell viability by MTS assay to confirm the specificity of AVE1642/ PGA-AVE1642 
towards T2E presence. 
As expected, AVE1642 and PGA-AVE1642 treatments provided similar 
results in the T2E-bearing VCaP cell line, which displayed a marked sensitivity to 




22Rv1 cells displayed slight sensitivity to the treatments, with an observed 20% 
decrease in cell viability observed at the higher concentrations (green line, Figures 
14.A and B). This result is most probably related to ERG levels. Although in our 
experiments using western blot technique (Figures 3.A and B), we failed to detect 
ERG levels most probably due to detection limits; it has been reported the existence 
of ERG levels in 22Rv1 cell line detected by qPCR [30]. Thus, these results suggest 
that the effectiveness of the treatment depends on the ERG cellular levels. To 
corroborate this finding, we would need further studies to detect ERG levels using 
a more sensitive technique such as qPCR.  
 
Figure 14: Lack of Cytotoxic Effects of AVE1642 and PGA-AVE1642 in Alternative PCa cell 
lines. Graphs depict cell viability vs. concentration (µg/ml AVE1642 equiv.) in VCaP, LnCaP, 
DU-145, 22Rv1, PC-3, and RWPE-1 cell lines. A) Cell viability in cells treated with AVE1642. 
B) Cell viability in cells treated with PGA-AVE1642. Both treatments were incubated in cells 
for 72 h at 37ºC, using concentrations between 0.003 and 50 µg/ml AVE1642 equiv. Data 




Overall, only VCaP cells significantly respond to AVE1642 and PGA-AVE1642 
exposure, most likely due to the high IGF-1R levels (induced by the overexpression 
of ERG protein caused by the presence of the T2E fusion gene) and the added 
overexpression of AR proteins (which also induce the expression of ERG) (Figures 
3.A and B).  
III.6.3. AVE1642 and PGA-AVE1642 Mediated Cytotoxicity depends on ERG 
Expression 
To ratify these results, we assessed the requirement of the T2E fusion gene 
for the activity of AVE1642 and PGA-AVE1642 by silencing ERG expression via small 
interfering (si)RNA and carrying out Trypan blue dye exclusion cell viability 
experiments and evaluating ERG protein expression by Western blot assay after 
treatment with AVE1642 and PGA-AVE1642 (Figure 15.A). Following the 
transfection of VCaP cells with the ERG siRNA or a scrambled siRNA control, we 
treated cells with AVE1642 and PGA-AVE1642 at 0.1 µg/ml AVE1642 equiv. for 72h. 
We also treated cells with PGA as control at 0.085 µg/ml (PGA equiv. in the  
PGA-AVE1642 conjugate at 0.1 µg/ml of AVE1642) and included control cells that 
were transfected but not treated with AVE1642 and PGA-AVE1642. 
Figure 15.B-D depicts the change in cell number (in fold) in response to the 
various treatments and a representative Western blot that confirms the effective 
silencing of ERG.  
After normalizing the data to the respective controls, we discovered that 
ERG silencing promotes cell survival during exposure of cells to AVE1642 (Figure 
15.B) and PGA-AVE1642 (Figure 15.C). We observed significant differences 
observed between untransfected AVE1642-treated cells (NT AVE1642) and ERG 
siRNA + AVE1642-treated cells (siERG AVE1642) and between the scrambled siRNA 




treated cells (siERG AVE1642). We also observed significant differences between 
untransfected PGA-AVE1642 treated cells (NT PGA-AVE1642) and ERG siRNA +  
PGA-AVE1642 treated cells (siERG PGA-AVE1642) and highly significant changes 
between scrambled siRNA control + PGA-AVE1642-treated cells (SCR  
PGA-AVE1642) and ERG siRNA + PGA-AVE1642-treated cells (siERG PGA-AVE1642). 
We also confirmed the lack of cytotoxicity of PGA (Figure 15.D).  
 
Figure 15: Cell Viability following AVE1642 and PGA-AVE1642 Treatment in the Absence 
of ERG Expression in VCaP Cells. A) Representative Western blot image shows ERG 
expression in untransfected VCaP cells (NT) and VCaP cells treated with scrambled siRNA 
(SCR) and ERG siRNA (siERG). B-D) Graph shows cell survival (as measured by Trypan Blue 
exclusion assay) in untransfected VCaP cells (NT), VCaP cells transfected with scrambled 
control siRNA (SCR), and VCaP cells transfected with siRNA against ERG (siERG) treated with 
AVE1642, PGA-AVE1642, or PGA at 0.1 µg/ml AVE1642 equiv. concentration and 0.085 
µg/ml PGA equiv. concentration. Data expressed as mean±SEM, n>3. Statistical analysis was 




Overall, these findings establish that the cytotoxic effects of AVE1642 and 
the PGA-AVE1642 in VCaP cells require the ERG overexpression associated with the 
presence of the T2E fusion gene. Furthermore, this data provides additional 
evidence that PGA modification does not alter the function of AVE1642. 
III.7. PGA-conjugation Leads to Altered Molecular Responses 
and Cellular Trafficking in vitro 
After establishing that AVE1642 and PGA-AVE1642 treatment promotes 
ERG-dependent cytotoxicity in VCaP cells, we investigated the possibly modified 
interaction of AVE1642 and PGA-AVE1642 with IGF-1R. To achieve this objective, 
we evaluated the internalization of IGF-1R, studied AVE1642 and PGA-AVE1642 
energy-dependent internalization, and explored cellular trafficking. 
III.7.1. PGA-conjugation Prevents IGF-1R Internalization after AVE1642 
Binding 
We investigated IGF-1R internalization in VCaP cells using the IN-Cell 
Analyzer 6500HS, a laser-based high-content imaging system featuring IRIS confocal 
technology to optimize cellular imaging. We treated cells for 15, 30, and 60 minutes 
in the presence of AVE1642, PGA-AVE1642, and the activating ligand Insulin-like 
growth factor 1 (IGF-1) as a positive control (0.1 g/ml) and untreated cells as a 
negative control and then assessed IGF-1R-β localization by immunofluorescence. 
Imaging analysis suggested the presence of IGF-1R primarily at the cell 
membrane in untreated cells (Figure 16.A - w/o treatment) with low levels of 
intracellular IGF-1R. Both IGF-1 and AVE1642 prompted similar levels of IGF-1R 
internalization; however, PGA-AVE1642 treatment did not prompt a similar level of 




Intracellular IGF-1R quantification (See Chapter II, Section II.2.8) confirmed 
the imaging results, demonstrating an increase in IGF-1R intracellular levels after 
IGF-1 treatment over time (Figure 16.B). While AVE1642 treatment provided a 
similar result, treatment with PGA-AVE1642 led to significantly reduced 
intracellular levels of IGF-1R at 30 and 60 minutes, 5 and 32 folds, respectively, 
compared with the AVE1642 treatment (Figure 16.B).  
 
Figure 16: Subcellular Localization and Quantification of IGF-1R by IN Cell analysis. VCaP 
cells treated for 15, 30, and 60 minutes with 0.1 µg/ml IGF-1, AVE1642, and PGA-AVE1642. 
A) Images show IGF-1R localization following different treatments over time. DAPI (blue) 
stains the nucleus, while Alexa Fluor anti-rabbit-488 (green) marks the presence of  
IGF-1R-β. B) The relative percentage of IGF-1R levels at different times in the different 
conditions normalized to basal IGF-1R levels in cells without treatment. Data expressed as 
mean±SEM, n=3. Statistical analysis performed using two-way ANOVA, *p < 0.05. 
These results suggest that PGA conjugation of AVE1642 allows for IGF1-R 
binding at the cell membrane but could delay IGF1-R internalization potentiating; 




III.7.2. PGA-conjugation of AVE1642 Prevents Energy-dependent 
Internalization 
We next performed endocytic studies to understand how PGA-conjugation 
affects AVE1642 cellular internalization. For this purpose, we fluorescently labeled 
AVE1642 and PGA-AVE1642 with the fluorophore Cy5.5 (See Chapter II, Section 
II.2.2). To select PGA-AVE1642-Cy5.5 and AVE1642-Cy5.5 concentrations, avoiding 
quenching effects, we generated fluorescent calibration curves for AVE1642-Cy5.5 
and PGA-AVE1642-Cy5.5 (See Chapter II, Section II.2.7.1). Final chosen 
concentrations were 0.16 mg/ml of AVE1642 equiv. (or 0.1 mg/ml of polymer). We 
then incubated VCaP cells for 15, 60, and 180 minutes at 4ºC and 37ºC to evaluate 
energy-dependent uptake mechanisms, analyzing both the percentage of positive 
cells (containing PGA-AVE1642-Cy5.5 or AVE1642-Cy5.5) and measuring the 
fluorescent intensity (FI) from each positive cell. With this data, we quantified the 
cell internalization efficacy.  
The percentage of positive cells (Figure 17.A) represents the cells that have 
internalized AVE1642-Cy5.5 or PGA-AVE1642-Cy5.5 at 4ºC and 37ºC; overall, we 
obtained the same profile under all conditions tested. We detected an increase in 
the percentage of positive cells up to 15 minutes, followed by a plateau. Also, a 
markedly higher uptake at 37ºC than at 4ºC for AVE1642 when compared to  
PGA-AVE1642 (Figure 17.A), suggesting that AVE1642 is internalized by energy-
dependent internalization. In contrast, PGA-AVE1642 showed inhibited energy-
dependent internalization, as can be shown by the lack of difference between 37ºC 







Figure 17: Cell Internalization of AVE1642-Cy5.5 and PGA-AVE1642-Cy5.5 in VCaP cells.    
A) Percentage of positive cells versus time. B) Energy-dependent internalization at 15, 60, 
and 180 minutes. Autofluorescence was subtracted from each measurement prior to 
analysis, and a minimum of 10,000 events per sample was analyzed in living single cells. 
Data expressed as mean±SEM, n=3. Statistical analysis was performed using ANOVA,  
*p < 0.05. 
This data illustrated in Figure 17.B depicts the amount of compound that 
internalized in the cell and confirms the different internalization mechanisms 
between AVE1642 and PGA-AVE1642, with a significant difference, observed at  
180 mins. Overall, PGA-AVE1642 displays less or inhibited energy-dependent 
internalization in VCaP cells when compared to AVE1642.  
In summary, we established a lower internalization rate for PGA-AVE1642 
when compared to AVE1642, which supports previous imaging-based analysis that 
indicated an increased colocalization of PGA-AVE1642 at the cell membrane. 
III.7.3. PGA-conjugation Modifies AVE1642 Cell Trafficking  
 Given that the data obtained so far supported differences occurring in the 
cell internalization mechanisms of PGA-AVE1642-Cy5.5 vs. free AVE1642-Cy5.5, we 




studied colocalization with endocytic vesicle markers clathrin and caveolin-1, as 
studies have suggested that IGF-1R internalizes via clathrin and caveolin-mediated 
endocytosis [31]. Furthermore, we studied the colocalization of the labeled 
compounds with cell organelle markers, including lysosomes (LAMP1) and early 
endosomes (EEA1), given that many macromolecular systems pass through the 
lysosomotropic endocytic pathway [32].  
We treated VCaP cells for 30 minutes with PGA-AVE1642-Cy5.5 and 
AVE1642-Cy5.5 at 0.1 mg/ml polymer (PGA-AVE1642) and AVE1642-Cy5.5 at  
0.16 mg/ml of AVE1642 equiv. We studied the interactions of PGA-AVE1642-Cy5.5 
and AVE1642-Cy5.5 with the endocytic pathway by evaluating colocalization with 
clathrin and caveolin-1 (Figure 18) via confocal microscopy. We discovered that 
AVE1642-Cy5.5 (red) colocalized with clathrin (blue) (Figure 18.A upper panel) and 
IGF-1R-β (green) to a higher degree than with caveolin-1 (blue) (Figure 18.A lower 
panel) as demonstrated in the merge and merge 3X images. We also established 
that PGA-AVE1642-Cy5.5 (red) colocalized with IGF-1R-β (green) and caveolin-1 
(blue) (Figure 18.B lower panel) but not clathrin (blue) (Figure 18.B upper panel), 
as demonstrated in the merge and merge 3X images. Of note, while both 
compounds colocalize with IGF-1R, the receptor displays retention at the 
membrane in PGA-AVE1642-Cy5.5 treated cells, while displaying a more 
cytoplasmic localization in AVE1642-Cy5.5 treated cells. 
These findings are supporting by the graphics to the far right of both upper 
and lower panels of Figure 18.A and B that illustrates the red, green, and blue 
channel fluorescent intensity profile across the added white line in the “Merge 3X” 

















































































































































































































































































































































































































































































































































It was clear that, while AVE1642 and PGA-AVE1642 mainly enter the cell by 
IGF-1R mediated endocytosis, PGA conjugation of AVE1642 altered endocytic 
pathway usage, which may be related to different interactions with IGF-1R. 
Colocalization studies were then performed to understand such different 
interactions further. Fluorescently labeled AVE1642 and PGA-AVE1642 were  
co-localized with IGF1-R and early endosomes/lysosomes under the same 
conditions as described in the previous section. Figure 19.A (upper panel) shows 
that AVE1642-Cy5.5 (red) colocalizes with IGF-1R (green) at the cell membrane and 
both colocalize with the early endosomal marker (EEA1 – in blue) inside the cell; 
however, PGA-AVE1642-Cy5.5 (red) only colocalizes with IGF-1R (Figure 19.A lower 
panel) at the cell membrane and inside the cell, as demonstrated in the merge 
images and fluorescent intensity graphs. Meanwhile, Figure 19.B shows that both 
AVE1642-Cy5.5 (red – upper panel) and PGA-AVE1642-Cy5.5 (red – lower panel) 
colocalized with the lysosomal marker LAMP-1 (green) inside the cell, as 
demonstrated in the merge images and graphs.  
Overall, these studies suggest that AVE1642 and PGA-AVE1642 cellular fate 
are the lysosomes but follow different endocytic pathways. While AVE1642 is 
primarily internalized via clathrin-mediated endocytosis and is directed to the 
lysosomes through endosomes, PGA-AVE1642 is instead internalized by caveolin 

















































































































































































































































































































































































































































































































































































III.7.3.1. Super-resolution Microscopy Confirms that PGA-conjugation 
Alters AVE1642 Internalization 
In order to corroborate our findings, we used stochastic optical 
reconstruction microscopy (STORM) to study the intracellular localization of 
AVE1642 and PGA-AVE1642 in the same cell. Super-resolution techniques 
represent useful tools to determine the detailed spatial distribution of molecules in 
cells [33]; furthermore, they reveal the ultrastructure of organelles [34].  
Fluorescent STORM images are constructed from the high-accuracy 
localization of individual fluorescent molecules that are switched on and off using 
light of different wavelengths. The STORM imaging process comprises a series of 
imaging cycles; in each cycle, only a fraction of the fluorophores in the field of view 
are switched on, such that each of the activated fluorophores is optically resolvable 
from the rest, thereby allowing the position of the fluorophore to be determined 
with high accuracy. Repeating this process for multiple cycles, each causing a 
stochastically different subset of fluorophores to be turned on, enables the 
positions of many fluorophores to be determined and the reconstruction of an 
overall image [35].  
For this approach, we labeled AVE1642 and PGA-AVE1642 with Cyanine 3 
(Cy3) and Cyanine 5 (Cy5), respectively (See Chapter II, Section II.2.2). To select a 
concentration that avoids quenching, we performed fluorescence calibration 
curves for AVE1642-Cy3 and PGA-AVE1642-Cy5, which suggested a lack of 
quenching for the concentrations tested (See Chapter II, Section II.2.7.3).  We  
co-incubated VCaP cells with both compounds at 5, 15, 30, and 60 mins to study 
any possible colocalization between AVE1642 and PGA-AVE1642; STORM images 
show PGA-AVE1642-Cy5 in red and AVE1642-Cy3 in green, with merged images 
showing any overlap (Figure 20). Images demonstrated higher intracellular 




membrane; however, we observed very little colocalization of AVE1642-Cy3 with 
PGA-AVE1642-Cy5 suggesting that the compounds use differing internalization 
pathways related with the altered interaction with IGF-1R. 
 
Figure 20: Internalization studies of PGA-AVE1642-Cy5 and AVE1642-Cy3 by STORM 
microscopy. VCaP cells were co-incubated for 5, 15, 30, and 60 minutes at with  
PGA-AVE1642-Cy5 (red) and AVE1642-Cy3 (green). The merged images show the overlap of 





Previous experiments (See Sections III.7.1, and III.7.2) demonstrated that 
PGA-AVE1642 is retained at the cell membrane for an extended period when 
compared to AVE1642; for this reason and to further explore colocalization, we first 
incubated VCaP cells with PGA-AVE1642-Cy5 for 60 mins to allow a higher level of 
internalization and then co-incubated with the AVE1642-Cy3 for 15 and 30 minutes 
(Figure 21). However, even given a higher level of PGA-AVE1642-Cy5 
internalization, we failed to observe remarkable levels of colocalization, providing 
further evidence that AVE1642-Cy3 with PGA-AVE1642-Cy5 employ differing 
internalization routes. 
 
Figure 21: Intracellular localization studies of PGA-AVE1642-Cy5 and AVE1642-Cy3 by 
STORM microscopy. VCaP cells first treated with PGA-AVE1642-Cy5 (red) for 60 minutes, 
followed by AVE1642-Cy3 (green) co-incubated for 15 and 30 minutes. Merge shows any 




III.7.3.2. PGA-conjugation Prevents the Activation of PI3K and MAPK 
Pathways by AVE1642 
Signaling through the IGF-1R controls cell growth and differentiation in 
normal and malignant cells. Ligands such as IGF-1 induce IGF-1R phosphorylation 
and activation and the induction of downstream signaling pathways. Following the 
activation of the Insulin receptor substrate 1 (IRS-1) and SHC-transforming protein 
1 (Shc) adaptor proteins by activated IGF-1R, IRS-1 binds the regulatory subunit of 
phosphoinositide 3-kinase (PI3K) stimulating its phosphorylation and activation, 
which then activates Protein kinase B (AKT) signaling via phosphorylation to 
regulate the mammalian target of rapamycin (mTOR) activity. Meanwhile, Shc 
phosphorylation and activation stimulates mitogen-activated protein kinase 
(MAPK) activation through phosphorylation. The activation of said pathways blocks 
apoptosis and promotes tumorigenesis [36-38], and so blocking the activation of 
these signaling pathways may help to inhibit tumor formation [2, 39].  
To determine the mechanism of action of the AVE1642 and PGA-AVE1642 
conjugate, we evaluated the phosphorylation and activation status of various 
proteins involved in downstream signaling from the IGF-1R pathway by Western 
blotting. We treated VCaP cells with IGF-1, AVE1642, and PGA-AVE1642 at 0.1 
µg/ml AVE1642 equiv. for 15 and 30 minutes and then probed cell lysates for levels 
of individual members of these signaling pathways - phospho-Shc and phospho-IRS-
1 (adaptor proteins phosphorylated after IGF-1R activation), phospho-MAPK 
(phosphorylated after Shc activation to promote downstream signaling), phospho-
PI3K (phosphorylated and activated by IRS-1), and α-tubulin (housekeeping protein 
used for normalization). 
Figure 22.A shows a representative Western blotting image, while Figures 
22.B-E depicts the densitometry analysis with ImageJ software after normalization 




significant increase in the phosphorylation of all proteins under study at 15 and 30 
mins. Interestingly, AVE1642 treatment induced a significant increase in the 
phosphorylation levels of Shc and MAPK (Figures 22.B and C) and a decrease in the 
phosphorylation levels of p-IRS-1 (Figure 22.D) at both time points times; 
furthermore, we detected similar phosphorylation levels of PI3K compared to the 
control (Figure 22.E).  
However, treatment with PGA-AVE1642 failed to induce phosphorylation 
of the proteins under study, and indeed, phosphorylation levels tended to fall to 
below those found in the untreated control. This inhibition displayed significance 
for p-Shc at 15 mins compared to AVE1642 treatment and at 30 minutes compared 
to IGF-1 and AVE1642 treatment (Figure 22.B). We also found a significant decrease 
at 15 mins for p-MAPK compared to IGF-1 and AVE1642 treatment, a highly 
significant decrease at 30 minutes for p-MAPK compared to both IGF-1 and 
AVE1642 treatment (Figure 22.C), and a significant decrease at 30 mins for p-IRS-1 
when compared to IGF-1 (Figure 22.D). However, p-PI3K displays a non-significant 
trend towards inhibition without reaching significance (Figure 22.E). 
Overall, these results suggest that PGA-AVE1642 treatment may improve 
IGF-1R inhibition by the inhibition of MAPK and PI3K downstream signaling 






Figure 22: Phosphorylation Status of IGF-1R Downstream Proteins Following AVE1642 
and PGA-AVE1642 Treatment. A) Western blot analysis of p-Shc, p-MAPK, p-IRS-1, p-PI3K, 
and α-tubulin expression in VCaP cells treated with IGF-1, AVE1642, and PGA-AVE1642 at 
0.1µg/ml AVE1642 equiv. at 15 and 30 minutes. B-E) Quantification of protein expression 
analysis normalized to α-tubulin expression with ImageJ software. Data expressed as 
mean±SEM, n>3. Statistical analysis was performed using two-way ANOVA, *p< 0.05,  




III.8. Development of an Orthotopic PCa Mouse model 
As our in vitro studies suggested the improved function of AVE1642 
following PGA-conjugation, related to an increase in stability, affinity, and IGF-1R 
inhibition, we next aimed to evaluate AVE1642 and PGA-AVE1642 in vivo in a newly 
developed preclinical orthotopic mouse model using modified T2E-expressing VCaP 
cells that would allow optical imaging monitoring. 
III.8.1. Development of Stable Luciferase Expressing VCaP Cells 
            We employed T2E-positive VCaP cells in the development of the orthotopic 
PCa mice model. To allow in vivo tumor growth monitoring using minimally invasive 
procedures (such as IVIS® Spectrum technology), we transfected VCaP cells with 
lentiviral particles containing a plasmid coding for luciferase (Luc) and an antibiotic 
resistance cassette (G418) to positively select transfected cells (Figure 23.A). We 
also transfected VCaP cells with a green fluorescent protein (GFP) plasmid as a 





Figure 23: Plasmid Map of pRNA-Tin-Luc2 and pRNA-Tin-tGFP. A) Luciferase and B) GFP 
transgenes are regulated under the same T3 promoter. The respective pRNA-Tin-Luc2 and 
pRNA-Tin-tGFP plasmids also contain a G418 (geneticin) antibiotic resistance cassette. 
After lentiviral transduction with the pRNA-Tin-Luc2 plasmid and antibiotic 
selection, we observed high and stable levels of luciferase expression (Figure 24.A). 
After the transduction of the pRNA-Tin-tGFP plasmid, we determined the GFP 
transfection rate by flow cytometry (Figure 24.B), discovering that 80% of cells 






Figure 24: Schematic Representation of Lentiviral infection of VCaP Cells. VCaP cells were 
infected with lentiviral particles containing plasmids encoding (A) luciferase and (B) GFP. 
After infection, luciferase and GFP positive cells were selected with G418. Luminescence 
analysis for luciferase (A) and flow cytometry analysis for GFP (B) demonstrates efficient 
and stable transfection.   
We next sought to confirm that lentiviral infection of the VCaP cell line 
(designated VCaP-Luc2) did not affect essential cell characteristics. Western 
blotting analysis confirmed the maintenance of IGF-1R-β, AR, and ERG expression 
levels after VCaP cell line transfection (Figure 25.A), while responses to AVE1642 
and PGA-AVE1642 remained the same in VCaP cells (Figure 13.A) and VCaP-Luc2 
cells (Figure 25.B); both cell lines demonstrated similar levels of cytotoxicity with 
increasing concentrations of both AVE1642 and PGA-AVE1642. 
These findings suggest the suitability of VCaP-Luc2 cells for the 






Figure 25: Protein Expression and AVE1642 and PGA-AVE1642 Response in VCaP-Luc2 
Cells. A) Western blot analysis of IGF-1R-β, AR, and ERG (α-tubulin as a housekeeping gene) 
in VCaP-Luc2 cells, demonstrating no significant changes after transfection. B) The response 
of VCaP-Luc2 cells to AVE1642 and PGA-AVE1642 treatment remains similar to that of 
parental cells (See Figure 13.A). 
III.8.2. Optimization of the Orthotopic PCa Mouse Model  
As a first step towards the optimization of the orthotopic PCa mouse model, 
we determined the required time for the tumor to reach the maximum allowed size 
of approximately 1.2 cm2 (See Chapter II, Section II.2.12). We injected 1 x 106 
million VCaP-Luc2 cells into the prostate glands of 28 male C.B-17/IcrHan®Hsd-
Prkdcscid mice between 6-8 weeks of age and evaluated tumor growth weekly 
through the IVIS® Spectrum after subcutaneous luciferin administration  
(150 mg/kg). We weighed animals each week and euthanized four animals per 
week after IVIS-based analyses to measure the extracted tumor using a caliper and 
to collect blood samples. 
We observed homogeneous and exponential tumor growth localized to the 
ventral prostate gland (Figure 26.A IVIS® Spectrum images and B expressed in 
photons per second for each week). Tumor volumes measured by caliper (Figure 




Furthermore, we analyzed prostate-specific antigen (PSA) levels in the 
blood as PSA testing represents a standard tool for PCa diagnosis [40]. Our analysis 
established an increase in PSA blood levels over time when compared with the 
healthy animals, with a clear correlation between PSA levels (Figure 26.D) and 
tumor size (Figure 26.C). 
Finally, from a safety point of view, daily monitoring of the general aspect 
of mice did not reveal any deterioration in animal welfare, while we failed to 
observe any weight loss in mice during the experimental timeframe (Figure 26.E).  
In summary, these analyses demonstrated that tumors reached a maximal 






Figure 26: Optimization of the Orthotopic PCa Mouse Model. C.B-17/IcrHan®Hsd-Prkdcscid 
mice were injected in the ventral prostate gland with 1 x 106 million VCaP-Luc2 cells.  
A) Topographic tumor growth images displaying growth, as evaluated using IVIS® Spectrum. 
B) Tumor growth over time evaluated as photons per second, data derived from IVIS® 
Spectrum analysis. C) Tumor volume expressed in cm3 over time, measured with a caliper. 
D) Relative body weight (as a percentage) over time suggests maintained mouse body 





III.8.3. Analysis of Luciferase Stability in vivo 
The next optimization step involved the optimization of the timeframe 
required to obtain a representative luminescent signal in the tumor and the 
“working window” in which the luminescent signal is maintained. This step ensures 
similar exposure times and reproducibility and comparability across experiments. 
We used three male C.B-17/IcrHan®Hsd-Prkdcscid mice between 6-8 weeks 
of age and injected 1 x 106 VCaP-Luc2 cells into the ventral prostate gland. After 
one week, we subcutaneously administered 150 mg/Kg of luciferin and introduced 
animals into the IVIS® Spectrum immediately following anesthesia. 
We then acquired luminescence data every five minutes (photons/second) 
for 50 mins. Figure 27 demonstrates a plateau of the luminescent signal between 
20 and 40 mins, suggesting this as the working window to detect the luciferase 
signal from the tumor.  
 
Figure 27: Luciferase Detection over Time in an Orthotopic PCa Mouse Model. Graph 
depicts luciferase detected signal expressed in photons per second versus time (minutes). 
150 mg/kg of luciferin was injected subcutaneously into three male C.B-17/IcrHan®Hsd-
Prkdcscid mice, and tumor luminescence acquired every 5 minutes for 50 minutes. Data 




Given the results of this experiment, we measured luminescence 20 
minutes post luciferin injection. 
III.8.4. Analysis of the Enhanced Permeability and Retention Effect  
 We analyzed the EPR effect in relation to tumor size to determine the 
optimal timeframe for treatment administration (AVE1642 and PGA-AVE1642)  
[41, 42] by assessing tumor vascular permeability; this can alter during tumor 
development, thereby affecting passive tumor accumulation of nanomedicines. 
We injected VCaP-Luc2 cells into the ventral prostate gland in male  
C.B-17/IcrHan®Hsd-Prkdcscid mice model at 6-8 weeks of age and evaluated tumor 
growth using the IVIS® Spectrum and animal weight for seven weeks. At various 
stages during tumor development, we intravenously injected four mice with a 
solution of Evans Blue/BSA and then euthanized the mice and extracted, measured, 
and weighed tumors one hour later. We next incubated tumors in formamide for 
48 h at 60ºC to extract any accumulated dye and quantified dye levels by measuring 
absorbance at 620 nm in a spectrophotometer and comparing against an Evans 
Blue/BSA calibration curve (See Chapter II, Section II.2.13). Higher dye levels 
generally correlate to higher levels of passive accumulation through the EPR effect. 
Figure 28 depicts changes to tumor weight volume in cm3 (red) and relative 
dye accumulation (green), showing a clear inverse correlation between these two 
parameters. Week 2 represents the maximal timepoint for dye accumulation, and 
hence the EPR effect, and we chose this time point to administer treatments. At 





Figure 28: Tumor Permeability as a Function of Tumor Weight. Graphic shows the 
percentage of injected EB dye dose per gram of tumor (dose (%)/tumor weight) (green) and 
tumor volume (cm3) (red) both versus time (weeks). Data expressed as mean ±SEM, n>3. 
IV.8.5. PGA-conjugation Maintains AVE1642 Tumor Accumulation 
To investigate tumor accumulation of AVE1642 and PGA-AVE1642, we 
intravenously injected PBS (control), AVE1642-Cy5.5, and PGA-AVE1642-Cy5.5 at 
10mg/kg AVE1642 equiv. into PCa model mice (n=4) at two weeks after tumor 
imitation to coincide with the maximum EPR effect (0.05 cm3). After four hours, we 
removed tumors, lysate, and detected fluorescence of Cy5.5 by spectrophotometer 
against a calibration curve (See Chapter II, Section II.2.14).  
Figure 29 shows the percentage of injected dose per gram of tissue in 
tumor samples treated with AVE1642-Cy5.5 and PGA-AVE1642-Cy5.5; overall, we 
did not detect significant differences between the two treatments suggesting 





Figure 29: Cy5.5 Tumor Accumulation following AVE1642 and PGA-AVE1642 
Administration to PCa Model Mice. Graph shows the percentage of dose per gram of tissue 
(Doses (%)/g Tissue) for AVE1642-Cy5.5 and PGA-AVE1642-Cy5.5 after 4 hours. Data 
expressed as mean±SEM, n>3.  
The lack of increased AVE1642 accumulation after PGA conjugation may be 
due to non-significant changes observed in the size of the PGA-AVE1642, as it has 
also been described that mAb active targeting prevalence is greater than passive 
targeting by EPR to enable specific binding receptors which are overexpressed in 
the tumor and not in the healthy tissue. In the case of a poor vasculature and low 
EPR effect, there are two primary strategies to increase the drug accumulation 
bypassing the EPR effect, such as targeting tumor blood vessels or release the drug 
within tumor vasculature [43].  
III.9. In vivo Antitumoral Activity of AVE1642 and  
PGA-AVE1642  
After characterizing and optimizing the orthotopic PCa mice model, we 
investigate the antitumoral potential and safety of the AVE1642 and PGA-AVE1642. 
Furthermore, we explored the mechanisms of action in the tumor samples to 






















III.9.1. PGA-conjugation Improves AVE1642 Antitumor Activity  
We next compared the antitumor activity of AVE1642 and PGA-AVE1642 
conjugate in vivo using our optimized PCa mouse model previously described (See 
Section III.8.2). We monitored tumor growth by IVIS® Spectrum and weighed 
animals weekly. At week 2, when tumors reach a size of 0.05 cm3, and the EPR effect 
is maximal, we randomly divided mice into three groups (n=9), and we euthanized 
mice two weeks after the final treatment (Figure 30.A).  
i. Control group with PBS (i.v.) 
ii. AVE1642 (i.v.) once a week for four weeks at 10 mg/kg 
iii. PGA-AVE1642 (i.v.) once a week for four weeks at 10mg/kg (AVE1642 
equiv.) 
Figure 30.B depicts representative IVIS® Spectrum luminescence pictures, 
which a comparable increase in tumor size for control-treated mice over seven 
weeks; furthermore, AVE1642 and PGA-AVE1642 treated mice displayed inhibited 
tumor growth as evidenced by lower luminescence compared with the control 
group. Moreover, PGA-AVE1642 treated mice showed lower luminescence signals 
in comparison with the AVE1642 group. However, the quantification of IVIS® 
Spectrum data, as shown in Figure 30.C, provides evidence of similar luminescence 
values in tumors following AVE1642 and PGA-AVE1642 treatment. This was 
probably due to the luminescence signal variation or differences in tumor density. 







Figure 30: Tumor Progression by Bioluminescence Detection Following AVE1642 and  
PGA-AVE1642 Treatment in an Orthotopic PCa Mouse Model. Mice were treated with 
AVE1642 and PGA-AVE1642 at 10 mg/kg (AVE1642 equiv.) or PBS vehicle control.  
A) Schematic representation for in vivo animal experiment timeline following AVE1642 and 
PGA-AVE1642 treatments. B) Topographic tumor growth images evaluated in IVIS® 
Spectrum over time in three different groups. C) Tumor growth over time evaluated in each 
group as photons/second (Data derives from IVIS® Spectrum experiments, black arrows 
indicate the timings of the treatments). Data expressed as mean±SEM, n>3. Statistical 
analysis was performed using ANOVA. 
Caliper measurements of tumor size, as shown in Figure 31.A, provide 
evidence of a highly significant reduction in tumor size following AVE1642 and  
PGA-AVE1642 treatment when compared to PBS control-treated mice, and a 
significant reduction in tumor size for PGA-AVE1642 when compared to AVE1642. 
Figure 31.B shows representative pictures of tumors at week 7 for the three 




We also analyzed serum levels of PSA (Figure 31.C); AVE1642 and  
PGA-AVE1642 treatment led to a significant reduction in PSA levels compared to 
control; furthermore, PGA-AVE1642 treatment showed a highly significant 
reduction in PSA levels compared to AVE1642 treated mice. 
We also analyzed tumor density following resection at the experimental 
endpoint. Figure 31.D demonstrates an inverse correlation between tumor density 
and tumor size (Figure 31.A) following treatments; mice treated with PGA-AVE1642 
possessed tumors with a significantly higher density than control or AVE1642 
treated mice, while we discovered no significant differences between control and 
AVE1642 treated mice.  This could support different cell death pathways triggered 
by the different compounds. Maybe for this reason, we observed a slightly 
increased luminescence in the tumors treated with PGA-AVE1642 compared with 
AVE1642 treatment (Figure 30.C). 
We also confirmed treatment safety, as we failed to observe significant 
losses in mouse body weight over time in response to any treatment modality 




Figure 31: Antitumor Activity of AVE1642 and PGA-AVE1642 in an Orthotopic PCa Mouse 
Model. A) Tumor volume expressed in cm3 at the experimental endpoint. B) Representative 
pictures of tumors at the experimental endpoint. C) PSA levels in the control animals and 
both treatments expressed in µg/ml. D) Tumor density measured in g/cm3. E) Relative body 
weight percentage after the first administration (black arrows indicate the timings of the 
treatments). Data expressed as mean±SEM, n>3. Statistical analysis performed using 




As a control, we also tested the effects of PGA treatment to determine the 
safety and any potential intrinsic antitumor activity using 8.45 mg/kg PGA per 
animal to provide an administration of PGA similar to mice treated with  
PGA-AVE1642. 
We failed to observe any differences between PBS vehicle control and PGA 
treated mice in IVIS® Spectrum analysis of tumor development (Figure 32.A), the 
quantification of tumor evolution in photons per second (derived from the IVIS® 
Spectrum analysis) (Figure 32.B), tumor size measured by caliper at experimental 
endpoint (Figures 32.C and D) , PSA levels (Figure 32.E), tumor density (Figure 32.F), 
or alteration to body weight (Figure 32.G). Overall, this suggests a lack of intrinsic 
antitumor activity for PGA. 
In summary, we provide evidence of the increased antitumor effect of  
PGA-AVE1642 in comparison to AVE1642, and to explore the mechanisms behind 
this improvement, we next investigated the mechanism of action in tumor samples 






Figure 32: Antitumor Activity of PGA in Orthotopic PCa Mouse Model. Mice were treated 
with PGA at 8.45 mg/kg (PGA equiv. in PGA-AVE1642 conjugate), and the same parameters 
in Figures 30 and 31 were determined. A) Topographic tumor growth images evaluated in 
IVIS® Spectrum over time. B) Tumor growth over time measured in photons/second (black 
arrows indicate the timings of the treatments). C) Tumor volume expressed in cm3 at the 
experimental endpoint. D) Representative pictures of tumors at the experimental endpoint. 
E) PSA levels measured in µg/ml at the experimental endpoint. F) Tumor density measured 
in g/cm3 at the experimental endpoint. G) Relative body weight percentage over time (black 
arrows indicate the timings of the treatments). Data expressed as mean±SEM, n>3. Any 




III.9.2. PGA Conjugation of AVE1642 Improves IGF-1R Inhibition 
Tumors of CRPC patients generally present with the overexpression of  
IGF-1R and AR [44, 45]; IGF-1R promotes PI3K and MAPK pathway activity and 
tumor progression, while AR enhances ERG gene expression in the T2E positive 
patients, with ERG then mediating the transcriptional upregulation of IGF-1R 
transcription. For these reasons, mirroring our previous in vitro analysis, we 
analyzed levels of proteins downstream of IGF-1R signaling present in tumor 
samples at experimental endpoint (phosphorylated p-Shc, p-MAPK, and p-PI3K 
proteins) (See Section III.7.3.2) to determine the activation status. We also 
evaluated total IGF-1R-β (t-IGF-1R-β), AR, and ERG protein levels, which are related 
to the presence of the T2E fusion gene, to study their modulation after exposure of 
tumor-bearing mice to the various treatment modalities (Figure 33). 
Overall, we observed a lack of significant changes for p-MAPK, AR, and ERG 
expression in response to any treatment (Figures 33.C, F, and G); however, we 
discovered a significant reduction in p-PI3K and t-IGF-1R expression in tumors from 
PGA-AVE1642 treated mice when compared to control (Figures 33.D and E).  
We also observed a significant reduction in protein levels between PGA-AVE1642 
and AVE1642 treated mice for p-Shc, p-PI3K, t-IGF-1R levels (Figures 33.B, D, and 
E). Compared to the findings from the in vitro studies, after AVE1642 treated 
tumors did not display a similar phosphorylation pattern, although PGA-AVE1642 
treated tumors did display a similar p-Shc and p-PI3K profile (See Section III.7.3.2).  
These results suggest that PGA conjugation enhances IGF-1R inhibition by 
AVE1642 due to the robust simultaneous inhibition of both the Shc adaptor protein 




Figure 33: Analysis of IGF-1R Downstream Protein Expression After AVE1642 and  
PGA-AVE1642 Treatment in the Orthotopic PCa Mouse Model. Protein expression in tumor 
lysates following treatment as analyzed by Western blot assay. A) Representative Western 
blot image. B-G) Graph represents the protein expression relative to α-tubulin expression, 
as quantified with ImageJ software. Data expressed as mean±SEM, n>3. Statistical analysis 





III.10. Modulation of the Tumor Microenvironment by 
AVE1642 and PGA-AVE1642  
The tumor microenvironment (TME) is the collective term for those 
components surrounding the tumor/tumor cells, comprising non-cancerous 
stromal components, such as the extracellular matrix (ECM), blood vessels, 
infiltrating inflammatory cells, and a variety of associated tissue-specific cells. This 
unique environment emerges during tumor progression via complex interactions 
between the host and tumor tissues and has been proposed as a target for  
anti-tumor therapies [46, 47].  
For these reasons, we studied PCa TME architecture and responses to 
AVE1642 and PGA-AVE1642 exposure in collaboration with Prof. Twan Lammers 
Laboratory at the Center for Biohybrid Medical Systems (CBMS), Aachen, Germany, 
during a short research visit. 
III.10.1. Evaluation of Tumor Vasculature in the Orthotopic PCa Mouse 
Model 
To evaluate the tumor-associated vasculature upon AVE1642 and  
PGA-AVE1642 therapies, we investigate important tumor vasculature parameters, 
such as vessel functionality and maturity, via immunofluorescence analysis of CD31, 
α-SMA, and Lectin distribution.  
CD31 (also known as platelet endothelial cell adhesion molecule-1 [PECAM-
1]) is a 140kDa type I integral membrane glycoprotein that is highly expressed on 
endothelial cells; therefore, it provides information about intratumoral micro-
vessels density. Lectin, a carbohydrate-binding protein, permits the visualization of 
perfused (functional) vessels to provide information on vessel functionality and 




isoform expressed by vascular smooth muscle cells, pericyte, and myofibroblasts 
and provides information regarding vessel maturity [48, 49].  
First, we analyzed the area fraction % (AF%) covered by CD31, α-SMA, and 
Lectin by acquiring representative images of tumor-bearing prostate tissue from 
C.B-17/IcrHan®Hsd-Prkdcscid male mice treated with PBS (Control), AVE1642, or 
PGA-AVE1642 using a fluorescence microscope at 20X magnification and quantified 
the fluorescent signal using AxioVision software (Figures 34.A and B).  
At the morphological level (Figure 34.A), blood vessels appeared elongated 
with a large lumen in the control group. In AVE1642 and PGA-AVE1642 treated 
mice, blood vessel number decreased, and morphology altered: AVE1642 
treatment promoted shorter and thinner vessels compared to control, while  
PGA-AVE1642 treatment prompted vessel fragmentation, as suggested by the 
appearance of “spot-like” vessel staining. 
The quantification of the fluorescence for each marker protein (Figures 
34.B, C and D) suggested a lack of significant alteration of CD31 expression, 
although we do note a trend for reduced expression upon AVE1642 and  
PGA-AVE1642 treatment, which agrees with the reduction in vessel number 
observed at the morphological level. We discovered significantly lower Lectin levels 
in PGA-AVE1642 treated mice when compared to both control and AVE1642 
treated mice, suggesting that PGA-AVE1642 treatment promotes a decrease in the 
perfusion of vessels. However, α-SMA levels displayed a significant reduction in the 
AVE1642 treated mice (in comparison to both control and PGA-AVE1642 treated 





Figure 34: Study of CD31, α-SMA, and Lectin as Markers of Tumor-Associated Vessels 
following Treatment with AVE1642 and PGA-AVE1642. A) Representative images of vessel 
morphology in response to each treatment at 20X magnification. CD31 (red) marks 
endothelial cells, Lectin (green) indicates perfused vessels, and α-SMA (blue) indicates 
mature vessels. Scale bar 20µm. B-D) The graph represents the area fraction % of CD31, 
Lectin, and α-SMA obtained with AxioVision software. Data expressed as mean±SEM, n>3. 
Statistical analysis was performed using ANOVA, **p< 0.01, ***p< 0.001.  
 To further understand tumor vasculature, we evaluated vessel functionality 
and maturity in more detail (Figure 35). To this end, we counted CD31+ vessels 
(indicates total number of vessels), CD31+ and Lectin+ vessels (indicates functional 
vessels) and CD31+, Lectin+, and α-SMA+ (indicates mature functional vessels). In 
order to normalize the values with the total number of vessels, the functionality 
was calculated by dividing the total number of double-positive vessels with the 
CD31 positive vessels, and maturity by dividing the total number of triple-positive 







Figure 35: Determination of the Functionality and Maturity of Tumor-Associated Vessels 
following Treatment with AVE1642 and PGA-AVE1642. A) Representative images of vessel 
morphology in response to treatments at 10X magnification. CD31 (red) marks endothelial 
cells, Lectin (green) indicates perfused vessels, and α-SMA (blue) indicates vessel maturity. 
Scale bar 10µm. B-C) Graphs represent the relative vessel count % percentage of functional 
vessels (CD31+ and lectin+/CD31+) and mature vessels (CD31+ lectin+ and α-SMA+/ CD31+). 
Data expressed as mean±SEM, n>3. Statistical analysis performed using ANOVA, **p< 0.01, 
****p< 0.0001. 
 Overall, our findings confirmed that AVE1642 and PGA-AVE1642 treatment 
promote changes in vessel functionality and maturity (Figures 35.B and C).  
PGA-AVE1642 treatment significantly reduced the number of functional vessels 
compared to both control and AVE1642 treatment. AVE1642 failed to promote 
significant differences when compared to control, although there does exist a 
downward trend. PGA-AVE1642 treatment also significantly reduced vessel 
maturity in comparison with control. Furthermore, there exist non-significant 
downward trends for AVE1642 when compared to control and PGA-AVE1642 when 




 As a summary, these analyses suggest that PGA conjugation promotes an 
AVE1642-mediated decrease in vessel functionality and maturity.  
III.10.2. Cell Proliferation and Angiogenic Studies in the Orthotopic PCa 
Mice Tumors  
 We also undertook a histological analysis of tumor samples in following 
AVE1642 and PGA-AVE1642 exposure to evaluate alterations to tumor cell 
proliferation and angiogenesis. 
III.10.2.1. PGA-conjugation Significantly Improves Inhibition of Prostate 
Tumor Proliferation by AVE1642 
 We investigated prostate tumor proliferation after treatment through the 
detection of the Ki67 proliferation marker in tumor tissues [50]. 
 We captured representative images of Ki67 stained tumor sections from 
each treatment group (Figure 36.A). Quantification of Ki67 staining (Figure 36.B) 
established that while AVE1642 treatment significantly reduced cell proliferation 
when compared to an untreated control, treatment with PGA-AVE1642 provided a 
significantly greater decrease in cell proliferation when compared to control and 






Figure 36: Histological analysis of Ki67 staining in Prostate Tumor Tissue Samples.  
A) Representative images of tumor samples in each treatment group at 20X magnification. 
Ki67 (red) marks proliferative cells, and DAPI (blue) marks nuclei. Scale bar 20µm. B) Graph 
represents the area fraction % of the Ki67 fluorescence signal for the three treatment 
groups analyzed with the AxioVision software. Data expressed as mean±SEM, n>3. 
Statistical analysis performed using ANOVA, **p< 0.01, ****p< 0.0001. 
III.10.2.2. PGA-conjugation Significantly Improves Inhibition of Tumor 
Angiogenesis by AVE1642 
 VEGFR2, the receptor for the angiogenic growth factor VEGF, is expressed 
by several cell types, including hematopoietic cells, but it is primarily observed in 
vasculature endothelial cells [51]. Abnormal tumor vasculature leads to severe 
alterations to the tumor microenvironment, such as decreased pH and hypoxia. 
These modifications result in the upregulation of VEGF and VEGFR2 through a 
paracrine positive feedback mechanism [52].  
As in the previous experiments, we captured representative images for 




(Figure 37.B) confirmed a significant reduction in VEGFR2 levels in AVE1642 treated 
mice and a highly significant reduction in VEGFR2 levels in PGA-AVE1642 treated 
mice when compared to control. Furthermore, PGA-AVE1642 treatment prompted 
a significant reduction in VEGFR2 levels when compared to AVE1642 treated mice. 
Overall, these results suggest PGA conjugation results in improved antiangiogenic 
effectiveness of AVE1642. 
Figure 37: Histological Analysis of VEGFR2 Staining in Prostate Tumor Samples.  
A) Representative images for each treatment group at 20X magnification. VEGFR2 (red) 
marks angiogenesis, and DAPI (blue) marks nuclei. Scale bar 20µm. B) Graph represents the 
quantification of the VEGFR2 signal expressed as the area fraction % in all the treatment 
groups analyzed with AxioVision software. Data expressed as mean±SEM, n>3. Statistical 





III.11. Conclusions  
As a conclusion from this chapter, chemical characterization promoted 
evidence to the presence of polymer conjugation to AVE1642 due to an increase in 
different parameters such as the Mw, the hydrodynamic volume, the diameter, and 
a more negative zeta potential value. Furthermore, PGA conjugation did not change 
the secondary AVE1642 structure, suggesting the same AVE1642 functionality, 
which shows us that PGA-AVE1642 maintained the antibody variable region and its 
specificity for binding. In addition, PGA conjugation may enhance AVE1642 stability 
because precipitation is avoided. Moreover, we provide evidence that PGA 
conjugation improves the activity of AVE1642 in vitro and in vivo. We demonstrate 
that PGA conjugation can enhance AVE1642 binding affinity to IGF-1R, protect 
AVE1642 from degradation in serum, and alter AVE1642 cellular trafficking. The 
subsequent robust inhibition of IGF-1R by PGA-AVE1642 prevents the activation of 
both MAPK and PI3K signaling pathways leading to enhanced antitumoral activity 
in vitro and in an orthotopic PCa mouse model. Finally, we analyzed crucial tumor-
associated vasculature parameters, including vessel functionality and maturity.  
We discovered that PGA-AVE1642 treatment significantly decreases vessel 
functionality and maturity and tumor angiogenesis when compared to 
unconjugated AVE1642, which is associated with decreased tumor cell 
proliferation. 
These encouraging results suggest that PGA-AVE1642 could be then 
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Evaluation of a Novel Combination 
























IV.1. Antecedents and Background  
Despite the promising initial responses of CRPC patients to strategies that 
block androgen signaling (e.g., abiraterone and enzalutamide [1]) or the PI3K/Akt 
pathway (e.g., PI3K/mTOR inhibitors, TKR inhibitors [1]), long term results have not 
proven as successful as anticipated, often due to the increased activity of reciprocal 
signaling pathways. 
For example, the PI3K/Akt pathway suffers from reciprocal feedback with 
the AR signaling pathway in PCa, and the cross-regulation of these oncogenic 
pathways promotes tumor growth [2, 3]. Therefore, the dual inhibition of these 
pathways may effectively inhibit prostate tumor growth; as an example, preclinical 
research has provided evidence for potent anti-tumor synergism between PI3K/Akt 
inhibition and androgen deprivation therapy (ADT) [4].  
 At the clinical level, multiple trials have assessed the outcomes of 
combination approaches involving immunotherapy, hormone therapy, 
chemotherapy, radiotherapy, and surgery to improve clinical outcomes, with many 
of them combining antibody-based approaches with conventional treatments. 
Focusing on the use of mAbs, for example, Phase II trials are underway to 
investigate combination immunotherapies for PCa; these include the combination 
of Sipuleucel-T, a personalized immunostimulant and the first immunotherapy for 
CRPC approved in 2010 by the FDA [5], with a PD-1 immune response inhibitor (anti-
PD-1 mAb, CT-011 - NCT01420965) or an inhibitor of T-cell proliferation and 
activation (anti-CTLA4 mAb, ipilimumab - NCT01804465). Several clinical trials are 
also evaluating combinations of ADTs with immunotherapies, including 
enzalutamide with anti-PD-1 mAbs (pembrolizumab - NCT03753243, and 
atezolizumab - NCT03016312). Furthermore, clinical trials of conventional 




Ipatasertib (a small molecule inhibitor of AKT) with atezolizumab (NCT03673787), 
evofosfamide and ipilimumab (NCT03098160), and cabozantinib (small-molecule 
inhibitor of the tyrosine kinases) with atezolizumab (NCT03170960). Additionally, 
various modes of radiation therapy have been assessed in combination with 
Sipuleucel-T (NCT02463799, NCT01807065) and different anti-PD-1 mAbs 
(pembrolizumab - NCT03093428 and nivolumab - NCT03543189) [6]. 
Of particular interest to our laboratory, polymer therapeutic-based 
approaches to single and combination therapies offer numerous advantages. The 
modification of active agents, such as those described above, with polymers, can 
allow for the enhanced passive targeting to adequately vascularized tumors [7-9], 
the crossing of critical biological barriers [10], elevated blood plasma stability, 
targeted release, altered trafficking, increased solubility and the chemical stability, 
modified pharmacokinetics, and reduced toxicity and adverse effects [11, 12]. In 
the realm of combination therapy, polymer-based approaches can promote tumor 
targeting of multiple active agents at the correct ratio for synergistic anti-tumor 
effects [13]. As an example of the potential of this approach, a recent study 
established that treatment with a polyacetal-based combination therapy 
combining curcumin as an antitumoral agent associated with Wnt/β-catenin 
pathway modulation and diethylstilbestrol as an ADT (PA-Curc-DES) induced  
S-phase cell cycle arrest in human PCa cell lines through the specific release of both 
drugs in the tumor cell or in the tumor microenvironment  [14].  
Irrespective of the therapeutic approach employed, enhanced treatment 
strategies must be provided to only those patients who will respond. Importantly 
to the work carried out in this chapter, inhibiting the IGF-1R and androgen 
pathways lead to increased cytotoxicity in only those PCa cells expressing the 
TMPRSS2-ERG (T2E) transgene [15]. Therefore, the construction of a polymer-




pathways in the same cell may further improve PCa treatment outcomes in  
T2E-positive patients. 
In the previous chapter, we highlighted the robust anti-tumor activity of 
PGA-AVE1642 in T2E-expressing cells. In this chapter, we evaluated the antitumoral 
synergy of PGA-AVE1642 with abiraterone, a drug that inhibits the generation of 
androgens, and hence acts to inhibit AR signaling. 
 Abiraterone is a selective inhibitor of the CYP17 enzyme - a 17,20-lyase, and 
17α-hydroxylase from the cytochrome P450 family that aids the synthesis of 
androgens and cortisol in the testicles, adrenal glands, and within tumors using 
cholesterol as an initial precursor. Therefore, the administration of abiraterone will 
inhibit androgen production and, in theory, inhibit the growth of androgen-
dependent PCa cells and tumors (Figure 1) [16, 17]. Following oral administration 
to CRPC patients, abiraterone acetate becomes rapidly hydrolyzed to abiraterone 
in the bloodstream [18]. 
Therefore, in this chapter, we sought to describe the possible synergism 
between AVE1642/PGA-AVE1642 and abiraterone in vitro and evaluate anti-tumor 








Figure 1: Overview of the Mechanisms of Action of Abiraterone. Abiraterone as an anti-
androgen drug blocks 17α-hydroxylase and 17,20-lyase enzymatic activity to avoid both the 
conversion of pregnenolone to 17-hydroxy-pregnenolone and dehydroepiandrosterone 
(DHEA) and the conversion of progesterone to 17-hydroxy-progesterone and 
androstenedione. 
IV.2. PGA-AVE1642 Synergizes with Abiraterone in VCaP cells 
In the previous chapter, we demonstrated that the T2E fusion gene-
expressing VCaP cell line, which expresses high levels of IGF-1R and AR, displayed 
sensitivity to AVE1642 and PGA-AVE1642. In vitro analyses demonstrated that PGA 
conjugation improved the stability and affinity and altered the cell trafficking of 
AVE1642, and in vivo experiments provided evidence for improved antitumorigenic 
activity. We next sought to evaluate the consequences of inhibiting both the 
PI3K/Akt and AR pathways in PCa cells/tumors by anti-IGF-1R inhibition using 





Figure 2: Synergism of AVE1642/PGA-AVE1642 and Abiraterone in VCaP cells. A) Graph 
depicts cell viability versus drug equiv. (µg/ml) for abiraterone and AVE1642 alone and in 
combination. Combination therapies are represented in AVE1642 µg/ml equiv. B) Graph 
depicts cell viability versus drug equiv. (µg/ml) for abiraterone and PGA-AVE1642 alone and 
in combination. Combination therapies are represented in AVE1642 µg/ml equiv. C) Plot of 
the log(CI) index vs. the effect (Fa) of AVE1642 in association with abiraterone at a 1:10 ratio 
using CompuSyn software. The plot of the CI indicates synergy between two treatments at 
0.01, 0.03, 0.1, 0.3, and 1 µg/ml AVE1642 in combination with abiraterone at 0.1, 0.3, 1, 3, 
and 10 µg/ml. D) Plot of the log(CI) index vs. the effect (Fa) of PGA-AVE1642 in association 
with abiraterone at a 1:10 ratio using CompuSyn software. The plot of the CI indicates 
synergy between two treatments at 0.03, 0.1, 0.3, and 1 µg/ml PGA-AVE1642 in 




We treated VCaP cells for 72 hours with AVE1642, PGA-AVE1642 (from 50 
to 0.003 µg/ml AVE1642 equiv.), or abiraterone (from 10 to 0.03 µg/ml), and 
combinations of AVE1642 or PGA-AVE1642 with abiraterone at a 1:10 ratio 
respectively (1 unit of AVE1642 equiv. and 10 units of abiraterone). Figures 2.A  
and B demonstrate that abiraterone treatment alone reduced cell viability at 
concentrations above 1 µg/ml drug equiv., while AVE1642 and PGA-AVE1642 
treatment produced the expected reduction in cell viability. The combination 
therapy of AVE1642 or PGA-AVE1642 with abiraterone provided a synergistic effect 
in both cases, with a more significant cytotoxic effect observed at reduced 
concentrations when compared to abiraterone or AVE1642/PGA-AVE1642 
treatments alone. Both combination therapies exhibited similar cytotoxicity 
profiles with the same IC50 concentration (~0.1 µg/ml drug equiv.). 
As synergistic interactions between drugs represent a crucial issue in 
pharmacology, we determined the combination index (CI) and the fraction affected 
(Fa) to study synergism using the CompuSyn software. The CI value is calculated 
from drug cytotoxicity, and indicates a synergistic (CI<1), additive (CI=1), or 
antagonist (CI>1) effect, while Fa values represent the cytotoxicity of the 
combination therapies [19]. Figures 2.C and D depict the plot of the log(CI) index 
versus the effect (Fa) of AVE1642/PGA-AVE1642 in combination with abiraterone 
to detect any synergy. Values above zero indicate antagonism, while a value below 
negative indicate synergy. Specifically, Figure 2.C demonstrates synergy (CI<1) for 
AVE1642 at 0.01, 0.03, 0.1, 0.3 and 1 µg/ml AVE1642 equiv. in combination with 
abiraterone at 0.1, 0.3, 1, 3, and 10 µg/ml. Moreover, Figure 2.D demonstrate 
synergy (CI<1) for PGA-AVE1642 at 0.03, 0.1, 0.3 and 1 µg/ml AVE1642 equiv. in 
combination with abiraterone at 0.3, 1, 3, and 10 µg/ml. 
The results confirm the results obtained in Figures 2.A and B for both 




Overall, AVE1642 or PGA-AVE1642 treatment, in combination with 
abiraterone, provided synergistic cytotoxic effects in VCaP cells when employed at 
a 1:10 ratio. For subsequent in vitro experiments, we used the IC50 values for both 
combination therapies (0.1 µg/ml AVE1642 equiv. with 1 µg/ml abiraterone) at 
which we found a synergistic effect. CI value analysis indicated the presence of a 
synergistic effect (CI<1) for abiraterone treatment in combination with either 
AVE1642 (CI=0.06) and PGA-AVE1642 (CI=0.07) in VCaP cells at IC50 µg/ml drug 
equiv. concentrations. 
IV.3. Combination Therapy Exhibits T2E-dependent 
Synergistic Effects in Prostate Cancer Cells 
We next determined the synergistic effect of AVE1642/PGA-AVE1642 and 
abiraterone in additional PCa cell lines (22Rv1, DU-145, LNCaP, and PC-3) and a 
normal prostate epithelial cell line (RWPE-1) and compared these findings to VCaP 
cells to study the requirement for the T2E fusion gene. Each PCa cell line also 
exhibits different androgen-responsiveness - 22Rv1, LNCaP, and VCaP cells are 
androgen-dependent, while the DU-145 and PC-3 cell lines are androgen-
independent. 
Treatment of cells with abiraterone alone for 72 hours demonstrated a 
trend towards increasing cytotoxicity with increasing abiraterone concentrations; 
treatment with 10 µg/ml abiraterone prompted a ~50% reduction in cell viability in 
22Rv1, VCaP, and RWPE-1 cells, and a ~25% reduction in PC-3, DU-145 and LNCaP 
cells (Figure 3). These results suggest 22Rv1 and VCaP androgen-dependent PCa 
cell lines display higher sensitivity to abiraterone, which may be due to higher AR 
levels when compared to androgen-independent PC-3 and DU-145 PCa cell lines 




Of note, although we detected an anti-androgenic effect in androgen-
independent PCa cell lines at higher abiraterone concentrations, we did not detect 
AR expression. Furthermore, we failed to detect a stronger abiraterone efficacy in 
LNCaP androgen-dependent cell lines despite showing higher AR levels. 
Additionally, normal prostate tissue showed an androgenic effect at higher 
concentrations despite not expressing AR (See Chapter III, Figure 3). 
 
Figure 3: Cytotoxic Effects of Abiraterone in Normal Prostate Epithelium and PCa Cell 
Lines. PCa cells (22Rv1, DU-145, LNCaP, PC-3, and VCaP) and RWPE-1 as a control normal 
prostate epithelium cell line were treated for 72 hours with increasing concentrations of 
abiraterone. Graph shows the cell viability (%) versus concentration of abiraterone (µg/ml). 
Data expressed as mean±SEM, n=3. 
Overall, the VCaP androgen-dependent cells generally displayed higher 
sensitivity to abiraterone at all the concentrations evaluated compared with the 
other cell lines. 
We next studied our combination therapies in these cell lines to determine 
the specificity of the synergistic effect; we treated cells with AVE1642 (Figure 4.A) 
or PGA-AVE1642 (Figure 4.B) combined with abiraterone at 1:10 ratio for 72 hours. 
Tables 1.A and B depict the observed reductions in cell viability (as a percentage) 




VCaP cell line displayed the highest sensitivity with both combination therapies 
providing for a similar decrease in cell viability at the IC50 values for the combination 
therapy (0.1 µg/ml AVE1642 equiv. and 1 µg/ml abiraterone) (Figures 4.A and B 
green line and Table 1.A). However, LNCaP, 22Rv1, and RWPE-1 also displayed a 
heightened response to AVE1642/PGA-AVE1642 and abiraterone at higher 
concentrations (ten times IC50 values) (Table 1.B). Moreover, DU-145 and PC-3 have 
a remarkably low response after both combination therapies compared with the 
other cell lines at higher concentrations (Table 1.B). 
 
Figure 4: VCaP Cells Display Higher Sensitivity to Combination Therapy. Graphs represent 
the cell viability percentage versus the concentration (µg/ml AVE1642 equiv.) in different 
PCa cell lines (VCaP, LnCaP, DU-145, 22Rv1, and PC-3) and RWPE-1 as normal tissue.  
A) AVE1642 in combination with abiraterone treatment. B) PGA-AVE1642 in combination 




Importantly, the responses of LNCaP and RWPE-1 cells to both combination 
therapies at higher concentrations derives solely from the effect of abiraterone, as 
these cell lines did not respond to AVE1642 or PGA-AVE1642 treatment (See 
Chapter III, Figure 13) (Table 1.B). In contrast, the response of the 22Rv1 cell line 
to the combination therapies at the higher concentrations provided further 
evidence for synergy between AVE1642/PGA-AVE1642 and abiraterone (Table 1.B).  
We next enumerated the synergistic effect of the combination therapies in 
each of the relevant cell lines. By the calculation of the CI value using the CompuSyn 
program, we detected a synergistic effect (CI<1) for abiraterone in combination 
with AVE1642 (CI=0.015) and PGA-AVE1642 (CI=0.017) in the 22Rv1 cell line with 















Table 1: Percent cell viability reduction in normal prostate and PCa cell lines in response 
to various treatment approaches. A) Values in % cell death for IC50 combination therapies 
concentrations (0.1 µg/ml AVE1642 equiv. and 1 µg/ml abiraterone). B) Values in % cell 
death for 10x IC50 combination therapies concentrations (1 µg/ml AVE1642 equiv. and 10 




Overall, while we observed a range of sensitivities in various cell lines to the 
combination therapies under evaluation, only the VCaP cell line provided evidence 
for an appreciable synergistic effect over a range of concentrations, we found 
synergism for our combination therapies in the 22Rv1 cell line only at 
concentrations of ten times the IC50 values. 
IV.4. The Synergistic Effect of the Combination Therapy 
Requires T2E Expression 
We next studied the specificity of the combination therapy in the presence 
of the T2E fusion gene in VCaP cells by assessing cell viability after ERG gene 
silencing via small interfering (si)RNA expression. We investigated ERG silencing in 
1) control VCaP cells, and VCaP cells treated with 2) AVE1642 and abiraterone  
(0.1 µg/ml and 1 µg/ml respectively), and 3) PGA-AVE1642 and abiraterone  
(0.1 µg/ml AVE1642 equiv. and 1 µg/ml respectively). 
Figure 5 shows the relative change in cell number (in fold) in response to 
each treatment and a representative Western blot image that confirms ERG 
silencing (Figure 5.A). We calculated the effectiveness of the various treatments 
after normalization to their respective untreated control groups. We discovered 
that ERG gene silencing (siERG) negates the effect of AVE1642 /abiraterone (Figure 
5.B) and PGA-AVE1642 /abiraterone treatments (Figure 5.C) on cell survival, with 
significant differences between the untreated (NT) and ERG siRNA (siERG) in the 
cells treated with AVE1642/abiraterone and highly significant changes between 
scramble siRNA control (SCR) and ERG siRNA (siERG) in the cells treated with 
AVE1642/abiraterone. Furthermore, we also observed significant differences 
between the NT and ERG siRNA (siERG) in the cells treated with  
PGA-AVE1642/abiraterone and between scramble siRNA control (SCR) and ERG 





Figure 5: Influence of ERG Expression on the Cytotoxic Effect of Single and Combination 
Therapies in VCaP Cells. A) Representative Western blot image shows ERG expression in 
VCaP cell line under untransfected (NT), scrambled siRNA (SCR), and ERG siRNA treated 
(siERG) conditions. B-C) Graph shows cell viability (as measured by Trypan Blue exclusion 
assay) in untransfected VCaP cells (NT), VCaP transfected with scrambled control siRNA 
(SCR), and VCaP transfected with siRNA against ERG (siERG) treated with AVE1642 at  
0.1 µg/ml in combination with abiraterone at 1 µg/ml, and PGA-AVE1642 at 0.1 µg/ml 
AVE1642 equiv. in combination with abiraterone at 1 µg/ml along 72 hours. Data expressed 
as mean±SEM, n>3. Statistical analysis was performed using ANOVA, *p< 0.05, **p< 0.01.  
These results suggest that the effectiveness of the AVE1642/PGA-AVE1642 
and abiraterone combination therapy requires ERG overexpression, which is caused 





IV.5. Antitumoral Activity of Prostate Cancer Combination 
Therapy In vivo 
Our next steps focused on the study of our combinatorial therapeutic 
approach in the preclinical PCa mouse model described in the previous chapter (See 
Section III.8.2) by comparing single and combination therapies and analyzing the 
mechanism of action in tumor samples to determine alterations to intracellular 
signaling pathways. 
IV.5.1. Optimization of the Orthotopic Mouse PCa Model to Evaluate 
Responses to Combination Therapy  
Abiraterone blocks CYP17A1 enzyme activity, thereby blocking 
dehydroepiandrosterone (DHEA) production. The loss of DHEA then impacts 
dihydrotestosterone (DHT) production and inhibits androgen synthesis in humans 
[20]. However, CYP17A1 expression differs between human and rodents. In 
humans, the CYP17A1 gene is expressed in the adrenal glands and in the gonads 
but not in the placenta; in the rodent, CYP17A1 is expressed in the gonads and the 
placenta but not in the adrenal glands [21]. In particular, the Cyp17a1 gene in 
rodents suffers from epigenetic silencing and the complete lack of adrenal 
androgens such as DHEA [21, 22]. Of note, androgen-dependent PCa cell lines 
present the CYP17A1 enzyme; in contrast, androgen-independent PCa cell lines fail 
to express CYP17A1 levels [23]. However, abiraterone also inhibits  
3β-hydroxysteroid dehydrogenase/isomerase (3βHSD), an enzyme that can 
synthesize DHT in CRPC from the DHEA precursor in the adrenal glands [24]. 
Therefore, to mimic human adrenal physiology conditions, we supplemented the 
mice with DHEA to study the effect of abiraterone in our mouse model (See 




As human CRPC is treated with abiraterone acetate (shortened to AA in 
figures below) orally, we also treated mice in this manner by oral gavage, with 
abiraterone acetate converted into abiraterone in the bloodstream. 
We first evaluated the effect of abiraterone acetate treatment without 
DHEA supplementation using our VCaP-Luc2 PCa mouse model (See Chapter III, 
Section III.8.2). At week two, we randomly divided mice into two groups (n=5), and 
we monitored tumor growth by IVIS® Spectrum and weighed animals weekly 
(Figure 6.A).   
i. Vehicle control group with 95% sunflower oil and 5% benzyl alcohol 
(abiraterone acetate vehicle) by oral gavage daily from the second to the 
seventh week 
ii. Abiraterone acetate treated group at 200 mg/kg by oral gavage daily from 
the second to the seventh week 
We failed to observe any differences between vehicle control and 
abiraterone acetate treatment in the IVIS® Spectrum analysis of tumor 
development (Figure 6.B), the quantification of tumor evolution expressed in 
photons per second (derived from the IVIS® Spectrum analysis) (Figure 6.C), tumor 
volume measured by caliper at the experimental endpoint (Figure 6.D), or in 
representative images of the tumors at the week seven (Figure 6.E). Furthermore, 
we failed to observe any significant loss in body weight during the experiment 
(Figure 6.F).  
Surprisingly, despite the expression of CYP17A1 and 3βHSD enzymes in the 
gonads, and the expression of 3βHSD enzyme in the adrenal glands, we failed to 
detect any antitumorigenic activity of abiraterone in vivo. These results provide 





Figure 6: Antitumor Activity of Abiraterone Acetate in the Absence of DHEA in a  
VCaP-Luc2 Orthotopic PCa Mouse Model. Mice were treated with vehicle (95% sunflower 
oil with 5% benzyl alcohol) as control and abiraterone acetate (AA) at 200 mg/kg, both 
administered by oral gavage daily from the second week until the seventh week after the 
surgery. A) Schematic representation of abiraterone acetate treatment without DHEA 
supplement. B) Topographic tumor growth images evaluated in IVIS® Spectrum over time. 
C) Tumor growth over time assessed in each group as photons/second. D) Tumor volume 
expressed in cm3 at the experimental endpoint measured by caliper. E) Representative 
tumor images after resection at the experimental point. F) Relative body weight percentage 




 We next investigated abiraterone acetate activity in our PCa mouse model 
in the presence of DHEA. DHEA supplementation promotes the synthesis of DHT 
through 3βHSD activity in the adrenal glands, and in the gonads. As in previous in 
vivo studies, following induction of tumors, we arbitrarily divided animals into three 
groups (n=5), and we evaluated tumor growth by IVIS® Spectrum twice a week and 
continuously monitored animal weight (Figure 7.A). 
i. Vehicle control group with s.c. injections of 10% DMSO (DHEA vehicle) each 
day until the end of the experiment (seventh week) and, from week 2, with 
95% sunflower oil and 5% benzyl alcohol daily by oral gavage (abiraterone 
acetate vehicle) 
ii. DHEA treated group with s.c. injections of 0.1 mg DHEA each day from the 
surgery until the end of the experiment. 
iii. DHEA and abiraterone acetate treated group with s.c. injections of 0.1 mg 
DHEA each day until the end of the experiment (seventh week) and, when 
tumors reached a size representative of the maximum EPR effect (0.05 cm3) 
(week 2), we administered abiraterone acetate by oral gavage daily at  
200 mg/kg each day until the end of the experiment 
Figure 7.B depicts representative IVIS® Spectrum luminescence images, 
which highlights a comparable increase in tumor size for vehicle control and DHEA-
only treated mice over seven weeks. We expected this result, as studies have shown 
that a lack of tumor response at the concentrations of DHEA employed (0.1 mg/day) 
[25]. However, the exposure of DHEA-treated mice to abiraterone acetate led to a 
significant reduction in tumor size compared to DHEA-only and vehicle control-
treated mice. Quantification of IVIS® Spectrum data for five mice in each group, as 
shown in Figure 7.C, established a general increase in tumor size over time for 




abiraterone acetate treated mice displayed lower tumor growth, although we did 
not find significant differences at the experimental endpoint due to the 
considerable variation in luminescent signal. Caliper measurements of tumor size, 
as shown in Figure 7.D, confirmed the reduction in tumor volume following 
abiraterone acetate treatment of DHEA-treated mice compared to vehicle and 
DHEA groups. In contrast, we failed to observe significant differences between 
vehicle and DHEA-supplemented only groups with regards to tumor size 
measurements made by caliper. Moreover, representative images of tumors from 
the three different groups of treated mice at week seven demonstrate similar 
tumor size between vehicle and DHEA treated groups; in contrast, the exposure of 
DHEA-treated mice to abiraterone acetate led to an evident reduction in tumor size 
(Figure 7.E). We also confirmed that treatment did not induce mouse body weight 
loss during the experiment, suggesting overall safety (Figure 7.F). 
In summary, these data indicate that abiraterone acetate treatment 
requires DHEA supplementation to exhibit an anti-tumor therapeutic effect, which 
causes 3βHSD inhibition and the blockade of DHT synthesis in both the adrenal 
glands and gonads. Tumors can also foster intratumoral steroidogenesis from 
adrenal androgens such as DHEA and androstenedione or by de novo synthesis in 
tumor tissue from cholesterol to promote continued tumor growth [20, 21]. 
Despite the possibility of using multiple pathways for intratumoral androgen 
synthesis, the conversion of DHT through the “backdoor pathway” seems to be the 
major route for producing DHT. The backdoor pathway is based on the synthesis of 
DHT through pregnenolone (primary backdoor) and DHEA (secondary backdoor) 
bypassing testosterone synthesis, in which both alternative pathways require 
3βHSD enzyme (Figure 8). For these reasons, our results confirm previous findings 
in which abiraterone inhibits the enzyme 3βHSD in the adrenal glands and the 
gonads, while also suggesting that abiraterone may also inhibit intratumoral 





Figure 7: Antitumor Activity of Abiraterone Acetate in an Orthotopic PCa Mouse Model 
Supplemented with DHEA. Mice were treated in three groups i) vehicle control 
(subcutaneous injection of 10% DMSO and with 95% sunflower oil with 5% benzyl by oral 
gavage), ii) DHEA supplementation at 0.1 mg/day, and iii) DHEA supplementation and 
abiraterone acetate (AA) treatment (200 mg/kg). The same parameters, as in Figure 6, were 
studied. A) Schematic representation of experimental setup. B) Topographic tumor growth 
images evaluated in IVIS® Spectrum over time. C) Tumor growth over time evaluated as 
photons/second from IVIS® Spectrum experiments. D) Tumor volume measured by calipers 
at the experimental endpoint (expressed in cm3). E) Representative images of tumors at the 
experimental endpoint. F) Changes to relative body weight percentage after the first 
administration. Data expressed as mean±SEM, n>3. Statistical analysis performed by 





Figure 8: “Backdoor Pathway” of DHT Synthesis. Frontdoor pathway is represented in pink, 
which is used to synthesize DHT through testosterone. Primary and secondary backdoor 
pathways are represented in green and blue, respectively. Both pathways synthesize DHT 
bypassing intratumoral testosterone production. Adapted from [27]. 
 
IV.5.2. DHEA Supplementation Does Not Interfere with the Anti-tumoral 
Activity of AVE1642 and PGA-AVE1642 
We next assessed the effect of DHEA supplementation on the anti-tumoral 
activity of AVE1642 and PGA-AVE1642 in vivo. After tumor induction in PCa mice 
model, we randomly divided the mice into five groups (n=6) in the second week 
coinciding with the maximum EPR effect (0.05 cm3) (Figure 9.A);  
i. Vehicle control injected with PBS (i.v.) and 10% DMSO (s.c.) 
ii. AVE1642 (i.v.) once a week for four weeks (10 mg/kg) 
iii. PGA-AVE1642 (i.v.) once a week for four weeks (10 mg/kg AVE1642 equiv.) 
iv. AVE1642 (i.v.) with DHEA supplementation (s.c. at 0.1 mg/day for the 
duration of the experiment) 
v. PGA-AVE1642 (i.v.) with DHEA supplementation (s.c. injection at  





Figure 9: Tumor Growth Monitoring by Bioluminescence Detection Following AVE1642 
and PGA-AVE1642 Treatment with and without DHEA in an Orthotopic PCa Mouse Model. 
Mice were treated with AVE1642 and PGA-AVE1642 at 10mg/kg (AVE1642 equiv.) with and 
without 0.1 mg/day of DHEA supplement and PBS/DMSO vehicle as a control. A) Schematic 
representation of experimental setup. B) Topographic tumor growth images evaluated in 
IVIS® Spectrum. C) Tumor growth expressed as photons/second (black arrows indicate the 
administering point of AVE1642 and PGA-AVE1642 treatments). Data expressed as 




Figures 9.B and C, which depict the IVIS® Spectrum analysis of tumor 
development and detection of photons/sec as a measure of tumor growth derived 
from IVIS® Spectrum analysis respectively, demonstrate higher tumor growth in the 
control group in comparison with the other four groups. In addition, we detected a 
similar lower tumor growth and tumor luminescence in mice treated with 
AVE1642/PGA-AVE1642 with and without DHEA supplement, confirming that the 
DHEA does not interfere with AVE1642/PGA-AVE1642 function.  
Figure 10.A shows tumor volume measured by caliper at the experimental 
endpoint; tumors from mice treated with AVE1642/PGA-AVE1642 with and without 
DHEA displayed a highly significant decrease in tumor volume in comparison with 
control mice. Moreover, we failed to obtain significant differences for AVE1642 and 
PGA-AVE1642 treatment groups when comparing those treated with DHEA and 
those untreated. Figure 10.B illustrates representative tumor pictures in the 
seventh week for the five different conditions, demonstrating a lack of difference 
in tumor size between DHEA treated and untreated mice. 
To further corroborate our results, we quantified serum PSA levels after the 
different treatment modalities. Both AVE1642 and PGA-AVE1642 with and without 
DHEA showed significant lower PSA levels compared with the vehicle-treated 
group, although again, we failed to find significant differences between DHEA 
treated and untreated mice (Figure 10.C). Finally, the treatments failed to induce 
significant losses o mouse body weight during the experimental timeframe (Figure 
10.D).  
Overall, these findings establish that DHEA supplementation does not 







Figure 10: Antitumor Activity of AVE1642 and PGA-AVE1642 Treatment with and without 
DHEA Supplement in an Orthotopic PCa Mouse Model. A) Tumor volume expressed in cm3 
at the experimental endpoint. B) Representative tumor images at the experimental point. 
C) Serum PSA levels expressed in µg/ml. D) Alterations to body weight percentage after the 
first treatment administration (black arrows indicate the administering point of the 
AVE1642 and PGA-AVE1642 treatments). Data expressed as mean±SEM, n>3. Statistical 





IV.5.3. Evaluation of Combination Therapy in an Orthotopic Prostate 
Cancer Mouse Model 
We next evaluated the combination of AVE1642 or PGA-AVE1642 with 
abiraterone acetate in an orthotopic PCa mouse model to investigate potential 
synergism in vivo.  
As in previous in vivo animal experiments, we induced tumors in mice and 
monitored tumor evolution by IVIS® Spectrum and animal weight. During the 
second week, we randomly divided mice into six separate groups (n=6) (Figure 
11.A).  
i. Vehicle control group treated with PBS (i.v. - AVE1642/PGA-AVE1642 
vehicle), 95% sunflower oil and 5% benzyl alcohol (oral gavage - 
(abiraterone acetate vehicle), and 10% DMSO (s.c. - DHEA vehicle) 
ii. AVE1642 (i.v.) once a week for four weeks at 10 mg/kg 
iii. PGA-AVE1642 (i.v.) once a week for four weeks at 10mg/kg (AVE1642 
equiv.) 
iv. Abiraterone acetate daily at 200 mg/kg from week 2 to week 7 (oral gavage) 
and DHEA at 0.1 mg per day (s.c.) for the entire experiment 
v. AVE1642 in combination with abiraterone acetate and DHEA 
vi. PGA-AVE1642 in combination with abiraterone acetate and DHEA 
Figure 11.B, which depicts the IVIS® Spectrum analysis of tumor 
development, demonstrates higher tumor growth in the vehicle control group (i) in 
comparison with the other five groups. In addition, the quantification of IVIS® 
Spectrum corroborated the reduction in tumor size for treatment modalities (ii)-(vi) 





Figure 11: Tumor Progression Following Treatment with Combination Therapies in an 
Orthotopic PCa Mouse Model. Mice were treated with AVE1642 and PGA-AVE1642 at  
10 mg/kg (AVE1642 equiv.) alone and in combination with 200 mg/kg abiraterone acetate 
and DHEA at 0.1mg/day. In addition, i.v. abiraterone acetate was administered alone with 
DHEA at 0.1mg/day. A) Schematic representation for abiraterone acetate treatment with 
DHEA in combination with AVE1642 and PGA-AVE1642. B) Representative topographic 
tumor growth images evaluated in IVIS® Spectrum over different time points for the six 
treatment modalities. C) Tumor growth over time evaluated in each group as 
photons/second (black arrows indicate the timings of the AVE1642 and PGA-AVE1642 




Figure 12.A (tumor volume measured by caliper at experimental endpoint) 
demonstrates a significant decrease in tumor size following treatment modalities 
(ii)-(vi) when compared to control. As single treatments, AVE1642 (ii),  
PGA-AVE1642 (iii), and abiraterone acetate in the presence of DHEA (iv) led to 
reduced tumor size. AVE1642 and abiraterone acetate (v) in the presence of DHEA 
led to a synergistic antitumoral effect with a significant decrease in tumor size 
observed when compared to AVE1642 treatment alone; however, we failed to see 
a similar synergistic antitumor effect for PGA-AVE1642 and abiraterone acetate (vi) 
in the presence of DHEA. Figure 12.B shows representative tumor images at the 
experimental timepoint for the five different treatment conditions.  
We also quantified serum PSA levels (Figure 12.C), and while abiraterone 
acetate alone failed to reduce PSA levels significantly in the presence of DHEA, 
AVE1642, PGA-AVE1642, and both combination therapies significantly 
downregulated PSA levels in the presence of DHEA. Interestingly, while abiraterone 
acetate treatment synergized with AVE1642 to produce a significant reduction in 
PSA levels compared to AVE1642 alone, we failed to observe a similar relationship 
for PGA-AVE1642. 
We also analyzed tumor density at the experimental endpoint (Figure 
12.D), finding a significant increase in tumor density following treatment with  
PGA-AVE1642, abiraterone acetate in the presence of DHEA, and PGA-AVE1642 in 
combination with abiraterone acetate in the presence of DHEA when compared to 
control. However, AVE1642 or AVE1642 and abiraterone acetate in the presence of 
DHEA failed to have a significant effect when compared to vehicle control. We also 
confirmed that the treatment modalities under evaluation did not significantly 







Figure 12: Antitumor Activity of Combination Therapies in the Presence of DHEA in an 
Orthotopic PCa Mouse Model. A) Tumor volume expressed in cm3 in the seventh week 
(measured by caliper). B) Representative tumor images at the experimental point. C) Serum 
PSA levels expressed in µg/ml measured at the experimental endpoint. D) Tumor density 
measured in g/cm3 at the experimental endpoint. E) Changes to body weight percentage 
following first treatment administration (black arrows indicate the timings of the AVE1642 
and PGA-AVE1642 treatments). Data expressed as mean±SEM, n>3. Statistical analysis was 




Overall, both combination therapies led to a significant reduction in tumor 
size. AVE1642 and abiraterone acetate treatment in the presence of DHEA has a 
synergistic effect, as we observed a significant reduction in tumor size and a 
reduction in PSA levels when compared to AVE1642. In contrast, we failed to find 
significant differences in tumor size and PSA levels for PGA-AVE1642 and 
abiraterone acetate treatment in the presence of DHEA when compared to  
PGA-AVE1642 treatment alone, suggesting a low level or a lack of any synergistic 
effect. 
IV.6. Combination Therapy Improves IGF-1R Inhibition  
To further investigate the potential synergetic effects of our combination 
therapies, understanding the differential outcome observed in the in vivo 
experiments, we evaluated tumor lysates derived from mice from the previous 
experiment for levels of phosphorylated proteins downstream of the IGF-1R 
signaling pathways (p-Shc, p-MAPK, p-PI3K, and p-IGF-1R-β) to determine the 
activation/inhibition of different signaling pathways. Furthermore, we also studied 
total IGF-1R-β, AR, and ERG protein levels (Figures 13.A and B). 
Figure 14 depicts the Western blotting analysis evaluated by band 
densitometry, and Table 1 provides a summary of the results. We observed similar 
profiles for total and phosphorylated IGF-1R-β (Figures 14.A and E), a lack of any 
effect following abiraterone acetate treatment, but a significant decrease in 
response to both combination therapies, with no significant differences observed 
between AVE1642/abiraterone acetate and PGA-AVE1642/abiraterone acetate.  
We observed an interesting phospho-Shc profile (Figure 14.B); while 
abiraterone acetate treatment significantly reduced p-Shc levels, 
AVE1642/abiraterone acetate failed to stimulate a similar response and displayed 




PGA-AVE1642/abiraterone acetate treatment did reduce p-Shc levels, although not 
to the level observed in the abiraterone acetate-only treated tumors.  
 
Figure 13: Protein expression in tumor lysates following treatment analyzed by Western 
blot for control and abiraterone acetate (AA) treatments (A) and control and combination 
therapy treatments (B) in the presence of DHEA. 
We observed a lack of significant differences for p-MAPK, p-PI3K, and AR 
expression in response to any treatment (Figures 14.C, D, and F), while we also 
observed a decrease in p-PI3K protein levels in response to both combination 
therapies, although this did not reach significance (Figure 14.D). We also detected 
a non-significant decrease in p-MAPK protein levels after AVE1642/abiraterone 
acetate treatment compared with the other treatments (Figure 14.C). Finally, 
AVE1642/abiraterone acetate treatment reduced levels of total ERG (Figure 14.G) 
compared to both control and abiraterone acetate-only treatment, although the 
reduction observed after PGA-AVE1642/abiraterone acetate treatment only 
displayed significance when compared to abiraterone acetate treatment and not 





Figure 14: Investigation of IGF-1R and AR Signaling Pathways Following Combination 
Therapy Treatment in an Orthotopic PCa Mouse Model in the Presence of DHEA. Protein 
quantification in tumor lysates. A-G) Graph represents protein expression relative to  
α-tubulin by quantification with the ImageJ software. Data expressed as mean±SEM, n>3. 
Statistical analysis was performed using ANOVA, *p < 0.05, **p < 0.01, ***p<0.001,  







In addition, and related to AVE1642 and PGA-AVE1642 data from the 
previous chapter (See Chapter III, Section III.9.2.), we detected a greater decrease 
in p-Shc protein levels with respect to the vehicle control after the combination 
therapy PGA-AVE1642/abiraterone acetate compared with PGA-AVE1642 
treatment alone, while, in contrast, we obtained similar results after 
AVE1642/abiraterone acetate combination therapy compared with AVE1642 
treatment alone (Data on all treatment modalities combined and presented in 
Table 1).  
We also detected a decrease in the p-MAPK levels with respect to the 
vehicle control after treatment with combination therapy AVE1642/abiraterone 
acetate compared with the free AVE1642 treatment, which showed similar 
phosphoprotein levels in comparison with control; in contrast, we obtained similar 
results after PGA-AVE1642/abiraterone acetate combination therapy compared 
with PGA-AVE1642 treatment (Table 1).  
Furthermore, we observed a decrease in p-PI3K protein levels with respect 
to the control after the combination therapy AVE1642/abiraterone acetate 
compared with the free AVE1642 treatment, which did not show differences in 
comparison with the control; in addition, p-PI3K levels remained lower than control 
after PGA-AVE1642 treatment with and without abiraterone acetate (Table 1).  
We detected a greater decrease in total IGF-1R protein levels with respect 
to the control after AVE1642/abiraterone acetate combination therapy compared 
with the free AVE1642 treatment, which did not show differences compared with 
the control; additionally, we detected a more significant decrease in t-IGF-1R after 
the combination therapy PGA-AVE1642/abiraterone acetate compared with  




Interestedly, we failed to detect any variations in AR levels after AVE1642 
and PGA-AVE1642 treatments with and without combination therapy with 
abiraterone acetate. Finally, we discovered a more robust decrease in ERG protein 
levels respect to the control after both combination therapies compared with the 
free AVE1642 and PGA-AVE1642 treatments, which did not show differences in 
comparison with the control (Table 1).  
Table 1: Summary table. Changes to total protein levels and protein phosphorylation in 
response to various treatment modalities expressed as a decrease in fold compared to the 
control (Data synthesized from this Chapter and Chapter III, Figure 33 and Chapter IV, 
Figure 14). nd: not detected, ~: no changes compared with the control.  
As a summary, both combination therapies inhibited IGF-1R signaling, as 
evidenced by the significant reduction of p-IGF-1R-β, t-IGF-1R-β, and ERG levels. 
Furthermore, responses to both combination therapies displayed broad similarities 
- the inhibition of both Shc or MAPK and PI3K signaling pathways.  
PGA-AVE1642/abiraterone acetate combination therapy provided a stronger 
inhibition of p-Shc levels when compared to AVE1642/abiraterone acetate 
treatment and also inhibited PI3K phosphorylation. In contrast, 




robustly when compared to PGA-AVE1642/abiraterone acetate treatment and also 
inhibited PI3K phosphorylation. 
We also discovered that the AVE1642/abiraterone acetate combination 
therapy produced stronger inhibition of p-MAPK, p-PI3K, t-IGF-1R, and ERG levels 
when compared AVE1642 treatment alone. Furthermore,  
PGA-AVE1642/abiraterone combination therapy provided for stronger inhibition of 
p-Shc, t-IGF-1R, and ERG protein levels when compared to PGA-AVE1642 treatment 
alone (Table 1).  
These results represent a synergistic effect after AVE1642/abiraterone 
acetate combination therapy; furthermore, the results from the  
PGA-AVE1642/abiraterone acetate combination therapy also suggests at least 
some level of synergism. Therefore, abiraterone acetate might not be necessary as 
co-administration with PGA-AVE1642 but could help to enhance the long-term 
anticancer activity in the clinics as a maintenance treatment after a possible  
PGA-AVE1642 regime due to our observations in the reinforcement of the effective 










IV.7. Conclusions  
As a summary, our in vitro analyses suggested a synergistic effect of both 
combination therapies, while our in vivo results indicated synergism for the 
AVE1642/abiraterone acetate combination therapy compared to lower synergism 
for PGA-AVE1642/abiraterone acetate due to the already enhanced activity of 
AVE1642 upon PGA conjugation. Although our results provide evidence that 
abiraterone acetate avoids AR transcription genes, our findings also suggest a 
correlation between abiraterone acetate treatment and p-Shc levels. We obtained 
similar tumor growth inhibition in response to both combination therapies due to 
the inhibition of both IGF-1R downstream signaling pathways. Abiraterone acetate 
treatment explains the in vivo synergy observed in AVE1642/abiraterone acetate 
combination therapy because we detect inhibition of MAPK pathway probably due 
to the inhibition of Shc phosphorylation through androgen crosstalk 
downregulation. For this reason, we detected lower tumor growth and PSA levels 
compared with free AVE1642 treatment. In contrast, we detected similar tumor 
growth, PSA levels, and inhibition of both Shc and PI3K signaling pathways after 
PGA-AVE1642 treatment with and without abiraterone acetate. The lack of a potent 
synergistic effect in this case perhaps derives from the already efficient inhibition 
of Shc phosphorylation by PGA-AVE1642 monotherapy; however, we detected a 
more significant inhibition of Shc phosphorylation after PGA-AVE1642/abiraterone 
acetate treatment compared with PGA-AVE1642 treatment alone. This could 
suggest that in any case, abiraterone could reinforce as an adjuvant or maintenance 
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PCa is the second most frequent cancer in men and the fifth major cause of 
cancer death around the world [1, 2]. Fortunately, an early diagnosis can provide a 
relatively good prognosis; however, the metastatic form of PCa (mainly castration-
resistant prostate cancer (mCRPC)), it is still an unmet clinical need and requires not 
only better diagnostic tools due to tumor heterogeneity (identification of 
biomarkers) but also for better therapeutic approaches adequate to the patient 
needs [3]. For these reasons, in this Ph.D. thesis, we aimed to design advanced 
therapeutics; in particular, we generated a polymer-based nanoconjugate, as part 
of a single and combination therapy [4], which specifically targeted mCRPC patients 
with poor prognosis (T2E-positive PCa subtype) [5].  
Mancarella et al. demonstrated that the AVE1642 anti-IGF-1R monoclonal 
antibody presented specific cytotoxic effects in T2E-positive PCa cell lines [6] and 
the combination of AVE1642 with abiraterone led to synergistic effects in this same 
cell type [6].  Unfortunately, AVE1642 was discontinued during phase II clinical trials 
in CRPC patients, due to a partial response to therapy and multiple side effects 
(neutropenia, diarrhea, hyperglycemia, etc.) [157, 158].  
Therefore, as a first step in this thesis, we investigated how conjugation of 
the PGA polypeptide altered the biological properties of a human mAb (AVE1642) 
in the hope of increased anti-tumoral activity of AVE1642 in aggressive PCa and 
reduced side effects.  
Many strategies exist to improve the stability of antibodies that are quickly 
eliminating by the renal system and reduce intrinsic immunogenicity which can 
promote an immune response [7]. PEGylation is the most widely explored strategy, 
providing increased stability to an antibody, with some examples in routine clinical 




limits its use in chronic administrations. Polypeptides represent a promising 
alternative [9]. PGA is fully biodegradable, multivalent, mimics natural proteins in 
the body, and displays biocompatibility and low immunogenicity [10]. Side-chain 
carboxylic groups make PGA a versatile multivalent platform for the conjugation of 
multiple differing moieties (allowing the development of combination therapies) 
and have already proved to be an effective drug delivery system [11]. 
To this end, we covalently conjugated AVE1642 to PGA through a reducible 
disulfide bridge and fully characterized the resultant polymer conjugate  
(PGA-AVE1642) by SDS-PAGE, size exclusion chromatography, amino acid analysis, 
and DLS analysis. These techniques demonstrated an increase in AVE1642 Mw, size, 
and the negative zeta potential after PGA conjugation, thereby demonstrating 
polymer conjugate formation (See Chapter III, Figures 5-7). CD analysis established 
a β-sheet structure for AVE1642, and a random-coiled structure for PGA polymer. 
Upon the PGA conjugation, the resulting spectra showed an additive contribution 
of both AVE1642 and PGA polymer. To confirm that conjugation does not negatively 
impact AVE1642 structure, we cleaved PGA from AVE1642 and found a similar CD 
spectra, thereby suggesting that PGA does not alter the structure of the antibody 
and has the same β-sheet structure as a parental AVE1642 (See Chapter III,  
Figure 8). Furthermore, we employed CD to analyze thermal stability, finding 
evidence that PGA conjugation may improve the stability of AVE1642 (See Chapter 
III, Figure 9).  
As we focused on a specific patient subtype, the selected preclinical models 
are crucial for the adequate development of our therapeutics. For this reason , we 
studied protein expression levels in different PCa cell lines (VCaP, LnCaP, DU-145, 
22Rv1, and PC-3) and in a non-cancerous prostate cell line (RWPE-1) to select those 
lines with the desired characteristic (overexpression of ERG protein due to the 




model due to the expression of the T2E fusion gene and high expression levels of 
IGF-1R-β and AR due to ERG protein overexpression (See Chapter III, Figure 3). This 
result also demonstrates a direct association between IGF-1R and T2E expression, 
in good agreement with the findings of Mancarella et al. [6], who described this 
relationship in patient-derived PCa samples [5]. 
The presence of the T2E fusion gene and high IGF-1R levels indicate the 
appearance of a malignant cellular phenotype that promotes CRPC progression 
 [5, 12]. The classification of PCa according to a specific molecular marker could 
allow for the identification of different aggressive PCa subtypes and the choice or 
design of specific therapeutic approaches. While many IGF-1R inhibitors have been 
developed as PCa therapies, none are targeted to a specific PCa patient subtype. 
Furthermore, clinical trials of IGF-1R inhibitors have not achieved the expected 
success due to partial responses [13-18] and side toxicities [12, 13, 19], and for this 
reason, most IGF-1R inhibitors have been discontinued. In the present study, we 
confirmed previously reported data [6] and demonstrated that only the  
T2E-positive expressing PCa cell (VCaP) displayed selected sensitivity in response to 
treatment with AVE1642 compared to T2E-negative PCa cell lines (DU-145, PC-3, 
22Rv1, LNCaP, and RWPE-1), mainly due elevated levels of ERG expression (See 
Chapter III, Figure 14-15). Overall, this highlights the potential utility of AVE1642 
treatment in patients with the T2E fusion gene. Of note, the modification of 
AVE1642 with increasing levels of PGA did not negatively impact the cytotoxic 
activity of the antibody (See Chapter III, Figure 4), as compared to the results 
described by Chapman et al., which demonstrated the loss of antigen-binding 
following modification with increasing levels of PEG [8]. 
We next focused on understanding the consequence of the inhibition of 
IGF-1R of AVE1642 after PGA conjugation. IGF-1R, a vital receptor tyrosine kinase 




normal and malignant cells [20]. Simpson et al. and Singh et al. demonstrated that 
the IGF-1 ligand binds to IGF-1R and promotes receptor autophosphorylation, 
internalization, and the activation of PI3K/Akt/mTOR and Ras/Raf/MAPK 
intracellular signaling pathways [21, 22]. Our results corroborate these findings, 
after IGF-1 positive ligand incubation, the IGF-1R internalizes (See Chapter III, 
Figure 16), triggering the phosphorylation of both MAPK and PI3K signaling 
pathways (See Chapter III, Figure 22). As King et al. previously reported [23], 
inhibition of IGF-1R activity by an anti-IGF-1R mAb or TKI treatment prevents 
IGF-1R autophosphorylation, inhibits activation of intracellular signaling pathways, 
and slows cell growth and proliferation. Fascinatingly, we discovered that inhibition 
of IGF1-R with PGA-AVE1642 inhibited downstream signaling pathways in a 
different manner to AVE1642. Treatment with AVE1642 did not inhibit IGF-1R 
internalization after binding, and IGF-1R became internalized in a similar manner to 
IGF-1 positive ligand stimulation (See Chapter III, Figure 16). These findings 
correlate well with our data regarding the mechanism of action evaluated by 
Western blot assays showing that AVE1642 inhibits only the PI3K signaling pathway 
and not the MAPK signaling pathway, which is involved in the receptor 
internalization (See Chapter III, Figure 22). These results differ from previous 
studies of AVE1642 by Geoerger et al. and Descamps et al., which established the 
inhibition of both MAPK and PI3K signaling pathways after AVE1642 incubation in 
neuroblastoma cells [24] and human myeloma cells [25]. The differential findings 
likely derive from the cell lines employed and the concentrations of AVE1642 used. 
However, a study by Crudden et al. established that some IGF-1R targeted 
antagonists actually functioned as agonists and promoted the activation of IGF-1R 
signaling [26]; this could also partly occur for AVE1642 in VCaP cells. In the case of 
the PGA-AVE1642 treatment, we observed an increase in the levels of IGF-1R at the 
cell membrane, with internalization inhibited (See Chapter III, Figure 16) and both 




findings suggest, for the first time, that polymer conjugation of AVE1642 leads to 
enhanced activity related to its interaction with IGF-1R at the cell membrane. 
Macromolecular systems such as antibodies [27, 28] are uptaken by cells 
by energy-dependent mechanisms employing endocytosis [29, 30]. Our results 
suggest that AVE1642 employs energy-dependent internalization mechanisms; 
however, we found more PGA-AVE1642 binding in the cell membrane (See Chapter 
III, Figure 17). These results are directly correlated with the previous IGF-1R 
internalization data (See Chapter III, Figure 16) in which we detected lower IGF-1R 
internalization following PGA-AVE1642 treatment. The lower IGF-1R internalization 
could be triggered by the higher PGA-AVE1642 cellular membrane binding, which 
results in different cell internalization pathways. Our results indicated that the 
AVE1642 mainly colocalized with clathrin, while PGA-AVE1642 mostly colocalized 
with caveolin-1 (See Chapter III, Figure 18). However, both AVE1642 and  
PGA-AVE1642 finally localized to the lysosomes. Osher et al. and Martins et al. 
demonstrated that IGF-1R internalization could be mediated by both clathrin and 
caveolin mediated endocytosis [31, 32]. We demonstrated that only AVE1642 and 
not PGA-AVE1642 colocalizes with early endosomes (See Chapter III, Figure 19), 
suggesting that PGA conjugation changes the cellular internalization pathway 
employed. We corroborated this data through studies of AVE1642-Cy3 and  
PGA-AVE1642-Cy5 at the same time in the same cell by STORM microscopy showing 
a very low colocalization between both compounds (See Chapter III, Figures 20  
and 21). With all these results in mind, we propose that AVE1642 promotes IGF-1R 
internalization via clathrin-mediated endocytosis and provides for only PI3K 
signaling pathway inhibition before being shuttled into early endosomes and 
degraded in the lysosome. Previous findings from Martins et al. demonstrated the 
MAPK pathway is mainly regulated by clathrin [32]; this result correlates with our 
AVE1642-Cy5.5 findings. In contrast, PGA-AVE1642 promotes lower IGF-1R 




and PI3K signaling pathways. The inhibition of IGF-1R activity may lead to inhibited 
internalization and migration to the endosomes and the subsequent avoidance of 
receptor recycling and IGF-1R transcriptional inhibition by inhibiting IGF-1R nuclear 
translocation [33, 34]. However, we do also observe evidence for the eventual 
internalization of PGA-AVE1642 via caveolae-dependent endocytosis and direct 
passage to the lysosome [35]. 
To validate our results in a preclinically relevant in vivo PCa model for the 
T2E subtype, we optimized an orthotopic PCa mouse model [36] employing 
luciferase-expressing VCaP cells to study the antitumoral activity of AVE1642 and 
PGA-AVE1642 therapies in vivo (See Chapter III, Figure 26 and Figure 28).  
We discovered similar safety profiles and tumor accumulation for AVE1642 and 
PGA-AVE1642 treatment (See Chapter III, Figure 29), which could be explained due 
to the relatively similar sizes, even given PGA conjugation (See Chapter III,  
Figure 7). Even given this similarity in tumor accumulation, we observed enhanced 
antitumoral activity for PGA-AVE1642 when compared to AVE1642 (See Chapter III, 
Figures 30 and 31). Furthermore, we detected a direct correlation between tumor 
size and PSA levels and an inverse correlation between tumor size and tumor 
density (See Chapter III, Figure 31). PSA levels are known to correlate with cancer 
progression [37], while higher density can indicate the presence of necrotic areas. 
Previous findings in PCa mouse tumors confirmed that the faster development of 
necrosis and an increase in tumor density associated with higher antitumor  
activity [38].  
Studies aiming to investigate mechanisms of action in tumor samples 
provided evidence for a lack of MAPK and PI3K pathway inhibition in response to 
AVE1642 treatment (See Chapter III, Figure 33). Even though IGF-1R activity is 
linked to tumor growth [39], we still observed an antitumorigenic effect  




experiment was performed two weeks after the last dose administration.  
We speculate that more rapid AVE1642 degradation and lower IGF-1R affinity in 
comparison with the PGA-AVE1642 conjugate might be the reason why AVE1642 
treatment promotes the activation of the pathways after this time. 
In contrast, PGA-AVE1642 treatment robustly inhibited the Shc adaptor 
protein and PI3K pathways in tumor samples demonstrating that the PGA-AVE1642 
therapy provides a complete IGF-1R inhibition that is correlated with the lower  
IGF-1R protein expression (See Chapter III, Figure 33.B, D and E). We believe that 
higher PGA-AVE1642 stability and the increased affinity of PGA-AVE1642 for IGF-1R 
leads to increased PGA-AVE1642-IGF-1R binding at the cell membrane, the more 
robust inhibition of downstream signaling, and the subsequent reduction in tumor 
growth. Furthermore, despite Shc adaptor protein inhibition following  
PGA-AVE1642 treatment, we fail to observe a decrease in the phosphorylation  
p-MAPK protein levels (See Chapter III, Figure 33.C), indicating that this protein can 
be activated by receptors other than IGF-1R, such as epidermal growth 
factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), VEGFR, 
fibroblast growth factor receptor (FGFR), IL-1R or tumor necrosis factor receptor 
(TNF-R) [40]. Furthermore, higher AR levels detected after PGA-AVE1642 treatment 
(See Chapter III, Figure 33.F) relate to the negative crosstalk between both PI3K 
and AR pathway [41]; the high AR may explain high ERG protein levels  
(See Chapter III, Figure 33.G), as AR acts as an ERG promotor [6]. 
Of note, we also demonstrated the safety but also the lack of  
anti-tumorigenic effect of PGA alone, suggesting that the enhanced 
antitumorigenic activity of PGA-AVE1642 treatment is not related to the inherent 
activity of PGA (See Chapter III, Figure 32). 
To achieve a better understanding of the differential therapeutic outputs 




on the TME by investigating blood vessel maturity, functionality, cellular 
proliferation, and angiogenesis via immunohistochemistry. Both therapeutic 
approaches promoted a decrease in vessel functionality; however, those tumors 
treated with PGA-AVE1642 displayed significantly lower vessel functionality  
(See Chapter III, Figure 35.B), which was associated with lower vessel maturity 
compared to the AVE1642 treatment and control groups (See Chapter III,  
Figure 35.C). The stronger decrease in vessel maturity in response to PGA-AVE1642 
treatment may be related to the function of pericytes, cells that bind to vascular 
endothelial cells [42] and play an essential role in structural regulation endothelial 
cells through angiogenesis [43]. The angiogenic process is considered finished when 
pericytes surround the endothelial cells; this activity is associated with vessel 
growth, maturation, and termination [44]. Since pericyte function relates to blood 
vessel maturation in the last step of angiogenesis, our hypothesis states that  
PGA-AVE1642 treatment inhibits the maturation of the vessels and prevents 
pericyte binding to endothelial cells. In order to confirm this hypothesis, our next 
step is to perform cellular migration studies in human VCaP cell line cocultivated 
with murine fibroblast cells following both AVE1642 and PGA-AVE1642 treatments. 
Through the histological characterization of tumor-associated microenvironment 
employing VEGFR2 as an angiogenic marker, we also found that both treatment 
approaches display an anti-angiogenic effect being significantly greater for  
PGA-AVE1642 (See Chapter III, Figure 37) perhaps due to a decrease in vessel 
maturity by the pericyte-mediated mechanism explained above. Histological 
analysis (Ki67) also provided evidence for a reduction in tumor cell proliferation in 
response to both treatment approaches; again, we observed a greater effect for 
PGA-AVE1642 when compared to AVE1642 (See Chapter III, Figure 36). 
 Angiogenesis plays a critical role in the progression of CRPC, and the 
inhibition of angiogenic pathways provide an effective strategy to prevent tumor 




and predict disease progression in PCa [45] and previous findings demonstrated a 
connection between the PI3K pathway and angiogenesis via increased VEGF 
secretion by hypoxia-inducible factor 1 (HIF-1) dependent and independent 
mechanisms [46]. We hypothesized that the observed decrease in angiogenesis 
might directly relate to the decrease in tumor cell proliferation and tumor growth 
through the inhibition of the PI3K signaling pathway. Furthermore, the possible role 
of AVE1642 and PGA-AVE1642 treatment approaches in the tumor 
microenvironment may prevent pericyte migration; for this reason, vessels remain 
immature, thereby preventing angiogenesis. 
In summary, while PGA protects AVE1642, offering a greater plasma 
stability, conjugation also modulates cell trafficking pathways and TME-targeted 
effects. This triggers an enhanced therapeutic output that allows enhanced tumor 
reduction at lower doses, which should provide for lower systemic side effects.  
To further improve PCa treatment with PGA-AVE1642, we next evaluated a 
combination therapy-based approach. Polymer-based combination therapeutics 
represent a fascinating approach to PCa treatment, with numerous advantages 
over single-drug treatments [47]. As both Carver et al. and Crumbaker et al. 
described a reciprocal feedback loop regulation between both PI3K/Akt and AR 
pathways in PCa; AR inhibition therapy can lead to the activation of PI3K/Akt 
signaling to drive PCa progression [48, 49]. Therefore, our second step in this thesis 
focused on the implementation of an anti-androgen drug (abiraterone) in 
combination with the AVE1642 and PGA-AVE1642 IGF-1R inhibitors in vitro and  
in vivo to study possible synergistic therapeutic effects towards improved advanced 
therapeutics. 
Several mechanisms are involved in CRPC progression, including AR gene 
amplification, protein overexpression, mutations, and splice variants, and the 




inhibit AR ligand-binding and androgen synthesis to block androgen-dependent AR 
signaling and thus prevent the CRPC progression. Abiraterone, irreversibly inhibits 
CYP17A1 and 3βHSD enzymes, prevents the nuclear translocation of AR and the 
subsequent increase in AR and TMPRSS2 levels and, additionally, blocks PSA 
synthesis [52-54]. 
Our in vitro results demonstrate that high concentrations of abiraterone 
promoted a cytotoxicity effect in all tested cell lines. The androgen-dependent 
VCaP cell line displayed the highest sensitivity to abiraterone; however, VCaP, 
22Rv1, and RWPE-1 cell lines all displayed a ~50% reduction in cell viability at higher 
drug concentrations (10 µg/ml). Furthermore, the androgen-independent cell lines 
(DU-145 and PC-3) displayed lower sensitivity to the treatment, with only a ~25% 
decrease in cell viability, similar to the LNCaP androgen-dependent cell line  
(See Chapter IV, Figure 3). We next studied the expression of AR levels by Western 
blot assay (See Chapter III, Section III.3.1), finding that PC-3 and DU-145 PCa cells 
fail to express AR levels, corroborating previous findings [55]. The effectiveness of 
abiraterone at high concentrations in the androgen-independent PC-3 and DU-145 
cell lines may be explained due to levels of AR below the detection level of the 
Western blot assay. Indeed, other studies have demonstrated that the PC-3 and 
DU-145 PCa cell lines express low but detectable AR by quantitative PCR [56, 57] 
and we hope evaluate AR mRNA levels in the near future. Furthermore, studies 
performed by Grossebrummel et al. reported that abiraterone influenced the cell 
cycle and apoptosis in androgen-independent PC-3 cells, which also could explain 
the responsiveness of the PC-3 cell line to abiraterone treatment [58]  
(See Chapter IV, Figure 3). We also found that abiraterone treatment did not affect 
the androgen-dependent LNCaP PCa cell line despite the presence of high levels of 
AR, although previous findings by Bedussi et al. and Fragni et al. demonstrated 
androgen-sensitivity in those PCa cell lines [50, 59]. For this reason, we believe that 




(See Chapter IV, Figure 3). Previous studies demonstrated that T2E-positive PCa 
tumors display better responses to abiraterone when compare to T2E-negative PCa 
tumors [6]. We confirmed a higher sensitivity of the VCaP cell line to abiraterone 
treatment, thereby suggesting that treatment effectiveness requires the presence 
of T2E (See Chapter IV, Figure 3).  
To investigate the functional effect of our combination therapies in 
different PCa cell lines, we studied the synergy between AVE1642 or PGA-AVE1642 
with abiraterone using cell viability data processed by CompuSyn software.  
We observe a synergistic effect in VCaP cells with AVE1642/abiraterone and  
PGA-AVE1642/abiraterone, demonstrating that polymer conjugation of the 
antibody does not detract from AVE1642 activity as part of a combination therapy 
(See Chapter IV, Figure 4). Moreover, we also discovered a synergistic effect in 
22Rv1 cells at the highest tested concentrations (for both AVE1642 and  
PGA-AVE1642), obtaining an ~60% loss in cell viability (See Chapter IV, Figure 4, 
Table 1.B). The results illustrate that the combination therapy promotes higher 
sensitivity in VCaP cells compared to 22Rv1 cells, most likely due to the presence of 
the T2E fusion gene (See Chapter IV, Figure 4). This suggests that by choosing  
T2E-positive patients, we could potentially improve outcomes with a reduced dose, 
thereby inhibiting any side-effects.   
To validate the importance of the T2E fusion gene in combination therapies, 
we performed similar cytotoxicity studies with ERG gene silencing in the VCaP cell 
line. We demonstrated that the sensitivity of VCaP cells to both 
AVE1642/abiraterone and PGA-AVE1642/abiraterone significantly decreases upon 
ERG gene silencing; however, PGA conjugation to AVE1642 does not alter the T2E 
dependence (See Chapter IV, Figures 5.B and C). 
Next, we determined the suitability and effectivity of both combination 




abiraterone acetate as a single therapy to confirm an effect before moving to the 
combination therapy. Due to the lack of CYP17A1 expression in mice adrenal 
glands, we administered the DHEA precursor supplement to mimic human adrenal 
physiology conditions [60, 61]. The second essential target for abiraterone 
treatment, as established by Riu et al., is 3β-hydroxysteroid 
dehydrogenase/isomerase (3βHSD), an enzyme that can synthesize DHT from DHEA 
in the adrenal glands [62]. 3βHSD also plays a vital role in intratumoral androgen 
synthesis by the “backdoor pathway” [63] involving the prevention of DHEA 
conversion to AD and blockage of AR nuclear translocation and the expression of 
AR target genes. Riu et al. demonstrated tumor growth inhibition after abiraterone 
acetate administration in those mice supplemented with DHEA [62]. Our model also 
required DHEA supplementation to achieve significant tumor reduction  
(See Chapter IV, Figure 7), most probably due to the extremely low levels of 
CYP17A1 enzyme (See Chapter IV, Figure 6). The mechanism of action is related to 
3βHSD inhibition and the blockade of DHT synthesis, as confirmed by the 
measurement of PSA levels. A significant decrease in PSA levels after abiraterone 
acetate treatment with DHEA supplementation (See Chapter IV, Figure 12.C) 
suggests inhibition of the 3βHSD enzyme due to DHT downregulation thus 
prevention of both AR activation as reported by Riu et al. [62] and subsequent AR 
nuclear translocation leading to inhibition of the AR-mediated PSA gene 
transcription [64]. These and previous results provide evidence for the fundamental 
nature of DHEA in the mouse model for the efficacy of abiraterone acetate efficacy 
at different levels (adrenal glands, gonads, and intratumorally). DHEA 
supplementation normally promotes tumor growth due to its status as an androgen 
precursor and an AR pathway activator; however, in our experiments, the animals 
treated with DHEA showed similar tumor growth to control, which agrees with a 
previous study that fails to report elevated tumor growth at the employed 




After confirming the efficacy of abiraterone acetate monotherapy, we 
moved to study the combination therapy. First, we corroborated that DHEA 
supplementation did not interfere with the therapeutic potential of AVE1642 and 
PGA-AVE1642 (See Chapter IV, Figures 9 and 10). Next, we identified a notable 
synergistic effect in tumors treated with AVE1642/abiraterone acetate; we 
observed a more significant inhibition of tumor growth and lower PSA levels when 
compared with AVE1642 alone or abiraterone acetate alone. However,  
PGA-AVE1642/abiraterone acetate treatment did not improve the anti-tumoral 
effect when compared to PGA-AVE1642 treatment alone, and we obtained similar 
alterations to tumor growth and PSA levels (See Chapter IV, Figure 12).  
To further understand the cellular mechanism at play in vivo, we studied 
alterations to the MAPK and PI3K signaling pathways in tumors extracted from mice 
from the previous experiment. While AVE1642 single treatment promoted only 
PI3K pathway inhibition (See Chapter IV, Table 1), the AVE1642/abiraterone 
acetate displayed obvious synergy (See Chapter IV, Figures 14.C and D) to allow for 
the inhibition of both PI3K and MAPK pathway inhibition. While 
AVE1642/abiraterone acetate treatment prompted reduced levels of p-MAPK and 
p-PI3K, AVE1642 monotherapy did not affect the phosphorylation levels of these 
proteins (See Chapter IV, Table 1). For AVE1642/abiraterone acetate treatment, we 
also detected a decrease in total IGF-1R protein levels (See Chapter IV, Figure 14.E), 
an effect possibly related to lower ERG protein expression as a consequence of the 
mechanism of action of abiraterone acetate, which inhibits androgen synthesis and 
avoids AR activation and binding to the ERG promotor [66, 67]. In addition, our 
findings for the AVE1642/abiraterone acetate combination therapy suggest that 
the MAPK inhibition pathway could impede IGF-1R internalization, thereby 




We also studied the PGA-AVE1642 conjugate in combination with 
abiraterone acetate in a similar manner. Studies regarding the mechanism of action 
in tumor samples after PGA-AVE1642 treatment, both in the presence and absence 
of abiraterone acetate, demonstrated a similar inhibition of tumor growth and the 
attenuation of both MAPK (through Shc) and PI3K signaling pathways (See Chapter 
IV, Figures 14.B and D). However, the attenuation of p-Shc is much stronger in the 
case of the PGA-AVE1642/abiraterone acetate combination treatment, (See 
Chapter IV, Table 1). The inhibition of both MAPK and PI3K pathways suggests that 
PGA-AVE1642 therapy provides a complete inhibition of IGF-1R with and without 
abiraterone acetate. However, we obtained stronger total IGF-1R inhibition and a 
more significant decrease in ERG protein levels in 
PGA-AVE1642/abiraterone acetate combination therapy compared with the  
PGA-AVE1642 treatment alone (See Chapter IV, Figure 13.G, Table 1). As for the 
data regarding AVE1642/abiraterone acetate treatment, we obtained similar levels 
of ERG and total IGF-1R inhibition after PGA-AVE1642/abiraterone acetate 
combination (See Chapter IV, Table 1). Additionally, we detected lower p-IGF-1R 
protein levels in comparison with the control group after both 
AVE1642/abiraterone acetate and PGA-AVE1642/abiraterone acetate treatments, 
indicating that both anti-IGF-1R inhibitors (AVE1642 and PGA-AVE1642) bind and 
block their therapeutic target (See Chapter IV, Figure 14.A). 
Unexpectedly, both combination therapies and abiraterone acetate 
treatment alone failed to decrease AR levels compared to the control group, even 
though our studies clearly demonstrate that abiraterone acetate promotes an  
anti-tumoral effect (See Chapter IV, Figure 14.F). Of note, our Western blot analysis 
detected total AR levels – further analysis of mRNA expression and AR 




After abiraterone acetate treatment alone, we found that p-MAPK and  
p-PI3K protein levels did not significantly change in comparison with the control 
group, a finding perhaps related to the crosstalk between AR and PI3K pathways, 
with the abiraterone acetate treatment promoting PI3K pathway activation [71]. 
Additionally, total IGF-1R-β maintained high expression levels due to ERG protein 
expression that acts on the IGF-1R promotor to stimulate higher levels of 
transcription levels (See Chapter IV, Figure 14.E) [6]. The unexpectedly high ERG 
protein levels after abiraterone acetate treatment suggest AR activation by an 
androgen-independent pathway; in this way, AR could be activated without 
androgen ligand promoting ERG transcription. Furthermore, p-IGF-1R-β protein 
expression studies did not reveal any significant alterations in response to 
abiraterone acetate treatment when compared with the control groups, indicating 
that IGF-1R is not affected by abiraterone acetate treatment alone (See Chapter IV, 
Figure 14.A).  
Interestingly, after abiraterone acetate treatment, we detected a 
significant reduction in p-Shc levels with respect to the control (See Chapter IV, 
Figure 14.B). The Shc adaptor protein plays a vital role in cancer progression and 
metastasis by transmitting activated TKR phosphorylation signaling downstream. 
Recent studies have established that androgens can increase p-Shc 
phosphorylation in hormone-sensitive human prostate or breast cancer cells 
promoting higher tumoral cell growth [72, 73], thereby helping to corroborate our 
findings. 
Furthermore, we hypothesize that AVE1642 requires abiraterone acetate 
treatment to promote a synergistic effect to inhibit both MAPK and PI3K signaling 
pathways and decreased tumor growth. In contrast, PGA-AVE1642 with and 
without abiraterone acetate treatment promote the same antitumor 




necessary after PGA-AVE1642 administration but could help to enhance the  
long-term anticancer activity as a maintenance treatment after a possible  
PGA-AVE1642 regime.  
As the main conclusions from our studies, we propose the following 
mechanism of action schemes for AVE1642 and PGA-AVE1642 with and without 
abiraterone acetate (Figures 1, 2, and 3).  
 
 
Figure 1: Proposed Differential Mechanisms of Action for AVE1642 vs. PGA-AVE1642 
Treatment. A) After AVE1642 treatment, p-Shc, p-MAPK, and p-PI3K levels remain similar 
and associated with significantly decreased tumor growth and PSA levels. B) After  
PGA-AVE1642 treatment, p-Shc, and p-PI3K levels decrease, suggesting inhibition of both 
MAPK and PI3K signaling pathways, and this associated with enhanced tumor growth 





Figure 2: Proposed Mechanism of Action for AVE1642/Abiraterone Acetate Combination 
Therapy. After AVE1642/abiraterone acetate combination therapy, inhibition of both MAPK 
and PI3K signaling pathways leads to decreased tumor growth. Reduced p-MAPK levels 
associate with crosstalk between androgen signaling and Shc. Abiraterone acetate 
treatment promotes a decrease in androgen levels and the subsequent inhibition of Shc 
phosphorylation, thereby avoiding the activation of the downstream signaling pathways. 
Abiraterone acetate treatment also prevents AR nuclear translocation, thereby decreasing 










Figure 3: Downstream Signaling Pathways In Vivo After PGA-AVE1642/Abiraterone 
Acetate Combination Therapy. After PGA-AVE1642/abiraterone acetate combination 
therapy, the lower p-Shc and p-PI3K protein levels observed suggest inhibition of both 
MAPK (through the p-Shc inhibition) and PI3K signaling pathways, leading to tumor growth 
inhibition. Higher p-Shc inhibition is promoted by both IGF-1R inhibition by PGA-AVE1642 
treatment and the crosstalk between androgen synthesis and Shc phosphorylation. 
Furthermore, abiraterone acetate treatment also avoids AR nuclear translocation, thereby 
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Final Conclusions  
Our work focused on a polymer therapeutics approach to PCa therapy, 
where we investigated how PGA conjugation altered the biological properties of a 
human monoclonal antibody (AVE1642) in the hope of increased anti-tumoral 
activity of AVE1642 in aggressive PCa. We demonstrated enhanced monoclonal 
antibody bioactivity after PGA conjugation and explored the potential of 
combination therapy as an advanced treatment option for a subtype of PCa 
patients, T2E positive patients.  
The main conclusions of this thesis can be summarized as follows: 
1. We developed a new polymer-antibody conjugate at an optimal ratio of 2:1 
(two PGA chains per one AVE1642). 
2. PGA conjugation increases the hydrodynamic volume and negative charge of 
AVE1642 although the secondary structure of AVE1642 is maintained. 
3. PGA conjugation does not promote hemolysis in mice serum, providing proof 
of safety, protects AVE1642 from degradation in serum improving AVE1642 
stability, improves thermal stability of AVE1642, but does not improve 
AVE1642 tumor accumulation. 
4. PGA conjugation does not alter AVE1642 function and maintains the selectivity 
of AVE1642 to ERG overexpression associated with the presence of T2E fusion 
gene in PCa cells.  
5. PGA conjugation modifies cellular trafficking in vitro. AVE1642 and  
PGA-AVE1642 become targeted to the lysosomes by different endocytic 
pathways. While AVE1642 primarily internalizes via clathrin-mediated 
endocytosis and is directed to the lysosomes through endosomes,  




directed to the lysosomes, with a lack of early endosomal colocalization 
probably due to differential interactions with the receptor. 
6. We optimized a novel preclinical orthotopic mice model of advanced PCa using 
the VCaP cell line transfected with luciferase.  
7. PGA conjugation of AVE1642 leads to an altered molecular response in vitro 
and in vivo, improving the antitumoral activity preventing the activation of 
both PI3K and MAPK signaling pathways, thus improving AVE1642 
effectiveness. However, while we obtain an inhibition of PI3K signaling 
pathway in vitro following AVE1642 treatment, we fail to detect pathway 
inhibition in vivo. 
8. PGA-AVE1642 improves IGF-1R inhibition by preventing energy-dependent 
internalization of IGF-1R, thereby inhibiting both the PI3K and MAPK 
pathways. AVE1642 allows IGF-1R internalization and prevents downstream 
PI3K signaling pathway activation. 
9. PGA-AVE1642 treatment promotes more robust alterations to the TME when 
compared to AVE1642, including a decrease in both the functionality and 
maturity of blood vessels. Furthermore, PGA-AVE1642 significantly improves 
the inhibition of prostate tumor proliferation and angiogenesis compared with 
AVE1642 treatment.   
10. In vitro studies demonstrated a T2E-dependent synergistic effect for  
PGA-AVE1642 and AVE1642 treatments in combination with abiraterone. 
However, while we obtained a synergistic anti-tumor effect for AVE1642 
treatment in combination with abiraterone in vivo, we failed to find an additive 
effect for PGA-AVE1642 and abiraterone treatment due to the differential 
molecular mechanism of action upon PGA conjugation as both combination 










































1.1. Cáncer de Próstata: Definición y Progresión  
La incidencia del cáncer ha aumentado recientemente debido a varios 
factores, entre ellos, el aumento de la esperanza de vida, las mejoras en el 
diagnóstico y el aumento de la exposición a diferentes factores de riesgo. El cáncer 
de próstata (CaP) representa el segundo cáncer más común y la quinta causa 
principal de muerte en hombres, con 1,3 millones de casos nuevos y 359.000 
muertes asociadas en el año 2018 [1]. 
Generalmente, la mayoría de los casos diagnosticados de CaP son 
adenocarcinomas, un tumor maligno formado por estructuras glandulares en el 
tejido epitelial [2]. Los CaP primarios o localizados presentan una amplia gama de 
opciones de tratamiento que varían según la edad del paciente, el estadio clínico 
del tumor, los niveles de biomarcadores (incluido el antígeno prostático específico 
(PSA)) o la puntuación de Gleason (un sistema de clasificación que mide la 
agresividad del tumor en función de su aspecto microscópico) [3]. La 
prostatectomía radical y la radioterapia representan tratamientos estándar para el 
CaP localizado. Independientemente de los resultados iniciales positivos obtenidos 
empleando estas terapias, la recurrencia de la enfermedad ocurre en un tercio de 
los pacientes. 
 En esta etapa recurrente, la terapia de privación de andrógenos (ADT) 
representa el tratamiento indicado. El CaP se considera un tumor 
hormonodependiente en el que se necesita la activación del receptor de 
andrógenos (AR) para su supervivencia. El CaP resistente a la castración (CRPC) se 
desarrolla como consecuencia de la resistencia a la ADT, lo que conduce a una alta 




 Existen varios mecanismos involucrados en la progresión del CRPC como 
son alteraciones en las vías involucradas en la reparación del DNA [5], la 
desregulación de los genes implicados en la señalización de la ruta PI3K-Akt mTOR 
[6] y las más frecuentes relacionadas con alteraciones del AR [7].  
 A pesar de los recientes avances en la detección temprana y tratamiento 
del CaP localizado, el número de muertes es elevado. Este hecho se debe a la 
ausencia de biomarcadores con utilidad clínica y la subclasificación molecular del 
CaP, además de la falta de terapias personalizadas [8]. Para resolver estos 
problemas, necesitamos una comprensión más profunda del desarrollo de la 
enfermedad y de los mecanismos biológicos que controlan la identidad del tumor. 
1.2. Biomarcadores en el Cáncer de Próstata 
 Actualmente, la detección del PSA, el examen rectal digital y la biopsia de 
tejido prostático representan las herramientas clínicas empleadas generalmente 
para diagnosticar el CaP. Cabe destacar que los niveles de PSA además de aumentar 
por el CaP, también pueden variar por enfermedades benignas de la próstata como 
la prostatitis o la hiperplasia prostática benigna [9]. Por lo tanto, el diagnóstico 
basado en los niveles de PSA no permite una gran precisión en la estrategia de 
tratamiento, lo que puede llevar a un tratamiento inadecuado de los pacientes. 
 La integración de datos genómicos, transcriptómicos, epigenéticos y 
metabolómicos ha llevado al descubrimiento de diversos biomarcadores de CaP de 
nueva generación. Estos avances aumentan la precisión en la decisión de un 
tratamiento efectivo. 
 Entre estos biomarcadores destacan: el gen PCA3, el cual está 
sobreexpresado en más del 95% de los casos primarios de CaP [10], el gen SCHLAP1 
el cual también está sobreexpresado en el CaP agresivo [11], la detección de la 




genómicas en PTEN, las cuales representan un paso clave en el desarrollo de CaP 
agresivo [13]. Además, el reordenamiento cromosómico y las deleciones 
intracromosómicas son aberraciones comunes en el CaP que llevan a la formación 
de genes de fusión. 
 Principalmente, la fusión del gen TMPRSS2-ERG (T2E) es el reordenamiento 
cromosómico más frecuente en CaP. El gen TMPRSS2 codifica una proteasa serina 
transmembrana regulada por AR, por lo tanto, está altamente expresada en el 
tejido prostático. Diversos estudios han demostrado que el promotor 5' del gen 
TMPRSS2 se puede fusionar con la región codificante del gen ERG produciendo un 
aumento de su expresión. ERG codifica una proteína oncogénica que desempeña 
un papel importante en la progresión de la enfermedad [14]. El gen de fusión T2E 
se ha visto que puede tener un papel crítico en la subclasificación de pacientes con 
CaP y en el desarrollo de estrategias terapéuticas específicas [14].  
1.3. Terapias para el Cáncer de Próstata 
Las terapias tradicionales empleadas para tratar el CRPC incluyen la 
quimioterapia y las terapias hormonales. Docetaxel y cabazitaxel son los agentes 
quimioterapéuticos más utilizados para el CRPC, pero, a pesar de mostrar 
resultados prometedores, presentan una supervivencia media de 18 meses [15]. 
 Se han desarrollado nuevas terapias hormonales basadas en el importante 
papel que el AR desempeña en el CaP. La evolución del CaP a CRPC depende de la 
capacidad que adquieren las células cancerosas para crecer con niveles bajos de 
andrógenos debido a las aberraciones en el AR que mantienen la actividad 
transcripcional en ausencia del ligando. La abiraterona es un inhibidor irreversible 
y altamente selectivo de la enzima CYP17A1 que, por lo tanto, bloquea la 
producción de andrógenos tanto en la próstata como en las glándulas adrenales. La 




translocación nuclear del AR y su unión al ADN. Otros fármacos antiandrogénicos 
incluyen apalutamida y darolutamida [16]. También se ha demostrado que las 
terapias hormonales pueden presentar ciertas sinergias con los agentes clásicos 
quimioterapéuticos. 
 Las nuevas terapias incluyen inhibidores de PARP como olaparib o niraparib 
[17], la aplicación de Radium-223, un radioisótopo que induce roturas de doble 
cadena de ADN [18], y Sipuleucel-T, la primera inmunoterapia para CRPC [16].  
1.4. Nanomedicina y Polímeros Terapéuticos 
Lamentablemente, a pesar de la gran cantidad de fármacos empleados para 
tratar el CaP avanzado, la falta de eficiencia ha provocado que no se mejoren las 
tasas de supervivencia ni se reduzcan los efectos secundarios, por lo que es 
necesario el desarrollo de nuevos tratamientos para el CRPC. 
En este contexto, la nanomedicina, definida como la aplicación de la 
nanotecnología en el campo médico, representa un medio prometedor para la 
creación de estrategias de tratamiento eficaces. Este enfoque ha permitido el 
desarrollo de nanofármacos y métodos para el transporte selectivo de 
medicamentos. 
 Los polímeros terapéuticos (PT) se consideran la primera generación de 
nanomedicamentos poliméricos más exitosa representando una de las disciplinas 
nanomédicas más innovadoras en cuanto al tratamiento del cáncer. Las terapias 
con polímeros abarcan una amplia familia de sistemas que incluyen conjugados de 
fármaco-polímero, proteína-polímero, micelas poliméricas, liposomas o cualquier 
agente terapéutico unido a una estructura polimérica [19]. 
 Las características intrínsecas de los PT ofrecen las siguientes ventajas:  una 




farmacocinética, una mayor acumulación pasiva en el tumor a través del efecto de 
permeabilidad y retención (EPR), un aumento en el tiempo de circulación 
sanguínea, aumentan la solubilidad, reducen la toxicidad e incluyen la capacidad de 
llevar más de un agente activo, permitiendo así la terapia combinada [20].  
1.5. Terapia Personalizada en el Cáncer de Próstata 
 Las nuevas estrategias de tratamiento contra el CRPC han tenido en cuenta 
los conocimientos sobre la biología del CaP y gracias a esto se han empezado a 
desarrollar enfoques terapéuticos utilizando polímeros. 
 Estudios previos demostraron una sobreexpresión de IGF-1R en un subtipo 
de pacientes de CaP caracterizado por la presencia de T2E. IGF-1R está relacionado 
con la invasión tumoral y metástasis a través de la activación de las rutas de 
señalización intracelular PI3K y MAPK [21]. 
 AVE1642 es un anticuerpo monoclonal humanizado (mAb) dirigido contra 
IGF-1R. Los ensayos clínicos en fase II que utilizan inhibidores de IGF-1R no han 
logrado demostrar la eficacia de este tratamiento en pacientes con CRPC, tal vez 
debido a una inhibición incompleta de la vía y a la falta de un subtipo adecuado de 
pacientes. Sin embargo, se demostró que el AVE1642 presenta efectos citotóxicos 
significativos en las líneas celulares T2E+ en comparación con las células T2E-. De 
esta manera, se demuestra que el AVE1642 tiene un efecto terapéutico específico 
en un subtipo específico de pacientes que presentan el gen de fusión T2E [21]. 
Es importante remarcar que la inhibición de la ruta PI3K ocasionada por el 
bloqueo del receptor IGF-1R utilizando AVE1642 produciría un aumento en los 
niveles de andrógenos ocasionando el crecimiento tumoral por la existencia de un 
entrecruzamiento entre las rutas PI3K y AR [22], por lo que, en esta tesis doctoral, 




PGA-AVE1642 para bloquear la ruta PI3K y la abiraterona para bloquear la síntesis 
de andrógenos en un subtipo específico de pacientes T2E+.   
2. Objetivos 
El objetivo a largo plazo de esta tesis doctoral es el desarrollo de terapias 
avanzadas para el tratamiento del CaP en un estadio avanzado de forma 
personalizada, siendo aún una necesidad clínica. En particular, nos centramos en el 
diseño y el desarrollo de un conjugado biocompatible y biodegradable formado por 
polímero unido a un anticuerpo (PGA-AVE1642) para bloquear IGF-1R con el fin de 
mejorar los resultados terapéuticos en el subtipo de cáncer de próstata positivos 
para T2E. Además, debido a la retroalimentación recíproca negativa entre el 
receptor de andrógenos (AR) y las vías de señalización PI3K/Akt, nuestro paso 
siguiente es estudiar la terapia de combinación utilizando AVE1642 o PGA-AVE1642 
con abiraterona para promover una mayor inhibición de ambas vías – una 
estrategia que podría representar un método prometedor para tratar el PCa 
avanzado. 
Estos aspectos principales se lograrán a través de los siguientes objetivos 
específicos: 
1. Desarrollo, síntesis y caracterización química de un nuevo conjugado 
utilizando un portador polimérico biodegradable y multivalente (ácido 
polilutámico L-glutámico o PGA) conjugado con un anticuerpo humano 
monoclonal anti-IGF-1R (AVE1642) para el tratamiento del cáncer de 
próstata resistente a la castración metastásica (mCRPC). La caracterización 
completa del PGA-AVE1642 se realizará mediante una serie de técnicas 
(por ejemplo, SEC, DLS y FUV-CD) para determinar parámetros como el 




2. Estudio del efecto que ejerce la conjugación del PGA en la estabilidad del 
AVE1642, mediante la evaluación de su afinidad al IGF-1R, y estudiar su 
seguridad a través de ensayos de hemocompatibilidad. 
3. Análisis de la citotoxicidad de AVE1642/PGA-AVE1642 y estudio de su 
dependencia con la sobreexpresión de ERG asociada con la presencia del 
gen de fusión T2E en varias líneas celulares de cáncer de próstata y células 
normales de próstata. 
4. Estudio de la influencia del PGA en el tráfico y el destino celular de AVE1642 
in vitro por microscopía confocal/STORM en la línea celular VCaP mediante 
el etiquetado de AVE1642 y PGA-AVE1642 con diferentes fluoróforos. 
5. Investigación de la respuesta molecular de AVE1642 y PGA-AVE1642 in vitro 
en la línea celular VCaP por análisis de proteínas. 
6. Diseño y optimización in vivo de un modelo de ratón ortotópico de cáncer 
de próstata avanzado utilizando la línea celular VCaP transfectada con 
luciferasa, que se utilizará para testar la actividad antitumoral de AVE1642 
y PGA-AVE1642 a través de la monitorización de la progresión tumoral por 
imagen óptica (IVIS Spectrum®). También se estudiarán los tumores a nivel 
proteico para explorar las diferentes respuestas moleculares a ambos 
tratamientos, AVE1642 y PGA-AVE1642. 
7. Evaluación de las alteraciones del microambiente tumoral, como la 
funcionalidad, la madurez de los vasos sanguíneos, la proliferación tumoral 
y la angiogénesis, después del tratamiento AVE1642 y PGA-AVE1642 
mediante inmunohistoquímica. 
8. Estudio in vitro e in vivo de la sinergia entre AVE1642/PGA-AVE1642 en 
combinación con abiraterona evaluando la dependencia de ambas terapias 




3. Material y Métodos 
3.1. Cromatografía de Exclusión Molecular 
La cromatografía de exclusión molecular se realizó en un sistema FPLC 
equipado con una columna Superdex. La elución de la muestra se realizó con Tris 
50 mM, NaCl 150 mM pH 7.5, y la absorbancia se determinó a 220 nm. 
3.2. Electroforesis SDS-PAGE 
Las muestras se mezclaron (1:2) con tampón de carga y se incubaron 
durante 5 minutos a 95ºC para desnaturalizar la proteína. A continuación, las 
muestras se cargaron en un gel SDS y migraron durante 1 h 45 min a 150 V. Las 
proteínas fueron visualizadas tras tinción con azul de Coomassie. 
3.3. Dispersión Dinámica de la Luz (DLS) y Medidas del Potencial Z 
Ambos parámetros se determinaron a 25ºC utilizando el detector Malvern 
Zetasizer Nano ZS equipado con un láser de 532 nm con un ángulo de dispersión 
fijo de 173º. Previamente, las muestras fueron preparadas en PBS a 0,2 mg/ml y 
filtradas a través de un filtro de membrana de celulosa de 0,22 μm. Las medidas de 
DLS mostraron el tamaño de la muestra y las medidas del potencial Z determinaron 
la carga superficial.  
3.4. Análisis de Aminoácidos 
La relación molar entre el PGA y el AVE1642 en el conjugado PGA-AVE1642 
se determinó mediante análisis de aminoácidos en la Universidad de Barcelona. Se 
hidrolizaron 100 µl de las muestras en ácido clorhídrico 6 M a 110ºC durante 24 
horas. A continuación, las muestras se evaporaron, se resuspendieron en 500 µl de 
agua Milli-Q y se filtraron utilizando una membrana de celulosa de 0,45 µm. La 




se derivatizaron con AQC según el método AccQ-TagTM. Los aminoácidos fueron 
analizados por HPLC mediante detección UV a 254 nm. 
3.5. Estudios ELISA 
Se realizaron ensayos ELISA para evaluar la estabilidad y afinidad del 
AVE1642 y PGA-AVE1642. En una placa ELISA se añadieron 40 µg/ml de lisado 
celular de VCaP diluido en PBS y la placa se incubó en agitación durante toda la 
noche a 4ºC. Al día siguiente, después de tres lavados con PBS-Tween, los lisados 
fueron bloqueados con tampón de bloqueo (0.2% (v/v) Tween 20 y 5 % leche) 
durante 2 horas a temperatura ambiente. El tampón de bloqueo fue eliminado tras 
tres lavados con PBS-Tween y se añadieron 100 µl de sus correspondientes curvas 
de calibración y 100 µl de las diferentes muestras. La placa se incubó en agitación 
durante toda la noche a 4ºC y, tras tres nuevos lavados con PBS-Tween, se 
incubaron durante 2 horas 100 µl del anticuerpo primario anti-humano. 
Finalmente, se retiró el anticuerpo y los lisados se incubaron con 100 µl de TMB 
durante 30 minutos en oscuridad. Después de este tiempo, se añadieron 100 µl de 
solución de parada. La absorbancia se midió en un espectrofotómetro a 450 nm. 
3.6. Estudios MTS 
Las células fueron sembradas en una placa estéril de 96 pocillos en un 
volumen de 50 µl de medio e incubadas durante 24 o 72 horas en función del 
crecimiento exponencial. Transcurrido este tiempo, los diferentes tratamientos 
fueron preparados en medio y filtrados utilizando una membrana de celulosa de 
0,22 μm.  Tras una incubación de 72 horas a 37ºC, se añadieron 20 µl de MTS/PMS 
(proporción 20:1) y permaneció a 37ºC durante 3 o 6 horas dependiendo de la línea 
celular y respiración mitocondrial. Finalmente, las muestras se midieron en el 





3.7. Estudios IN Cell 
Las células fueron incubadas en una placa de 96 pocillos en un volumen de 
100 µl de medio durante 72 horas. Posteriormente, las células se trataron durante 
15, 30 y 60 minutos con 0,1 µg/ml de IGF-1, AVE1642 y PGA-AVE1642. Después de 
lavar con PBS, las células se fijaron con 100 µl de PFA durante 20 minutos a 37ºC y 
fueron bloqueadas durante una hora a la misma temperatura. Luego, se incubaron 
50 µl de anticuerpo primario IGF-1R-β durante toda la noche a 4ºC en agitación. A 
continuación, después de tres lavados con PBS, se añadieron 50 µl del anticuerpo 
secundario anti-conejo Alexa-488 y la placa fue incubada durante una hora en 
oscuridad. Después de lavar con PBS, la señal de IGF-1R fue adquirida y analizada 
en IN-Cell Analyzer.  
3.8. Citometría de Flujo 
Las células se sembraron en una placa de 12 pocillos y fueron incubadas 
durante 72 horas. Después, se incubaron 2 nM del inhibidor de la catepsina B  
(CA-074) durante 30 minutos para evitar la degradación de la PGA. A continuación, 
unas placas se mantuvieron a 37ºC para estudiar la endocitosis dependiente de 
energía mientras que otras se incubaron a 4ºC para inhibir este mecanismo. Luego, 
los compuestos AVE1642-Cy5.5 (0,16 mg/ml) y PGA-AVE1642-Cy5.5 (0,1 mg/ml) 
fueron añadidos directamente al medio celular y se incubaron durante 3 horas, 1 
hora, 15 minutos y 0 minutos a 37ºC y 4ºC. Finalmente, las células fueron lavadas 
con PBS-BSA y se recogieron en un volumen final de 400 µl. Los datos se obtuvieron 
empleando el citómetro de flujo CytoFLEX S. 
3.9. Microscopía Confocal  
Las células fueron sembradas en una placa de 24 pocillos sobre un 
portaobjetos de vidrio redondo. Tras 72 horas de incubación, las células fueron 




(0,16 mg/ml). A continuación, el medio fue retirado y las células se fijaron con PFA 
durante 20 minutos a 37ºC para después bloquear con tampón de bloqueo (10% 
(v/v) FBS diluido con PBS) durante 1 hora a 37ºC. Posteriormente, las células se 
incubaron toda la noche a 4ºC con 50 µl de las siguientes combinaciones de 
anticuerpos primarios: (i) anti-conejo IGF-1R-β con anti-ratón EEA1; (ii) anti-conejo 
LAMP1; (iii) anti-conejo IGF-1R-β con anti-ratón Clathrin (1/50); (iv) anti-conejo  
IGF-1R-β con anti-cabra Caveolin-1. Al día siguiente, se descartaron los anticuerpos 
primarios y las células se incubaron durante una hora en oscuridad con 50 µl de la 
siguiente combinación de anticuerpos secundarios: i) anti-conejo Alexa-488 con 
anti-ratón Pacific blue; ii) anti-conejo Alexa-488; iii) anti-conejo Alexa-488 con  
anti-ratón Alexa-568; iv) anti-conejo Alexa-488 con anti-cabra-Cy3 
respectivamente. Finalmente, las células fueron lavadas con PBS y diferentes 
imágenes se adquirieron con el microscopio Leica TCS SP8 para su análisis utilizando 
el software LAS X Life Science. 
3.10. Western Blot  
Las muestras celulares y tumorales fueron procesadas de forma diferente.  
Las células fueron sembradas en una placa de 6 pocillos y se incubaron durante 72 
horas antes de ser tratadas con IGF-1, AVE1642 y PGA-AVE1642 a 0,1 µg/ml durante 
15 y 30 minutos. A continuación, se retiró el medio y, tras lavar con PBS, las células 
se incubaron con tripsina-EDTA durante 1 minuto a 37 ºC para posteriormente 
inactivarla añadiendo 1,5 ml de medio. Finalmente, las células se centrifugaron 
durante 5 minutos a 400 rcf y el sedimento celular se introdujo en hielo para su 
posterior extracción proteica. En cambio, los tumores fueron extraídos e 
introducidos en nitrógeno líquido.  Una vez congelados, fueron machacados y el 
polvo obtenido fue introducido en un tubo para su posterior extracción proteica.  
Para extraer las proteínas celulares y tumorales, 100 µl de tampón de 




10 minutos en hielo y se agitaron en vórtex 10 segundos durante tres sucesivos 
ciclos. A continuación, las muestras se centrifugaron 20 minutos, a 13.200 rpm a 
4ºC y en el sobrenadante, mediante absorbancia a 595 nm, se cuantificó la cantidad 
de proteína utilizando el reactivo Bradford.  
50 µg de las muestras de proteína obtenidas fueron diluidas en tampón de 
carga y posteriormente se desnaturalizaron a 95ºC durante 7 minutos. Las muestras 
se separaron electroforéticamente en geles de poliacrilamida del 8% en tampón 
Running 1X. Después, las muestras se transfirieron a una membrana PVDF con 
tampón de transferencia a 400 mA durante dos horas a 4ºC. Una vez transferidas 
las proteínas, las membranas se bloquearon durante una hora a temperatura 
ambiente y diferentes anticuerpos primarios fueron diluidos en tampón de bloqueo 
e incubados en agitación durante toda la noche a 4ºC (anti-conejo p-MAPK,  
anti-ratón p-Shc, anti-conejo p-PI3K, anti-conejo IGF-1R-β, anti-conejo AR,  
anti-ratón ERG y anti-ratón α-tubulina). Al día siguiente, los anticuerpos primarios 
fueron retirados tras tres lavados con PBS-Tween y las membranas se incubaron 
durante una hora en agitación a temperatura ambiente con los anticuerpos 
secundarios anti-conejo y anti-ratón. A continuación, la señal quimioluminiscente 
se detectó empleando el sustrato ECL y la imagen fue adquirida en Amercham 
Hyperfilm. Finalmente, las imágenes fueron analizadas por densitometría utilizando 
el programa ImageJ.  
3.11. Infección Lentiviral  
Para monitorizar el crecimiento tumoral in vivo, la línea celular VCaP fue 
infectada por separado con el vector lentiviral luciferasa y con el vector lentiviral 
GFP como control de transfección positivo. Las células fueron sembradas en una 
placa de 6 pocillos y se incubaron a 37ºC hasta la obtención de un 80% de 
confluencia. A continuación, se prepararon ambas soluciones lentivirales por 




Transcurrido este tiempo, el medio fue reemplazado por medio completo y se 
procedió a la selección de aquellas células positivas para la infección empleando 
500 µg/ml del antibiótico geneticina. 
3.12. Efecto de Permeabilidad y Retención (EPR) 
Para determinar el EPR en el modelo animal, el colorante Evans blue:BSA 
(proporción 8:1) fue disuelto en una solución de cloruro de sodio al 0,9%. Cada 
semana, un grupo de seis ratones portadores de tumores sin tratar fueron 
sacrificados una hora después de la inyección por vía intravenosa de 10 mg/kg de 
colorante. Los tumores fueron pesados e incubados a 60ºC durante 48 horas en 3 
ml de formamida para extraer el colorante del tumor. El porcentaje de este 
colorante fue determinado mediante absorbancia a 620 nm. 
 3.13. Efectividad Antitumoral en el Modelo Animal 
Para desarrollar el modelo ortotópico animal de CaP se empleó la cepa  
C.B-17/IcrHan®Hsd-Prkdcscid. Los ratones fueron inyectados subcutáneamente con 
morfina (5 mg/kg) treinta minutos antes de la cirugía, y fueron anestesiados por 
inhalación con isoflurano (2-5%) durante todo el proceso quirúrgico. Una vez 
localizada la glándula prostática, se inyectaron un millón de células VCaP-Luc2 
ortotópicamente en un volumen final de 40 µl empleando una aguja de insulina 
(29G). A continuación, el área muscular y la piel se suturaron por separado y, 
después de la cirugía, se administró buprenorfina subcutánea (0,1 mg/kg) cada 12 
horas durante 72 horas como analgésico antiinflamatorio. El crecimiento tumoral 
fue monitorizado dos veces por semana a través de la señal luminiscente tumoral 
mediante la tecnología IVIS Spectrum. Para poder visualizar la luminiscencia del 
tumor, se administraron por vía subcutánea 150 mg/kg del sustrato luciferina.  
Los compuestos se administraron una vez los tumores alcanzaron un 




segunda semana) con 6 animales utilizados en cada grupo. AVE1642 y  
PGA-AVE1642 como terapia única y combinada con acetato de Abi se administraron 
por vía intravenosa tras dos semanas a 10 mg/kg una vez a la semana durante 
cuatro semanas. El acetato de abiraterona se administró por vía oral a 200 mg/kg 
una vez al día durante 35 días consecutivos también a partir de la segunda semana, 
y el DHEA se administró como suplemento diario por vía subcutánea a 0,1 mg. 
Cuando los tumores de los animales control (animales sin tratamiento) alcanzaron 
un tamaño de 1,2 cm3 (correspondiente a la séptima semana), todos los animales 
fueron sacrificados por inhalación de dióxido de carbono (CO2), y los tumores 
fueron pesados y medidos con calibre después de la extracción. También se extrajo 
sangre del corazón, la cual se centrifugó durante 10 minutos a 4000 rpm a 4ºC para 
obtener el plasma utilizado y cuantificar los niveles de PSA. 
 3.14. Inmunohistoquímica Tumoral 
Para los análisis inmunohistoquímicos tumorales, los ratones tratados con 
los diferentes compuestos fueron inyectados con 80 µl de FITC-lectina para 
identificar los vasos perfundidos en el tumor. Después, los tumores fueron 
extraídos, incluidos en OCT y congelados, conservándolos a -80ºC hasta su análisis 
histológico. Se hicieron secciones tumorales de 8 µm de grosor con el criostato y se 
fijaron en un portaobjetos. 
Para el análisis de los marcadores VEGFR2 y Ki67 se empleó un 
procedimiento experimental similar. Para eliminar el OCT, las muestras se lavaron 
en PBS y posteriormente se fijaron inicialmente con metanol al 80% durante cinco 
minutos y luego con acetona a -20ºC durante dos minutos a temperatura ambiente. 
A continuación, las muestras se lavaron tres veces con PBS durante cinco minutos. 
Para facilitar la difusión del anticuerpo Ki67 hacia el núcleo, se realizó un paso 
adicional de permeabilización con 0,1% de Triton-X 100 en PBS durante tres 




minutos con PBS y se incubaron en una cámara húmeda durante una hora con los 
respectivos anticuerpos primarios diluidos en 12% BSA (anti-cabra VEGFR2 y  
anti-conejo Ki67). Posteriormente, las muestras se lavaron tres veces durante cinco 
minutos con PBS y se incubaron durante 45 minutos en una cámara húmeda con 
los respectivos anticuerpos secundarios diluidos en 12% BSA (anti-cabra-Cy3 y anti-
conejo-Cy3). Después de lavar tres veces con PBS durante cinco minutos, las 
secciones tumorales se analizaron con el microscopio de fluorescencia Axio Imager 
M2 y las imágenes fueron cuantificadas utilizando el programa Dongle.  
4. Resultados  
4.1. La Conjugación del PGA Altera la Bioactividad de AVE1642 en Modelos 
de Cáncer de Próstata 
4.1.1. Síntesis y Caracterización Química de PGA-AVE1642 
La unión del PGA al AVE-1642 se realizó mediante dos pasos. En el primer 
paso, los grupos amida del AVE1642 fueron modificados con SATP y la 
concentración del AVE1642 se determinó midiendo la absorbancia a 280 nm. El 
segundo paso consistió en la conjugación del PGA al AVE1642-SATP, en la que fue 
necesaria una modificación previa del PGA con PD para obtener PGA-PD. 
Una vez obtenido el PGA-AVE1642, se caracterizó siguiendo diferentes 
técnicas para determinar el tamaño, la carga superficial y el número de cadenas de 
PGA. Mediante cromatografía de exclusión molecular y análisis SDS-PAGE 
encontramos un incremento en el volumen hidrodinámico del PGA-AVE1642 
respecto al AVE1642. Además, la técnica de DLS corroboró estos resultados 
mostrando un tamaño de 13,5 ± 1,7 nm para AVE1642, mientras que el tamaño 
para el conjugado PGA-AVE1642 fue de 17,5 ± 0,6 nm. Además, el potencial Z 
mostró una carga superficial para el PGA-AVE1642 más negativa con un valor de  




aminoácidos determinó la conjugación de un promedio de 2,8 cadenas de PGA por 
cada molécula de AVE1642. 
4.1.2. La Conjugación del PGA Aumenta la Estabilidad y la Afinidad de 
AVE1642 
La estabilidad y la afinidad de AVE1642 y PGA-AVE1642 se evaluaron 
mediante ensayos ELISA. Para determinar la estabilidad, ambos compuestos se 
diluyeron en suero y se incubaron a 37ºC durante 72 horas. Durante este periodo 
se recogieron alícuotas a diferentes tiempos (0, 24, 48 y 72 horas) y se incubaron 
con lisados proteicos de la línea celular VCaP que sobreexpresaba IGF-1R. Mientras 
el PGA-AVE1642 se mantiene estable a lo largo del tiempo, el AVE1642 muestra una 
mayor degradación. Estos resultados sugieren que la conjugación del AVE1642 al 
PGA puede ayudar a mantener la estabilidad del AVE1642 y, por lo tanto, funcionar 
durante largos periodos de tiempo después de la administración. Para estudiar la 
afinidad, diferentes concentraciones de AVE1642 y PGA-AVE1642 fueron testadas 
tras diluirlas en PBS y posteriormente incubadas en este lisado para detectar la 
concentración a la que el IGF-1R empieza a saturarse. Se demostró que  
PGA-AVE1642 produce una saturación del IGF-1R a 2 µg/ml de AVE1642 
equivalentes. Sin embargo, no pudimos apreciar la saturación de IGF-1R con 
AVE1642 en ninguna de las concentraciones probadas. Esto indica que el  
PGA-AVE1642 mejora la interacción con el IGF-1R en comparación con el AVE1642. 
4.1.3. Citotoxicidad de AVE1642 y PGA-AVE1642 en la Línea Celular VCaP 
Tratamos las células VCaP con AVE1642 y PGA-AVE1642 durante 72 horas 
a 37ºC entre 50 y 0,003 µg/ml en equivalentes de AVE1642. Adicionalmente, se 
comprobó la citotoxicidad de portador PGA entre 64,37 y 0,0064 µg/ml. La 
viabilidad celular fue evaluada mediante ensayos MTS. Ambos tratamientos 




el portador PGA no mostró efectos citotóxicos. Estos resultados nos muestran que 
la unión del PGA al AVE1642 no afecta a la estructura de este ni a su funcionalidad, 
por lo que el AVE1642 sigue manteniendo su actividad. Además, se realizaron 
estudios in vitro en diferentes líneas celulares de CaP (VCaP, LNCaP, PC-3, DU145 y 
22Rv1) y en la línea celular control (RWPE-1) para determinar mediante ensayos 
MTS la actividad toxicológica del AVE1642 y PGA-AVE1642. En general, sólo las 
células VCaP portadoras del gen de fusión T2E respondieron a los tratamientos 
AVE1642 y PGA-AVE1642.  
4.1.4. La Conjugación Previene la Internalización de IGF-1R 
Investigamos la internalización de IGF-1R en las células VCaP usando  
“IN Cell Analyzer”. Se trataron las células durante 15, 30 y 60 minutos en presencia 
de AVE1642, PGA-AVE1642 y el factor de crecimiento insulínico activador 1 (IGF-1) 
como control positivo a 0,1 µg/ml y se cuantificó los niveles de IGF-1R por 
inmunofluorescencia. Tanto el IGF1 como el AVE1642 provocaron la internalización 
citoplasmática del IGF-1R, mientras que el tratamiento con PGA-AVE1642 evitó la 
internalización de IGF-1R. Estos resultados sugieren que la conjugación de PGA 
podría modificar la interacción con IGF-1R evitando su internalización celular. 
4.1.5. La Conjugación Mejora la inhibición de IGF-1R  
Para llevar a cabo este experimento, previamente ambos compuestos 
fueron marcados con el fluoróforo Ciane 5.5 para poder visualizarlos y 
cuantificarlos mediante citometría de flujo. Una vez marcados, cada uno de los 
compuestos se incubó durante 0, 15, 60 y 180 minutos tanto a 37ºC como a 4ºC. La 
incubación a 4ºC permite inhibir los mecanismos de internalización dependientes 
de energía, de este modo podemos determinar si la internalización es dependiente 
o independiente de energía comparando con los resultados obtenidos a 37ºC. Los 




PGA-AVE1642 en comparación con AVE1642. En resumen, PGA-AVE1642 mejora la 
unión celular a IGF-1R mejorando su inhibición y posterior internalización. 
4.1.6. La Conjugación Altera el Tráfico Celular  
Para realizar este experimento, ambos compuestos fueron marcados con el 
fluoróforo Ciane 5.5 para poder visualizarlos mediante microscopía confocal. Cada 
uno de ellos se incubó durante 30 minutos en las células VCaP para permitir su 
internalización. Posteriormente, mediante inmunofluorescencia, se estudió la 
interacción de ambos compuestos con su receptor IGF-1R, mostrando una 
colocalización tanto con el PGA-AVE1642 como con el AVE1642. Seguidamente, 
empleando la misma técnica, se estudió la interacción de ambos compuestos con 
la clatrina, la caveolina-1, los endosomas y los lisosomas para estudiar las diferentes 
vías de endocitosis. El PGA-AVE1642 principalmente colocalizó con caveolina-1 y los 
lisosomas, en cambio el AVE1642 colocalizó en su mayoría con la clatrina, los 
endosomas y los lisosomas. Este resultado nos sugiere la posibilidad que ambos 
compuestos internalicen por rutas endocíticas diferentes, relacionado con los 
cambios en su bioactividad y tal vez con la diferente interacción con el IGF-1R. 
4.1.7. PGA-AVE1642 Evita la Activación de las Rutas PI3K y MAPK  
Para determinar el mecanismo de acción de ambos compuestos, las 
proteínas involucradas en la ruta endocítica del receptor IGF-1R fueron detectadas 
mediante ensayos de Western blot. Las células fueron tratadas con el ligando 
positivo (IGF-1) y ambos inhibidores (PGA-AVE1642 y AVE1642) durante 15 y 30 
minutos. Una vez transcurrido este tiempo se realizó una extracción proteica y se 
estudió la expresión de diferentes proteínas fosforiladas mediante western blot 
para detectar la activación y/o inhibición de las distintas rutas dependiendo del 
tratamiento administrado. Las proteínas detectadas fueron las siguientes: p-Shc,  




activación de ambas rutas (Shc/MAPK y PI3K) debido a la fosforilación de las 
proteínas Shc, MAPK y PI3K. En el caso de las células tratadas con AVE1642, 
pudimos observar una inhibición de la ruta PI3K debido a los bajos niveles de 
expresión de la proteína p-PI3K, pero observamos una activación de la ruta 
Shc/MAPK indicada por una fosforilación de las proteínas p-Shc y p-MAPK. En 
cambio, cuando las células fueron tratadas con PGA-AVE1642 se detectó la 
inhibición de ambas rutas (Shc/MAPK y PI3K) debido a los bajos niveles de 
expresión de las proteínas p-Shc, p-MAPK y p-PI3K. Estos resultados sugieren un 
mecanismo de acción diferente para ambos inhibidores: por un lado, el AVE1642 
inhibe la ruta PI3K y mantiene activa la ruta de Shc/MAPK, la cual está involucrada 
en la internalización de IGF-1R, mientras que el tratamiento con PGA-AVE1642 
inhibe ambas rutas, Shc/MAPK y PI3K, lo cual explica que en experimentos previos 
no observáramos una internalización de IGF-1R. En general, estos resultados 
sugieren que el tratamiento con PGA-AVE1642 mejora la inhibición de IGF-1R 
mostrada por la inactivación de las rutas de señalización intracelulares.  
4.1.8. La Conjugación Mejora la Actividad Antitumoral de AVE1642  
Para validar los resultados obtenidos en los ensayos in vitro, se optimizó un 
modelo ortotópico de CaP. Para poder evaluar el crecimiento tumoral en el modelo 
ortotópico es necesario que las células de interés expresen luciferasa. Una vez 
transfectada la línea celular VCaP con luciferasa (VCaP-Luc2), se confirmó mediante 
Western Blot y ensayos de viabilidad celular que dicha transfección no afectaba a 
los diferentes niveles de expresión de las proteínas involucradas en la diana 
terapéutica del tratamiento (IGF-1R-β, AR y ERG) y que mantenía la viabilidad 
celular comparándola con la línea celular sin transfectar. 
Seguidamente, la optimización del modelo se llevó a cabo utilizando 
ratones C.B-17/IcrHan®Hsd-Prkdcscid e inyectando un millón de células VCaP-Luc2 en 




semanalmente utilizando la tecnología IVIS® Spectrum. Se pudo observar un 
crecimiento tumoral homogéneo y una localización intraprostática obteniendo el 
máximo volumen tumoral permitido a las siete semanas. Para determinar el punto 
máximo de acumulación tumoral y de este modo empezar a administrar el 
tratamiento en dicho punto, se realizaron estudios de EPR. Los resultados 
mostraron una mayor acumulación en la segunda semana de crecimiento tumoral.  
Una vez establecido y optimizado el modelo animal, se administró el 
tratamiento a partir de la segunda semana tras la inyección celular a una 
concentración de 10 mg/kg tanto del AVE1642 como del PGA-AVE1642 una vez por 
semana durante cuatro semanas y se evaluó el crecimiento del tumor mediante 
IVIS hasta la séptima semana. Ambos compuestos mostraron una reducción 
significativa del crecimiento del tumor comparado con el tumor no tratado, pero 
aquellos tumores tratados con PGA-AVE1642 tuvieron significativamente una 
mayor actividad antitumoral en comparación con los tumores tratados con 
AVE1642. Posteriormente, se midieron los niveles de PSA y se determinó la 
densidad de los tumores. Los niveles de PSA se correlacionaron directamente con 
el volumen tumoral, en cambio, se pudo observar una correlación inversa entre el 
volumen tumoral y la densidad. Aquellos tumores con un menor volumen 
presentaron una mayor densidad posiblemente ocasionado por la presencia de 
zonas necróticas y calcificaciones. Adicionalmente, como control, los animales 
fueron tratados con el portador PGA a 8,45 mg/kg empleando la misma pauta de 
administración anteriormente descrita. El tamaño tumoral, los niveles de PSA y la 
densidad no mostraron diferencias en comparación con el control, confirmando de 






4.1.9. PGA-AVE1642 Mejora la Inhibición de IGF-1R In Vivo 
Para explicar la mayor efectividad antitumoral con el tratamiento  
PGA-AVE1642, nuestro siguiente paso se centró en el estudio de las diferentes rutas 
de señalización en el tumor comparando ambos tratamientos con el grupo control. 
Se estudió la expresión de diferentes proteínas fosforiladas mediante western blot 
para detectar la activación y/o inhibición de las distintas rutas dependiendo del 
tratamiento administrado. Las proteínas detectadas fueron las siguientes: p-Shc,  
p-MAPK, p-PI3K, IGF-1R total, AR y ERG. En general, no se observaron cambios 
significativos en la expresión de p-MAPK, AR y ERG, sin embargo, cuando se 
comparó con el control, se descubrió una reducción significativa en la expresión de 
IGF-1R-β y p-PI3K en los tumores tratados con PGA-AVE1642. Además, también 
observamos una reducción significativa en los niveles de proteínas p-Shc, p-PI3K e 
IGF-1R-β entre los tumores tratados con PGA-AVE1642 y AVE1642. Estos resultados 
sugieren que el PGA-AVE1642 mejora la inhibición del IGF-1R debido a la 
inactivación de las vías de señalización p-Shc y p-PI3K. 
4.1.10. PGA-AVE1642 Mejora la Inhibición de la Proliferación Celular y la 
Angiogénesis  
Se investigó la proliferación celular en las muestras tumorales mediante la 
detección del marcador de proliferación Ki67. La cuantificación de este marcador 
reveló una reducción significativa de la proliferación celular en los tumores tratados 
con AVE1642 en comparación con el grupo control. En cambio, el tratamiento con 
PGA-AVE1642 proporcionó una disminución significativamente más robusta en la 
proliferación celular en comparación con el grupo control y AVE1642. 
Adicionalmente, se estudió el marcador angiogénico VEGFR2 después de 
los diferentes tratamientos. La cuantificación de este marcador confirmó una 




AVE1642 y una reducción significativa más marcada en los tumores tratados con 
PGA-AVE1642. Además, el tratamiento PGA-AVE1642 provocó una reducción 
significativa de los niveles de VEGFR2 en comparación con los tumores tratados con 
AVE1642. Estos resultados sugieren que la conjugación de PGA mejora la eficacia 
antiangiogénica de AVE1642. 
4.2. Evaluación de una Nueva Terapia de Combinación para el Cáncer de 
Próstata Resistente a Castración 
4.2.1. La Terapia de Combinación Mantiene la Inhibición de IGF-1R In Vivo 
Para estudiar la terapia de combinación en el modelo animal, el acetato de 
abiraterona fue administrado solo y en combinación con los tratamientos AVE1642 
y PGA-AVE1642. Ambas terapias de combinación mostraron una reducción 
significativa del crecimiento tumoral en comparación con el grupo control, pero hay 
que remarcar que los tumores tratados con AVE1642 en combinación con acetato 
de abiraterona tuvieron significativamente una mayor actividad antitumoral en 
comparación con los tumores tratados con cada tratamiento por separado, 
mostrando de este modo un efecto sinérgico in vivo. En cambio, los tumores 
tratados con PGA-AVE1642 en combinación con acetato de abiraterona no 
mostraron un efecto sinérgico in vivo ya que el crecimiento tumoral no reveló 
diferencias significativas en comparación con los tumores tratados con  
PGA-AVE1642.  Posteriormente, se determinaron los niveles de PSA y la densidad 
tumoral. Los niveles de PSA se correlacionaron con el volumen tumoral, en cambio, 
solo los tumores tratados con acetato de abiraterona mostraron un aumento de la 
densidad en comparación con el resto de los tratamientos.  
Para explicar el efecto antitumoral obtenido, se estudiaron diferentes 
proteínas fosforiladas y no fosforiladas para detectar el estado de activación y/o 




siguientes: p-Shc, p-MAPK, p-PI3K, p-IGF-1R-β, IGF-1R-β AR y ERG. En general, no se 
observaron cambios significativos en la expresión de p-MAPK y AR. Sin embargo, 
cuando se comparó con el control, se descubrió una reducción significativa de  
p-IGF-1R-β, p-Shc, p-PI3K, IGF-1R-β y ERG en ambas terapias de combinación y una 
reducción significativa en p-Shc en los tumores tratados con acetato de 
abiraterona. Estos resultados sugieren que ambas terapias de combinación inhiben 
completamente el IGF-1R debido a la inactivación de las vías de señalización p-Shc 
y p-PI3K.  
5. Conclusiones 
Nuestro trabajo se centró en el uso de polímeros terapéuticos como 
enfoque terapéutico para la terapia de CaP, donde investigamos cómo la 
conjugación del PGA alteraba las propiedades biológicas de un anticuerpo 
monoclonal humano (AVE1642) con la esperanza de aumentar la actividad 
antitumoral de AVE1642 en el CaP agresivo. Demostramos una mayor bioactividad 
del anticuerpo monoclonal después de la conjugación con PGA y exploramos el 
potencial de la terapia de combinación como una opción de tratamiento avanzada 
para un subtipo de pacientes con CaP.  
Las principales conclusiones de esta tesis son las siguientes: 
1. Hemos optimizado el desarrollo de un nuevo conjugado formado por la unión 
del polímero a un anticuerpo, siendo la mejor relación 2:1 (dos cadenas de 
poliglutamato (PGA) por cada AVE1642). 
2. La conjugación del PGA aumenta el volumen hidrodinámico y la carga negativa 
de AVE1642, aunque se mantiene la estructura secundaria del AVE1642. 
3. La conjugación del PGA no promueve la hemólisis en suero de ratón, lo que 




mejorando la estabilidad del AVE1642, mejora la estabilidad térmica del 
AVE1642, sin embargo, no mejora la acumulación de AVE1642 en los tumores. 
4. La conjugación del PGA no altera la funcionalidad de AVE1642 y mantiene la 
selectividad de AVE1642 para la sobreexpresión de ERG asociada con la 
presencia del gen de fusión T2E en las células de CaP. 
5. La conjugación del PGA modifica el tráfico celular in vitro. AVE1642 y  
PGA-AVE1642 se dirigen a los lisosomas por diferentes vías endocíticas. 
Mientras que el AVE1642 se internaliza principalmente por endocitosis 
mediada por clatrina y se dirige a los lisosomas a través de endosomas, el  
PGA-AVE1642 se internaliza principalmente por endocitosis mediada por 
caveolina y se dirige a los lisosomas con una ausencia de colocalización 
endosómica probablemente debido a interacciones diferenciales con el 
receptor. 
6. Optimizamos un nuevo modelo de ratón ortotópico para el CaP avanzado 
utilizando la línea celular VCaP transfectada con luciferasa. 
7. La conjugación del PGA permite una alteración de la respuesta molecular  
in vitro e in vivo mejorando la actividad antitumoral evitando la activación de 
ambas vías de señalización PI3K y MAPK, mejorando así la efectividad del 
AVE1642. Sin embargo, mientras obtenemos una inhibición de la activación de 
la vía de señalización PI3K después del tratamiento con AVE1642 in vitro, no 
detectamos ninguna inhibición de las vías in vivo. 
8. PGA-AVE1642 mejora la inhibición de IGF-1R al prevenir la internalización 
dependiente de energía de IGF-1R, inhibiendo tanto la vía del PI3K como la del 
MAPK. AVE1642 permite la internalización de IGF-1R y evita la activación de la 




9. El tratamiento PGA-AVE1642 promueve alteraciones más robustas en el 
microambiente tumoral en comparación con el AVE1642, como una 
disminución tanto en la funcionalidad como de la madurez de los vasos 
sanguíneos. Además, el PGA-AVE1642 mejora significativamente la inhibición 
de la proliferación del tumor de próstata y la angiogénesis en comparación con 
AVE1642.  
10. Los estudios in vitro mostraron un efecto sinérgico dependiente de la 
presencia del gen de fusión T2E para los tratamientos con PGA-AVE1642 y 
AVE1642 en combinación con abiraterona. Sin embargo, mientras se obtuvo 
un efecto antitumoral sinérgico para el tratamiento con AVE1642 en 
combinación con abiraterona in vivo, no se encontró un efecto aditivo para el 
tratamiento con PGA-AVE1642 y abiraterona debido al mecanismo de acción 
molecular diferencial tras la conjugación del PGA ya que ambas terapias de 
combinación promovieron una doble vía de inhibición a través de PI3K y MAPK. 
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